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Problem: Diarrhea is the fourth leading killer of children under 5 worldwide, with India bearing 
the largest national burden. Effective and low-cost treatment is available through oral rehydration 
salts and zinc supplementation, and trial based literature suggests that these interventions are cost-
effective. However, coverage of these interventions remains low, and strategies are being 
developed for scaling them up. It is less certain whether this health systems strategy is cost-
effective at scale, or what economic impact it will have on caregivers. This dissertation evaluates 
the Diarrhea Alleviation through Zinc and ORS Treatment (DAZT) program in rural Gujarat 
India in terms of impact on caregiver costs, cost-effectiveness, and cost-effectiveness of different 
bundles of diarrhea and pneumonia prevention and treatment interventions.  
Methods: The influence of factors on the odds and amount of economic costs to caregivers was 
evaluated with a two-part model. Due to the uncontrolled non-randomized study design, a net-
benefit regression approach was used to evaluate cost-effectiveness while controlling for 
covariates. Cost-effectiveness of bundled services was evaluated with a mathematical model 
using probabilistic sensitivity analysis to evaluate uncertainty, and the Lives Saved Tool to 
project the number of deaths averted over five years.  
Results: The DAZT program was not associated with a change in odds of incurring an economic 
cost, although was associated with a $1.49 lower amount spent controlling for covariates. While a 
14% to 11% reduction in diarrhea prevalence was observed, it is difficult to infer causality due to 
study design limitations. Estimates of cost-effectiveness were highly dependent on covariates 
included, never falling below 95% certainty in the fully specified and interacted model. The cost-
effectiveness of the program bundled with other services was favorable relative to a ceiling ratio 
of per capita Gross National Income. 
Conclusions: The DAZT intervention was cost saving to caregivers and may be a good 
investment in rural Gujarat based on its potential impact on diarrhea outcomes. With investment 
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decisions based on expected values of the data taken at face value, the program is recommended 
in terms of cost-effectiveness. Zinc and oral rehydration salts may be bundled with other services, 
while maintaining cost-effectiveness.  
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1 Introduction and background 
1.1 Problem statement 
Worldwide, diarrhea is fourth only to pneumonia (17%), complications of preterm birth (15%), 
and complications during birth (10%) as the leading cause of mortality among children under 5 
years old, accounting for 9% of total deaths (1), and  killing more children than HIV, malaria, and 
measles combined (2). Annual mortality from child diarrhea has declined from 4.6 million in 
1980 to 700,000 in 2011 (Figure 1) (3-5). Disability Adjusted Life Years (DALYs) decreased by 
51% since 1990 to 89 million in 2010 (6), mostly due to averted mortality (7). In low- and 
middle-income countries (LMICs), the incidence of diarrhea in children under 5 is 2.9 (2.3-3.4) 
episodes/child year (2010 estimate) (8), but only 39% of children are treated appropriately (9). 
These trends are occurring in the context of a triple burden of disease (10, 11), particularly in 
countries in economic transition (12, 13), and difficult decisions exist in balancing infectious 
disease programs against other priorities.  
1.2 India profile 
India is a lower middle income country in southeast Asia with a per capita Gross National Income 
(GNI) of US$1,530 (14),
1
 a Gini coefficient of 33.9 (14),
2
 and a rapidly increasing lifespan (15).
3
 
Mortality among children under five years old decreased from 109 to 74 per 1,000 between 1987-
91 and 2001-5 (16). India has had success in its infectious disease agenda, such as eradicating 
polio,
4
 and the elimination of several other diseases is predicted for the near future (17). 
However, infectious disease continues to account for 30% of India’s disease burden, with 
                                                          
1
 The range used by the World Bank for defining a lower middle income country is $1,036-$4,085 (World 
Databank 2013) 
2
 The Gini coefficient in the United States is 46.9, reflecting more inequality. In India people are more 
equal because so many people are poor. 
3





diarrhea accounting for 5.7% (18). Between 1990 and 2010 diarrhea fell from first to third largest 
contributor of premature death to the burden of disease (19), although India is still recognized as 
one of 15 high burden countries that account for 53% of global episodes, with 312.22 million 
episodes and 205,600 deaths each year nationwide (5). Approximately 9% of children under 5 
experience diarrhea in any given two week period (16). 
1.3 Gujarat profile 
The state of Gujarat is in the northwest corner of India, bordering Maharashtra to the south, 
Madhya Pradesh to the east, and Rajasthan and Pakistan to the north. It has an area of 75,685 
square miles, with a 992 mile coastline bordering the Arabian Sea, most of which is on the 
Kathiawar peninsula.
5
 The capital city is Gandhinagar, with the largest cities being Ahmedabad 
(5.6 million), Surat (4.5 million), and Vadodara (1.7 million).
6
 57.40% of the state is rural (20),
7
  
with desert in the north and northwest, wetlands in the west, forests in the east, and fertile 
farmland in the south. 
 
The official languages in Gujarat are Gujarati and Hindi,
8
 with the most widely spoken language 
being Gujarati. English is spoken by a substantial number of people, particularly in urban areas, 
and different regions have a wide variety of languages and dialects. The ‘tribal belt’ of north 
India extends to Gujarat, with forest tribes and forest dwellers in East Gujarat. Currently, it is one 
of the fastest developing states in modern India, although vestiges of the caste system leave many 
people in rural areas in poverty traps (21). 
 











Industrial development in Gujarat has been substantial, with the largest oil refinery in the world 
(Jamnagar) (22), commissioned as a special economic zone in 2008.
9
 Other important industries 
include textiles, machinery, metal products, chemicals and minerals, rubber and plastic, wood and 
paper, and food (23). Engineering output has flourished, accounting for 9% of the national total 
(24). Large scale agriculture has grown, particularly for cash crops such as cotton, tobacco, 
groundnuts, and sugar cane – in addition to grains, oilseeds, vegetables and spices (25).  
 
The 2011 population in Gujarat was 60,439,692 (6.04 crores), ranking 10
th
 among Indian states, 
and being similar in population size to the United Kingdom (UK) (20). Nationwide, Gujarat 
accounts for 5% of the population of India, and has shown growth in recent years (19% per year) 
(20). Population density is about 300 people per square mile, below the national average. 57.4% 
live in rural areas, although this proportion is decreasing  (20). The sex ratio in rural areas of 
Gujarat is 949 females per male, which is approximately the natural sex ratio, and above the 
national average of 933 (20). 
 
Literacy in Gujarat in 2011 was 71.7% in rural areas (86.3% urban), with a female literacy rate of 
57.8% (20).
10
 This amounts to 21.4 million illiterate people, although the government is making 
efforts to improve literacy in the state. About half of age-eligible children in marginalized groups 
use services offered by Anganwadi centers, such as preschool, immunization, and supplementary 
food (20). The infant mortality rate was 58 in rural areas, which is approximately the national 
average. 45% of children age 12-23 months are fully vaccinated against the six major childhood 
illnesses (tuberculosis, diphtheria, pertussis, tetanus, polio, and measles), and 5% received no 
vaccination at all (26). 13% of children in rural areas had diarrhea in the two weeks prior to the 
survey, with 52% taken to a health facility (26). 25% received Oral Rehydration Salt (ORS) 
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packets, 9% received antibiotics, 27% received another drug, and 36% received no treatment  
(26). 3.5% of children in rural areas had symptoms of Acute Respiratory Infection (ARI) in the 
previous two weeks, and 13.8% had a fever (26). 51.5% with symptoms of ARI were taken for 
treatment from a health facility or provider, and 3% received antibiotics (26). 
1.4 Types of diarrhea and its persistence in India 
Diarrhea is mainly caused by fecal-oral transmission of viruses, bacteria, protozoa, and 
helminthes (4). Rotavirus is the most common cause of diarrhea, accounting for 40% of hospital 
admissions, 100 million episodes of acute diarrhea each year (9), and is the leading cause of 
diarrhea death (27). Escherichia coli, Salmonella, Shigella, Campylobacter, and Vibrio cholerae 





Three types of diarrhea syndromes exist including acute watery diarrhea, persistent diarrhea, and 
bloody diarrhea. Acute watery diarrhea results in dehydration with 250 mg/kg stool losses per day 
and usually lasts for several hours. It has multiple etiologies (usually rotavirus, enterotoxogenic 
Escherichia coli, or Vibrio cholerae) and is most dangerous in young infants (4, 9). Persistent 
diarrhea lasts 14 days or longer, is associated with malnutrition either preceding or resulting from 
the infection, and can lead to wasting. Bloody diarrhea indicates intestinal damage caused by 
inflammation, is most commonly caused by Shigella, and occurs more often in an episode of 
persistent rather than watery diarrhea (2). Dysentery is a specific form of bloody diarrhea 
consisting of the passage of frequent small volume, bloody mucoid stools, abdominal cramps, and 
tenesemus (a severe pain that results from trying to pass a stool) (4). 
 





Diarrhea kills children principally through loss of water and electrolytes.
12
 Children are 
particularly at risk as a greater proportion of their body weight is water compared to adults. If 
they survive, long term sequelae may include impaired physical growth, cognition, and 
concentration (4). In addition, obesity and related conditions can occur later in life such as 
cardiovascular disease and diabetes (28). 
 
A combination of economics, culture, and health systems factors have led to the persistence of 
diarrhea in India. India accounts for nearly two thirds of the 1 billion people worldwide that 
practice open defecation (29). Poverty is widespread with lack of improved sanitary facilities 
affecting 792 million people (29), in addition to inadequate housing, crowded living conditions, 
dirt floors, inadequate access to sufficient clean water, cohabitation with domestic animals, and a 
lack of refrigerated storage of food (4). Historically, there has been a lack of adequate medical 
care that people can afford and access, although close to client services are being improved 
through the Accredited Social Health Activist (ASHA) program. The ASHA program was started 
in 2005, and has since scaled up to having 835,808 ASHAs in 2011, which is 94% of its target of 
1 ASHA per 1000 people (30). To different extents, other risk factors may be amenable to 
change. For example, Bangladesh reduced the percent of people practicing open defecation from 
34% to 3% between 1990 and 2012 (29), although the feasibility of achieving this level in Gujarat 
will be affected by the growth of infrastructure and social and cultural factors. For example, 
Gujarat is 89% Hindu, where Bangladesh is 90% Muslim,
13
 and open defecation is 40% more 
prevalent among Hindus despite being more educated and wealthier than Muslims in India (31).
14
 








 A key determinant of diarrhea transmission is the defecation practices of a person’s neighbors and people 
often live near other people of the same religion in India. 
6 
  
The poverty headcount ratio of people living below $1.25 per day in India was halved between 
1978 and 2010 to be 32.7% (14), and Gini coefficient has increased to 23.8 in rural Gujarat (32).  
1.5 Intervention and barriers 
Oral Rehydration Salts (ORS), recognized as potentially one of the most important medical 
advances of the 20
th
 century (9, 33), is the standard treatment for diarrhea to replace lost fluids 
and electrolytes. ORS consists of sodium, chloride, potassium bicarbonate, citrate and glucose or 
another form of sugar and starch mixed with water to form an electrolyte solution (34). After its 
scientific development in Dhaka and Calcutta in the late 1960s (35), the use of ORS spread 
rapidly, reaching coverage levels of 25% and access levels of 60% worldwide by the mid-1980s 
and achieving high levels of local production with two thirds made in LMICs (36). In 2004, the 
311 mmol/L formula was replaced by a 245 mmol/L formula as it was associated with less 
vomiting, stool output, and need for unscheduled intravenous therapy (34), as well as being 17% 
less expensive than standard ORS (37). In India, ORS costs only $0.20-$0.35 for a 20g sachet 
(38), and national estimates of the proportion of children with diarrhea that receive ORS has risen 
dramatically from 26% in 2005-6 to 43% in 2010 (39, 40).  
 
In 2004, the World Health Organization (WHO) and United Nations Children’s Fund (UNICEF) 
advocated that zinc supplementation be used with ORS for managing diarrhea among young 
children, both to treat existing disease and avert further episodes (41). In 2006, the Government 
of India incorporated this recommendation into its national policy, making zinc and low 
osmolarity ORS part of its Integrated Management of Neonatal and Childhood Illness (IMNCI) 
strategy (42). The dose of zinc recommended was 20 mg per day for 10-14 days (10mg per day 
for infants under six months) (41). This recommendation cites a pooled analysis of ten trials that 
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found that zinc has beneficial effects on both incidence and prevalence (43).
15
 Subsequent to zinc 
supplementation becoming the recommended treatment, nine meta-analyses confirmed its overall 
effectiveness in reducing duration and severity of diarrhea (44-52), although there is a significant 
amount of heterogeneity among patient subgroups (49, 51). Lazzerini et al (2013) (51) present 
results indicating that child age and nutritional status are important, particularly in zinc deficient 
children. In addition, effect size varies in different Asian studies. Four studies were reviewed 
from the community setting evaluating zinc supplements (53-55). 
 
The public health and policy importance of zinc research in India is enormous. With a drug cost 
of $0.28-$0.75 for 10-14 days treatment of ORS and zinc (56),
16
 appropriately treating all child 
diarrhea episodes in India costs $92-$246 million (5). However only 54% of caregivers that 
receive a prescription adhere to the full dose in rural areas (57), and only 0.2%-0.3% of children 
with diarrhea receive zinc (16). Policy reasons include that zinc was only added to the National 
List of Essential Medicines India in 2011 (58), and that the formula included syrup, not the 
dispersible tablets advocated by the Government and used in the National Rural Health Mission 
(NRHM) (59, 60). There is ambiguity of the official policy of the Drugs Controller General of 
India around whether zinc is a prescription drug (56).  In addition, the Drug and Remedies Act 
regulations impose restrictions on the stocking and sale of zinc, preventing end users from 
obtaining ORS and zinc from a single supplier (61). 
 
Economic barriers present further problems. Supply-side barriers include the low profit margin 
given the official wholesale price and input prices (staff, capital equipment, buildings), lack of 
                                                          
15
 Zinc is thought to avert diarrhea morbidity and mortality by strengthening the immune system, 
improving absorption of water and electrolytes in the intestines, enhancing the regeneration of the gut 
epithelium, increasing levels of enzymes in the epithelium, and helping the body clear diarrheal pathogens 
from the intestines (Baqui et al 2002). 
16
 Calculated from costs of INR 13.68 for 100 zinc tablets, and INR 1.58 per sachet of ORS, and 
1 INR = 0.0160485 USD (www.xe.com 19 Nov 2013). $0.75 derives from drug costs from the International 
Drug Price Indicator Guide. 
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knowledge of technology and treatments among manufacturers, and low levels of management 
efficiency (62). Prescribers are reluctant to prescribe zinc (56), and when they do, usually 
prescribe syrup form (61). It is not clear if zinc is included in supply kits provided to ASHAs 
(61). In addition, locally produced zinc may be of questionable quality, and there is no current 
global funding mechanism for financing zinc through international support (37). Demand-side 
barriers include lack of knowledge among caregivers about zinc, reluctance to give treatment 
after diarrhea is over, palatability issues, and need for a prescription (56). 
 
Community based programs have been developed as potential solutions for scaling up zinc for 
treatment of child diarrhea, such as the Anganwadi worker (AWW) program evaluated in the 
Haryana India trial (63). These workers are particularly essential to address shortfalls of higher 
cadre human resources in rural areas of India (64), which are served by 40% of India’s health 
workforce (65) but are home to 68% of the population (14).  
 
The private sector is particularly important for addressing barriers to diarrhea treatment in India. 
As mentioned above, it has been effectively utilized in previous research on delivering zinc at the 
community level in Haryana India (63). In formative research for the DAZT program, 73% of 
caregivers in Gujarat sought treatment for diarrhea from private providers (66). However, if 
current health systems trends continue, health care costs are expected to rise and inequalities in 
access are expected to widen (67). More research is needed on feasible delivery mechanisms of 
zinc that balances public and private sector channels. 
 
Zinc supplementation may have a favorable impact on health systems costs. Patel et al (2003) 
found that adding zinc and copper to ORS treatment decreased costs of diarrhea treatment by 8% 
in hospitalized children (68). At public hospitals in India, the government pays two thirds of the 
cost of diarrhea treatment (69), and the potential cost savings are substantial. In the second half of 
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a trial in Haryana India which delivered zinc through both facility and community based workers, 
user costs for diarrhea treatment declined by 70% in the intervention arm and 46% in the control 
arm (70). In 2005 in Pakistan, a training, provision, and marketing program was implemented 
through facility and community channels of both the public and private components of the health 
system (71). This program lowered household costs by 12.8% ($0.50), but increased the cost to 
the health system overall (71). In 2006 in Mali, zinc and ORS were introduced at first level 
facilities which passed drug kits to community health workers. This program increased ORS use 
rates by 10% to 43%, doubling sales levels in the community (72). Households incurred a mean 
total cost of between $0.17-$0.19 per case, and CHWs sold $5.81 worth of ORS in the 
intervention area and $2.80 in the control area over the course of the trial (72). Cost savings are 
possible due to reductions in prescriptions of antibiotics, which are prescribed to 80% of patients 
in India whether they are needed or not as providers are overly cautious about not neglecting to 
treat a relevant infection (38). In addition, demand for antibiotics among caregivers is high, as 
they are perceived as the strongest and most effective treatment for this deadly disease (73). 
1.6 Diarrhea Alleviation through Zinc and ORS Therapy (DAZT) 
program 
From 2010 to 2013, the Diarrhea Alleviation through Zinc and ORS Therapy (DAZT) program 
was conducted in 12 districts of Uttar Pradesh and 6 districts of Gujarat, supported by the Bill and 
Melinda Gates Foundation (BMGF) (38, 74).
17
 These states were chosen as they have particularly 
low levels of diarrhea treatment (any Oral Rehydration Therapy (ORT) or increased fluids) at 
29% in Uttar Pradesh and 63% in Gujarat (39). The DAZT program had a ‘before and after’ study 
design, with an initial survey conducted in Mar-June 2011 representing the ‘before’ phase, phase 
1 occurring between May 2011-Oct 2011, and phase 2 occurring from Nov 2012-Dec 2013. It 
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  Districts in Gujarat included Banas Kantha, Sabar Kantha, Patan, Surendranagar, Dohad, and Panch 
Mahals. Districts in Uttar Pradesh included Kanpur Dehat, Lucknow, Sitapur, Hardoi, Faizabad, Sultanpur, 
Budaun, Shahjahanpur, Barabanki, Unnao, Bareilly, and Ambedkar Nagar (FHI-360, 2013). 
10 
  
was a follow on to the Point of Use water disinfection and Zinc treatment (POUZN) project, 
which made zinc available through private sector providers nationwide between 2005-10 (75). 
DAZT builds on POUZN by introducing zinc through all levels of the public sector and clinics in 
the private sector.  
 
Interventions were delivered through two international non-governmental organizations (NGO) – 
FHI-360 in the private sector (74) and Micronutrient Initiative in the public sector (76) – with 
political and managerial support from UNICEF (Table 1). State level policy changes and 
agreements with professional associations, NGOs, and pharmaceutical companies provided high 
level frameworks to facilitate provision. Staff were trained at all levels in diarrhea epidemiology, 
the importance of zinc and ORS, dosing and regulatory guidelines, promotional strategies, the 
role of the implementing agencies, and the use of Short Message Service (SMS) messaging to 
monitor sales. Procurement, supply, and distribution systems were developed in both public and 
private sectors. At formal provider facilities in the private sector, DAZT corners were set up to 
create awareness among caregivers, remind providers to prescribe zinc, and track prescribing and 
purchasing patterns. Both sectors involved informal providers to improve coverage in patients’ 
homes (74). Constraints to the program were weak program monitoring, difficulties in increasing 
the priority placed on ORS, the fact that zinc does not stop diarrhea, problems in sustaining 
demand, and difficulties improving standards of care and accountability of providers (38).  
1.7 Other diarrhea programs delivered at scale 
In addition to the POUZN and DAZT programs, there are a number of at-scale private sector 
projects emerging in the implementation science literature. These evaluations consist mainly of 
project reports, with a few published studies. The Scaling Up Zinc for Young children (SUZY) 
project in Bangladesh represents one of the first national scale zinc programs, occurring between 
2003-8 and rolling out zinc in 2006 (77-79). The Strengthening Health Outcomes through the 
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Private Sector (SHOPS) program is the United States Agency for International Development’s 
(USAID) principal initiative to strengthen the private sector to provide services addressing a wide 
variety of priority disease areas including zinc for diarrhea. Since its inception, SHOPS has 
expanded to fourteen countries in Africa (Benin, Ghana, Kenya, Madagascar, Malawi, Mali, 
Nigeria, Tanzania, and Uganda have zinc programs), four countries in Asia and the Middle East 
(India, Bangladesh, Jordan, and Nepal have zinc programs), four countries in Latin America, and 
Russia in Eastern Europe (80).  
 
The SUZY program in Bangladesh was led by Charles Larson of the International Center for 
Diarrheal Disease Research, Bangladesh (ICDDR,B) in collaboration with the Ministry of Health 
and Family Welfare (MHFW) and Acme Laboratories (79). SUZY focused primarily on the 
private sector based on results from formative research, which indicated that it was the source of 
care for 90% of caregivers that sought attention (77). Initial research also developed key 
messages for marketing,
18
 and determined that most poor people in rural areas would be willing 
to pay $0.25 for a 10 tablet blister pack (77). Safety was established through a series of 
randomized control trials, one in Bangladesh, in addition to monitoring outcomes among 24,000 
patients at the ICDDR,B hospital (77). The patent for the dispersible zinc pill was obtained from 
the French company Nutriset and approval was obtained from the Bangladesh Drug 
Administration for Acme Laboratories to produce and distribute a 20mg product branded 
BabyZinc (79). The MHFW created two governmental committees in support of the zinc scale up, 
and the Bill and Melinda Gates Foundation contributed $8 million in funding through the course 
of the project (79).  
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 The four key messages that the SUZY program targeted towards caretakers included 1) Baby Zinc is for 
the treatment and prevention of diarrhea  2) One tablet should be taken each day for 10 days  3) Dissolve 
the tablet in water  4) Use in conjunction with ORS 
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The outcomes of the program were that there was a rapid increase in awareness about zinc among 
caregivers, followed by an increase in its use (10% in rural areas, and 26% in city non-slum 
areas), and no decrease in coverage of ORS  (77). The poorest households spent an average of 
$0.50 per episode, and the average amount households were willing to pay for a ten day course of 
zinc after explanation of benefits was $0.45 (77). Mainly through information from the 
pharmaceutical industry, caretaker awareness of zinc increased from 5% to 50% in rural areas, 
and 90% in urban non-slum areas (78).  
1.8  Bundling services 
Bundling services into packages that can be delivered by one modality of the health system has 
been discussed as a policy strategy for improving efficiency. Early thinking about bundling 
services was stimulated by the essential health packages designed by the World Bank and WHO 
in the 1990s (81), and the Commission on Macroeconomics and Health (CMH) report (82). In 
addition to efficiency, poverty reduction and equity have been highlighted as benefits as many of 
the interventions included address illnesses that affect the poor (81). However, services are often 
'Bundled out of logistical convenience, donor directives, organizational expertise, or specific lines 
of scientific inquiry rather than consideration of delivery mode, biological or behavioral synergy, 
or cost effectiveness' (83). Further work should evaluate the cost-effectiveness of different 




2 Thesis overview 
2.1 Study aims 
The aims of this study are to describe the factors influencing odds of having a cost of diarrhea 
treatment, amount of cost, and cost-effectiveness of the DAZT program in Gujarat India. It 
advances the current body of knowledge by using a multistage modeling approach assessing the 
importance of the health systems intervention, use of zinc and ORS, source of care, wealth 
quintile, and other factors.  
 
Aim 1: To estimate the odds that caregivers of children with diarrhea incurred an economic cost 
during the child’s last episode of diarrhea, estimate the magnitude of economic costs, and 
evaluate which factors influence these outcomes. 
 This aim was evaluated with a two-part model, using a multivariable logistic regression 
followed by generalized linear modeling with a gamma distribution. The hypothesis of 
the first part is that the proportion of children incurring a cost will remain equivalent after 
the introduction of the program as compared to before, if not increase since more children 
are expected to receive treatment. It is expected that costs were incurred more frequently 
for younger children and those of mid-range wealth index quintiles (84). Hypotheses for 
the second part are mixed whether magnitude of costs will increase or decrease after 
program implementation. In favor of an increase, zinc supplements add an additional cost 
and the amount of ORS consumed may increase (37, 85). In favor of decrease, inefficient 
drug prescription patterns are likely to be reduced, cases may become less severe, and 
fewer hospitalizations may be necessary. Costs are expected to have an upside down U-
shaped curve with the least and most wealthy quintiles having the lowest costs (84). 
Older children are expected to incur lower costs due to their stronger health status relative 
14 
  
to children under six months  (85). Caregivers seeking care from government facilities 




Aim 2: To estimate the cost-effectiveness of zinc provision through the DAZT program relative 
to the status quo that preceded the program adjusted for covariates. 
 This aim will be evaluated using a multivariable linear regression framework, using a 
methodology that combines economic evaluation and econometric methods described by 
Hoch et al (2002) (86). The hypothesis of this aim is that the program was cost-effective 
relative to status quo conditions at the start of the survey due to improved health 
outcomes and economic cost saving to caregivers. It is not expected that the intervention 
was more costly with more health benefit, consistent with other studies (68, 87), since 
program costs are expected to be substantial in the intervention phase (70). However, 
results are expected to remain highly cost-effective.  
 
Aim 3: To calculate the modeled cost-effectiveness of delivering zinc as a bundled package of 
interventions to prevent and treat diarrhea and pneumonia 
 This aim builds on methods from previous work for calculating the cost and cost-
effectiveness of bundled services (88-90). The hypothesis of this aim is that cost 
effectiveness of bundling services is synergistic, with the bundled services being more 
cost-effective than the services provided individually (89), since several interventions can 
be delivered through the same modality.  
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 Only nominal user fees of Rs 5 (US$0.12) were charged for outpatient visits at government run health 
facilities in 2007 in Uttar Pradesh (Rao and Peters 2007) and the public sector also levies nominal charges 




2.2.1 General project rationale 
Results from this project will inform policy making related to child health in low- and middle-
income countries (LMICs). Across countries, only modest progress has been made in increasing 
coverage of ORS in LMICs (91), and coverage of zinc is surprisingly low. Evidence is needed to 
make zinc supplementation an international priority and scale up its use for children with diarrhea 
(37). The Dissertations Abstracts Database indicates that while doctoral research on tuberculosis 
and malaria has steadily increased in recent decades, the number of dissertations on diarrhea have 
remained relatively constant since the 1990s (92). In addition, the number of publications on 
diarrhea in LMICs have declined substantially since their peak in the 1990s (92).  
  
Implementation science research on zinc in India has been conducted through the POUZN study, 
which indicates that diarrhea treatment can be enhanced through zinc introduction in the private 
sector (38, 75). However, programmatic effectiveness varies according to delivery strategy and 
coverage levels, and each community and geographic area presents different constraints. These 
factors affect impact, and little is known about the cost and cost-effectiveness of different 
approaches delivered at scale. The analyses in this thesis can inform which program 
characteristics were the most responsible for achieving health systems goals and for what groups 
they can be achieved. 
2.2.2 Costing component rationale 
Despite the low cost associated with diarrhea treatment, understanding relevant determinants of 
costs is important. The number of people living on less than $1.25 per day in India is the highest 
in the world (93), making even minor costs significant barriers to health care. In addition, 
episodes occur frequently among children in LMICs (1.7-3.5 episodes per child per year) (4, 59). 
Understanding costs can help policy makers understand the impact of treatment and the disease 
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burden on the economic well-being of households, inform financing schemes to enhance risk 
pooling, promote equity, and promote a positive perception of the health system. From a 
programmatic perspective, costing data is helpful to inform plans for scaling up interventions.
20
 
Studies exist to evaluate the cost of zinc supplementation for hospitalized cases of diarrhea (68, 
85) as well as studies that use population level survey drawn from the Demographic Surveillance 
System (DSS) (94, 95), and community based surveys (70, 96). Only two studies evaluate factors 
associated with costs (85, 95), and neither is from a program setting. From an implementation 
science perspective,  evaluating the incremental cost of delivery strategies of health interventions 
is a key research priority (97). 
2.2.3 Cost-effectiveness component rationale 
Evidence to promote diarrhea management programs and improve efficiency in the health sector 
is particularly important in India where a LMIC level budget is spread thinly across a massive 
population (14, 98). Cost-effectiveness analysis (CEA) is a useful tool for informing prioritization 
decisions between unrelated health care interventions to maximize health gain given these limited 
health budgets. Currently, PubMed reveals over 30 English language cost-effectiveness analyses 
evaluating interventions in the Indian context; however the set of interventions relevant to India’s 
health sector that has been assessed is far from complete. A growing body of knowledge supports 
the effectiveness and cost-effectiveness of zinc supplementation in hospital settings and economic 
modeling studies (4, 68, 87, 99); and further cost-effectiveness work was ranked as a research 
priority using the Child Health and Nutrition Research Initiative framework (100) (although the 
cost-effectiveness of zinc was not mentioned in a similar study in 2009 (101)). In particular, 
evidence for its cost-effectiveness in real world conditions must be strengthened. 
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 Costs to caregivers can be used to predict demand for services, and might be considered when devising 
revenue generating strategies to finance scaling up of this type of program. 
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Methodologically, cost-effectiveness analyses of before and after studies are emerging (102-107); 
however, these studies are not well established in the literature and thought is needed about 
methodological considerations that should be made for evaluating these studies. For example, 
before and after studies often overstate treatment effect and may require adjustment. The 
Cochrane Consortium provides some guidance for other sources of bias (108), however, specific 
methods for evaluating these studies need further development.  
 
The net benefit regression approach is relevant for this type of analysis two main reasons. First, 
when covariates are important for equity considerations, this technique can have relevant policy 
implications (109). For example, it can address the question of how cost-effective it is to provide 
the intervention to people according to wealth quintile. Second, net benefit regression is relevant 
to control for confounding. While the approach is equally valid for randomized (86, 110) and 
non-randomized studies (109, 111), it may be even more appropriate for non-randomized studies 
as covariates are even more likely to be unevenly distributed across study phases than in RCTs 
(112). Kreif et al (2013) note that most cost-effectiveness analyses of studies with a non-
randomized design do not account for imbalances in covariates, which can lead to biased 
estimates of cost-effectiveness (113). 
2.2.4 Cost-effectiveness of bundled services rationale 
Model results are mixed whether bundling services enhances the cost-effectiveness of their 
delivery. A study by Darmstadt et al (2005) suggests that newborn health services become more 
cost-effective when delivered in packages, although the risk of over-bundling is noted (89). 
World Health Organization Choosing Interventions that are Cost-Effective (WHO-CHOICE) 
models show that cost-effectiveness became less favorable with additional services added to 
delivery packages of child health interventions (102). An existing projection of the costs and 
effects of scaling up interventions to prevent and treat diarrhea relies on old data (90), which 
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overestimates worldwide levels of child mortality due to diarrhea (5, 114). Other precedent exists 
in several studies that evaluate the costs associated with interventions associated with the Lives 
Saved Tool (LiST), which use a variety of primary and secondary data sources to calculate costs 
(90, 115-118). Further data exists from the Haryana India trial (70), estimates can be refined 
through consultation with local stakeholders, and full cost-effectiveness analysis is needed. 
2.3 Organization of the document 
This dissertation follows a progression from a review of previous work, describing elements of 
cost-effectiveness analysis, presentation of the three analyses conducted, and finishing with a 
discussion of their relevance to policy. Chapter 3 reviews costing and cost-effectiveness studies 
from India and similar countries, including a review of studies that use a net-benefit regression 
framework in the LMIC context. Chapter 4 discusses key concepts in health economics and 
economic evaluation, philosophical underpinnings of economic evaluation, and a continuum of 
research through which evidence can be built up to inform policy. It concludes by connecting a 
conceptual framework based the Andersen and Newman framework for treatment seeking to the 
study questions of this thesis (119). Chapter 5 discusses key topics relevant to understanding the 
methods used in data collection and the analytic approaches taken. Chapter 6 (paper 1) evaluates 
the impact that the DAZT program had on economic costs to caregivers of infants with diarrhea, 
and shows which covariates were associated with the count and amount of these costs. Chapter 7 
(paper 2) evaluates the cost-effectiveness of the DAZT program using net-benefit regression 
methods to control for imbalances in covariates resulting from its study design (86). Chapter 8 
(paper 3) evaluates the cost-effectiveness of zinc and ORS in the broader context of the set of 
preventive and curative interventions that can be used to address the burden of diarrhea and 
pneumonia through the health sector, quantifying lives saved with LiST tool projections and 
uncertainty around estimates using probabilistic sensitivity analysis. Chapter 9 summarizes 
findings and discusses key topics that flow from them that are relevant to policy. It indicates the 
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strengths and limitations of this research, identifies areas of further study, and provides 




3. Literature review 
The purpose of this literature review is to describe the evidence base that puts results from this 
dissertation research into context, and to provide ideas for analytic methods. Described studies 
include evaluations of similar programs providing zinc at scale, evaluations of expenditures 
associated with diarrhea treatment according to covariates, cost-effectiveness analyses of the 
therapeutic use of zinc to treat child diarrhea, cost-effectiveness analyses that have been done in 
LMICs according to the net-benefit regression approach developed by Hoch and colleagues (86), 
reviews that summarize subgroup analyses on zinc supplementation for child diarrhea, and 
economic evaluations of bundled services. 
3.1 Costing studies 
Patel et al (2013) evaluated the importance of different factors on cost of diarrhea treatment in a 
hospital setting through a linear regression framework in Nagpur India (85). The average cost of 
treating a diarrhea episode without zinc was $15.19 (sd $7.18). Cost of treatment was more in the 
supplemented group due to the cost of the zinc supplements and the fact that more ORS was 
consumed. Other determinants of total cost included older ages, hospital days, intravenous fluid 
use, dehydration, use of antibiotics, and complications. A methodological limitation of Patel et al 
(2013) was that it did not retransform variables onto their original scale with a smearing estimator 
(120). In addition, its single hospital perspective is of limited application to health systems 
planners interested in a broader perspective on the economic impact of widespread introduction 
of zinc into a geographic area.   
 
Rheingans et al (2012) evaluated the cost of diarrhea treatment in Bangladesh, India, and Pakistan 
as part of the Global Enteric Multicenter Study (GEMS) (95), with the study site in India located 
in Kolkata, West Bengal (94). Average costs per episode in India were $3.33, mainly due to direct 
medical costs. As expected, costs had a positive skew, with 10% of episodes having a cost 
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exceeding $8.07. Logistic regression was performed on the log odds of incurring costs; however, 
other forms of regression were not conducted due to small sample size (n = 154). Direct and total 
medical costs were stratified by wealth quintile (classified by principal components analysis), sex 
of child, maternal education, age of child, severity of episode, and duration of episode. Of note, 
poorer households had lower direct and total costs, possibly indicating that they were not 
adequately accessing the health system; however, this result was only marginally significant. In 
addition, richer families had lower costs, producing an upside-down U-shaped curve. Older 
children incurred lower costs due to the greater effectiveness of zinc in that cohort (51). 87% of 
costs were in the formal sector, possibly reflecting the use of ORS and other low cost 
interventions from chemists. 48% of out of pocket expenditures were from savings. There was 
little difference between costs among girls and boys. 
 
A second study was published with results from the African countries of the GEMS trial, 
including Gambia, Kenya and Mali (84). The range of total costs was narrower than in Asia, 
ranging from $2.63-$6.24, with the data having the expected positive skew. Expenditures for each 
episode according to the socioeconomic status of the household had a U-shaped curve in Gambia, 
was relatively uniform in Kenya, and had an upside-down U-shaped curve in Mali. Like India, 
there was not a significant difference in expenditure between boys and girls, women with 
different levels of education, children of different ages, and different severity of diarrhea.  
 
As Patel et al (2013) transformed costs in their model (85), neither two-part models nor gamma 
regression have been used to evaluate costs associated with child diarrhea treatment in LMICs. 
However, the probability of treatment seeking and out of pocket costs among the elderly in China 
has been modeled with a two part model using gamma regression (121). A study from Finland 
compared the performance of an unadjusted bootstrap approach to cost-effectiveness analysis to a 
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two-part modeling approach using logit and gamma regressions (122). This study emphasized the 
importance of controlling for covariates when evaluating an observational study.  
3.2 Cost-effectiveness analyses 
Cost-effectiveness analyses evaluating zinc and ORS for treating child diarrhea have found mixed 
results between evidence in favor (68, 87, 99, 102), and more recent evidence against which 
emphasizes the importance of heterogeneity and context (85). Study designs have included 
randomized controlled trials (68, 70, 85, 87) and secondary data analyses (4, 99). Other 
evaluations have been done on widespread prophylactic zinc supplementation to prevent diarrhea 
(102, 123-125), and cost-benefit analyses were performed as part of the Copenhagen Consensus 
on disseminating iron and zinc dense rice (126), prophylactic zinc supplementation for children 6-
12 months as part of a set of micronutrients (127), and zinc supplementation alone for children 6-
59 months (128). However, this review will focus on CEA of therapeutic zinc supplementation of 
ORS to treat acute diarrhea.  
3.2.1 Trial based evaluations 
Patel et al (2003) evaluated the cost-effectiveness of zinc and copper supplements and standard 
ORS compared to standard ORS alone for treating 200 children 6-59 months old with acute 
diarrhea at a government hospital in Nagpur India (68). This study took a patient’s and provider’s 
perspective to costing, and evaluated outcomes as deaths averted and cases averted. The 
intervention was found to cost $14 per child and have dominant cost-effectiveness, although 
confidence intervals of both costs and effects included zero (dominance was not statistically 
significant). As Lefevre points out (129), the generalizability may be limited as the dose of zinc 
was two times the WHO guidelines (40 mg instead of 20mg) (41) and copper was also 
administered with the zinc. In addition (129), standard ORS was used instead of the reduced 
osmolarity formula (44), although the latter can be expected to improve cost-effectiveness as it is 
more effective (41) and 17% cheaper than standard ORS (37). Finally, the duration of 
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Gregorio et al (2007) evaluated the cost-effectiveness of zinc supplementation to ORS relative to 
ORS alone among 117 patients presenting to the emergency room of a government hospital in the 
Philippines (87). The WHO standard dosage of zinc (20mg for 14 days) was used in this study, 
although was not accompanied by low osmolarity ORS. Costing was done from a societal 
perspective, and outcomes were measured as day of diarrhea and case averted among diarrhea <4 
days. The intervention was found to be dominant, saving $2.40 per day of diarrhea averted, 
although differences in costs and cost-effectiveness were not significant. There were limitations 
in the costing performed in this study, with utilities and building services and salary subsidies for 
government employees not included. In addition, direct non-medical and indirect costs were 
modeled instead of being based on collected data. 
 
Patel et al (2013) evaluated the cost-effectiveness of zinc supplementation relative to two 
comparators, 1) zinc with copper supplementation and 2) a placebo at a public tertiary hospital in 
Nagpur (85). Zinc doses were set according to weight at 2/mg/kg/day for two weeks, and it is 
probable that low osmolarity ORS was used. Costing was conducted from a provider’s 
perspective and patient’s perspective, and outcomes were assessed per hour of diarrhea averted. 
Both intervention arms had higher costs with no additional benefits, contradicting the main 
conclusions of previous studies (68, 87, 99). Reasons for not finding a clinically significant effect 
are cited (131), and a sensitivity analysis from Gregorio et al (2007) is cited as corroborative 
evidence (87); however, reasons for having different results from their previous study are not 
stated (68).  
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Lefevre et al (forthcoming) evaluated the cost-effectiveness of zinc supplementation of ORS 
relative to standard treatment through a combination of four delivery channels in Haryana India 
(70). Fourteen 20mg zinc tablets and two ORS packets were administered to all children with 
diarrhea aged 1 month to 4 years (63). These channels included public primary health centers, 
public subcenters in their catchments areas, private practitioners, and home treatments by 
Anganwadi Workers (AWW). This study included an extensive costing exercise involving 
reviews of program records, in depth interviews and observation to assess staff time invested in 
the project, and household surveys to assess out of pocket costs. Outcomes were assessed with 
surveys at two points, and translated to per death and DALY averted based on assumptions about 
duration and mortality. Cost-effectiveness was found to be $0.24/DALY averted from a societal 
perspective, $13.51/DALY averted from a program perspective, and $6.68/death averted. 
Limitations include that costing was done on reported estimates, uncertainty was quantified on 
only a subset of model inputs, and results may not represent cost-effectiveness when the 
intervention is introduced at scale. 
 
Most recently, an economic evaluation was conducted of scaling up zinc and ORS coverage 
through a social franchising program in Burma to provide a package of these interventions called 
Orasel in rural areas (132). This program utilized a network of private providers managed by 
Population Services International, providing them with regular stocks of ORS and zinc kits and 
training in how to distribute them. Evaluation included an extensive costing, which included 
packaging, marketing, and distributing zinc; while outcomes were measured in terms of deaths 
and DALYs averted,
22
 calculated from coverage based projections estimated by the LiST tool. 
The wholesale cost of Orasel kits was $0.23 after subsidy, and providers were instructed to sell 
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them at a retail price of $0.35. The cost-effectiveness of the program relative to the status quo 
was $5,955 (IQR: $3437-$7589) per death averted and $214 (IQR: $127-$287) per DALY 
averted, with confidence intervals determined through Monte Carlo Simulation. However it was 
necessary to model some variables including adherence, attribution of overhead costs, and 
number of franchising officers. The generalizability is limited due to the pre-existing presence of 
a social franchising network. Notably, this study is the first to model uncertainty around both 
program costs and costs to households. The number of episodes per child appears low compared 
to other estimates – 0.6 per child per year compared to 1.7-3.5 reported in the literature (4, 59). 
 
All of these studies quantified uncertainty through probabilistic sensitivity analysis using the non-
parametric bootstrap (133), with one also using Fieller’s theorem (87). None were powered to 
detect differences in mortality (68, 70, 85, 87), and none calculated the necessary sample size 
required or power available in terms of cost-effectiveness outcomes (134, 135). The hospital 
settings of the trial based studies may have important differences from the community setting 
such as severity of cases and intensity of treatment measures available (68, 85, 87). In two of 
these studies, wages lost by the caregiver was a key driver of costs (68, 87). Three studies 
attempted to quantify health outcomes as DALYs (68, 70, 132), although only one had reason to 
report incremental cost-effectiveness ratios (ICERs) with DALYs averted as the denominator (70, 
132). None of these studies attempted to capture long term health effects such as cognitive 
deficits, stunting, and obesity and related conditions that occur later in life (cardiovascular disease 
and diabetes) (4, 28). 
3.2.2 Model based evaluation  
The first model-based estimate of the cost-effectiveness of zinc supplementation was conducted 
by Robberstad et al (2004) in the Tanzanian context (99). Zinc supplementation (20mg for 14 
days) of standard ORS  and standard ORS alone were compared to a no-treatment comparator, 
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consistent with generalized CEA (136). Cost-effectiveness was calculated assuming two 
populations of children: 1) those with non-dysenteric diarrhea, and 2) those with both dysenteric 
and non-dysenteric forms. Costing was done from a societal perspective, with data drawn from 
four dispensaries. Mortality estimates were based on a meta-analysis (137), and outcomes were 
translated to DALYs. Calculations were performed with a disability weight of 0.119, which 
compares to recently released values by the Global Burden of Disease (GBD) 2010 (mild 0.061, 
moderate 0.202, severe 0.281) (138). A decision tree was used with probabilistic sensitivity 
analysis to quantify uncertainty, although with triangular distributions (which are convenient to 
fit but implausible representations of the true distributional form (139)). Cost-effectiveness was 
found to be $40/DALY averted for zinc supplementation for non-dysenteric diarrhea ($1200/child 
death averted), $73/DALY averted for zinc supplementation for all diarrhea ($2100/child death 
averted), and $113/DALY averted for ORS alone ($3,200/child death averted). Gaps existed in 
their costing of case management; however, authors indicate that the cost of ORS was four times 
more than previously reported estimates, mainly due to differences in fatality rates assumed 
(140). Indirect costs and effects were not included, such as wages lost for caregivers and effects 
on acute respiratory infection, all-cause mortality, and stunting. Capital costs were considered, 
but it is not clear what components they included. It is not certain whether the four dispensaries 
are representative, and was not clear how generalizable costs would be across settings. 
Nevertheless, Scoups indicates that this paper has been cited at least 30 times and has had a 
significant impact on public health policy (37, 69, 85, 87, 95, 141, 142). 
 
Based on very old evidence from South Asia (143, 144), the cost-effectiveness of ORS was 
reported in the Disease Control Priorities Project second edition (DCP2); however, the benefits of 
zinc were not formally quantified. Included studies found a median cost per child of $2.91 (range 
$0.02-$5.80) (4). Estimates specific to India were calculated in a follow-on report using an 
expanded set of sources (102, 144-146) and finding a cost per episode of $0.07-$0.50 considering 
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ORT costs only, or $5.08-$5.51 when including other costs (147). Importantly, these studies were 
published before the widespread use of low osmolarity ORS, which began in the early 2000s 
(148). 
3.2.3 Cost-effectiveness using the net benefit regression framework 
Two studies have calculated the cost-effectiveness of interventions in LMICs using net-benefit 
regression (86), both on non-randomized maternal and newborn health programs in Burkina Faso 
(109, 111). The first evaluated the Skilled Care Initiative, calculating cost-effectiveness according 
to head of household education, distance to facility, and asset ownership (111). The second 
evaluated a community based health insurance scheme, calculating cost-effectiveness according 
to education, place of residence, and asset ownership (109). These studies included institutional 
delivery and use of health services as their program outcomes instead of DALYs or another 
summary measure of population health. Results are presented as tables of coefficients and ICERs, 
and adjusted cost-effectiveness acceptability curves (CEACs). An important distinction between 
these studies and our proposed research is that neither of these studies had a cluster randomized 
study design; therefore, they do not use generalized estimating equations or robust standard 
errors. 
3.3 Costing of bundled services 
Several studies have evaluated the costs associated with interventions associated with the Lives 
Saved Tool (90, 115-118). These models draw data from a variety of sources including WHO-
CHOICE (90, 115, 118), the UNICEF supply catalogue (90, 115), the OneHealth tool (118), 
International Drug Price Indicator Guide directly (115), Marginal Budgeting for Bottlenecks tool 
(117), and primary source data (116, 118). This review will focus on two studies; Fischer-Walker 
et al (2011) for its focus on diarrhea prevention and treatment interventions (90), and Adesina et 




Fischer-Walker et al (2010) (90) calculated the costs of scaling up diarrhea related interventions 
for children under 5 years old according to a five year projection of outcomes for the 68 countries 
included in LiST. Interventions assessed included preventive measures (vitamin A 
supplementation, rotavirus immunization, and breastfeeding), treatment measures (ORS and zinc, 
antibiotics), and water, sanitation, and hygiene (WASH) interventions (improved water source, 
water connection in the home, improved sanitation, hand washing, hygienic disposal of children’s 
stools). This model assumed that all children with diarrhea received ORS and zinc, and that the 
proportion of children with dysentery correctly received antibiotics. Costing was done using an 
ingredients approach, using data from the WHO-CHOICE database, UNICEF supply catalogue, 
and consultation with experts. WHO protocols and expert opinion were used to estimate amounts 
of necessary drugs, supplies, and personnel time. Results for the ambitious scenario indicated that 
1 million lives would be saved in 2015, and that scaling up would cost $49.2 billion over five 
years. The universal coverage scenario predicted that 1.4 million deaths would be averted, costing 
$84.8 billion over five years. 
 
Adesina et al (2013) (118) evaluated a broader set of child health interventions delivered at 
hospitals and health centers, but did not include diarrhea treatment. The importance of this model 
is its emphasis on bundling services. Methodologically, it used a translog function to calculate 
factor shares of different cost components. Facility level data were drawn from primary sources 
in six African countries, supplemented with indirect and direct cost data from WHO-CHOICE, 
and labor, consumables, and drug costs the OneHealth Tool. Results indicated a cost of $1.21 for 
a basic antenatal care (ANC) visit, or $4.81 for combined personnel, drugs, and consumable cost 
(personnel costs accounted for the largest share). Conclusions emphasized that the bundled cost 




4. Conceptual framework 
4.1 Definition and purpose 
A conceptual framework is ‘a diagram of proposed causal linkages among a set of concepts 
related to a public health problem’ (149). It ‘explains graphically or in narrative form, the main 
things to be studied – the key factors, concepts, or variables – and the presumed relationship 
between them (150)’. The development of a conceptual framework is vital for this dissertation to 
define a research question narrow enough for analysis, and relevant to current policy. The 
approach taken will be inductive, with key variables chosen according to existing literature to 
justify them, and arranged according to the conceptual structure of Andersen and Newman (1973) 
(119), with diagrammatic structure expanded from Shah (151). This section will describe the 
theory that is relevant for this dissertation, and outline the relationships between the variables that 
are relevant for the regression analysis.   
4.2 Health economics and economic evaluation 
Health economics is the science of making choices in the face of scarcity to promote health and 
prevent and treat disease. While scarcity is widely acknowledged in other sectors, it is often 
denied in the health sector while existing in many forms; global budgeting in the UK National 
Health Service (NHS), ability to pay in the USA, and systematic rationing in league table 
experiments such as occurred in Oregon (152). The health sector is also unique to other markets 
due to the extent of government involvement; uncertainty from patient, provider, and payer 
perspectives; imbalances of information between these parties; and significant presence of 
externalities (153). Analyses can have a positive or normative perspective, with positive 
economics describing observations about a research question, and normative economics 




Prioritization of health interventions is particularly relevant in LMICs both for national health 
budgets and for international development assistance (154). The number of interventions 
available to health systems planners in the marketplace exceeds capacity to afford all of them 
(155), new interventions are being developed (156), and others are gaining relevance as lifespans 
increase and new risk factors gain importance as societies progress through the ‘demographic 
transition’ (157) and face a ‘triple burden of disease’ (10, 11). The population of India is 
increasing – currently 1.21 billion and not projected to stabilize until mid-century at 1.72 billion 
(12). Lifespans have increased 11 years in the last three decades to 65 (14). In addition, 
prioritization between interventions delivered by the health system is vital to maintain equity, 
which is gaining in importance as the world becomes more inter-connected, supply and human 
resource constraints are addressed, and people become empowered to raise their expectations and 
demand (156).  
 
Despite the fact that government health expenditures are growing along with GDP (158), budgets 
are unlikely to be sufficient to provide universal coverage of a minimum number of services to 
these growing needs in the near future. In addition, current spending is very inefficient in terms of 
cost-effectiveness – for example, in India, open heart surgery is subsidized in national public 
hospitals (154), but ORS packets being used in only 26% of diarrhea episodes (16). Overseas 
international assistance for health is growing (159), particularly bilateral funding from the USA 
(160), and donors expect good return on their investment.  
 
Development and proliferation of economic evaluation methods and published studies are making 
evidence based priority setting more feasible in LMICs, with at least seven Health Technology 
Assessment (HTA) bodies forming in upper-middle income countries (154, 161). Economic 
evaluation is a sub-discipline of health economics that compares the costs and health outcomes of 
an intervention relative to an alternative scenario to assess the extent to which it is a good 
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investment, thus informing how to allocate limited healthcare resources. Three types of economic 
evaluation are available including cost-effectiveness analysis (CEA), cost-utility analysis (CUA), 
and cost-benefit analysis (CBA) (133).
23
 CEA and CUA are identical except in their methods for 
assessing outcomes. CEA measures outcomes in natural units, either health outcomes or clinical 
objectives that can be linked to health outcomes (such as contraceptive user generated). CUA 
measures outcomes in terms of generic metrics that combine morbidity and mortality into a single 
metric.
24
 The distinction between CEA and CUA is emphasized by Drummond et al (2005) (133), 
although the distinction was not made by the US Public Health Service (155) or WHO (162). 
Ratios resulting from CEA and CUA may be compared to a threshold to determine whether they 
are considered favorable (163), and are helpful for making decisions within specific budgets. 
CBA values outcomes in terms of monetary units, often in terms of willingness to pay, which is 
useful for allocating resources across budgets from different economic sectors. The advantage of 
CEA and CUA over CBA is that they make health the objective function of the health system, 
which is a widely accepted extra-welfarist assumption (164). CBA is grounded in economic 
theory, but willingness to pay may be tied to ability to pay and reflects non-health benefits of 
health interventions (133). 
 
India has had mixed success in addressing challenges in the development and use of economic 
evaluation. Data and analytic methods for economic evaluation in low- and middle-income 
studies is generally of low quality, but higher quality evidence from India is proliferating through 
the second and third editions of the Disease Control Priorities Project and other international 
collaborations (147, 165-168). Local capacity to produce evidence is being further developed 
with the creation of an International Fellowship on Health Technology Assessment to provide 
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 Cost minimization analysis is not included in this list as it is not considered an adequate form of 
economic evaluation by many economists. Relative costs between comparison strategies are not 
informative if it is not clear what the outcomes are of each. 
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 However, formal institutional structures are only at their formation stage 
for health technology assessment (169), and it follows that legal frameworks have not yet 
developed either. In addition, India has had difficulty in updating benefits packages and drug lists 
regularly; for example, the National List of Essential Medicines of India was updated in 2011, 
eight years after its previous version (60), where the WHO list of essential medicines is updated 
every 1-3 years (170).  
4.3 Philosophical underpinnings 
The philosophical assumptions of this dissertation are grounded in the ethical case for supporting 
child health interventions. Very little direct evidence exists on the ethical motivations of zinc 
treatment for child diarrhea; however, reasons for protecting child health are a subject of debate 
in the international health community.  
 Access to health care is often marginalized for children 
 Children are a vulnerable population 
 Zinc for child diarrhea can be a life-saving intervention 
 Diarrhea affects everyone, but disproportionately affects the poor 
 Diarrhea deaths are a solvable problem, despite their acceptance as inevitable by people 
in poverty 
 Saving child lives has intergenerational effects 
 
The case against prioritizing saving child lives exists in assumptions behind the age weighting 
function of the DALY formula (171). This perspective argues that young and old people depend 
on people between 15-50 years old for their health and survival both physically and emotionally 
(172). Other possible arguments are that people between 15-50 are the most economically 






productive in society and that they pay the taxes that support the health system, although these 
considerations are rejected by the GBD team as they have undesirable implications in terms of 
equity. 
 
However, the above arguments reflect a ‘human capital’ point of view, which can be countered 
from a variety of perspectives. Children are a vulnerable population (173), and the max-min 
principle of Rawls’ Theory of Justice is to improve the situation of the worst off in society (174). 
In addition, life-saving interventions are supported by the ‘rule of rescue’ (175), and zinc has 
been shown to be life-saving and effective in a variety of settings (50). However, it must be noted 
that the ‘rule of rescue’ refers to saving an identifiable child from imminent risk of death, when 
the same amount of investment could be used to protect all of the children in an entire community 
(173). In terms of vertical equity, diarrhea is a disease that preferentially affects the poor (4), with 
dysenteric diarrhea particularly affecting disadvantaged people (16), and principles of fairness 
give special priority to the worst off in society (176). Gujarat has levels of diarrhea treatment of 
59% (39),
26
 has levels of poverty around the national average (177),
27
 and the poorest quintile of 
people in India is more than twice as likely not to receive treatment for diarrhea as those in the 
richest quintile (16). 
 
This equity argument might be challenged from a utilitarian perspective according to the equity-
efficiency tradeoff argument. However, equity and efficiency are not necessarily mutually 
exclusive; a key conclusion of the Disease Control Priorities Project is that sometimes the most 
cost-effective interventions are also the most equitable (178), and the CMH report indicates that 
sometimes investment in LMIC health sector ‘pays for itself’ in terms of economic development 
benefits (176). The potential for solving diarrhea deaths can be seen in the global trend (Figure 1). 
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 Including ORS or gruel, but excluding increased fluid or other home remedies 
27
 The national proportion of people in poverty is 25.7%. The proportion of people in poverty in Gujarat is 
21.5% and is 30.4% in Uttar Pradesh. 
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Child health interventions have intergenerational effects as living healthy children grow up to 
have living healthy children, and the objective of the DAZT program is to stimulate a virtuous 
cycle. 
4.4 Continuum of cost-effectiveness analysis 
Sculpher et al (2006) proposed an iterative approach to guide the development of economic 
evaluation to inform policy making (179). These stages of economic evaluation that could be 
relevant to the Indian HTA body (180). 
 
1. Identify potentially relevant decision problems affecting prevention and treatment 
strategies affecting the Indian population. These questions could reflect priorities of the 
authorities of the Indian health system, international community, pharmaceutical 
industry, or the general public. To avoid imbalances in what research topics take priority  
encountered in some high income countries (181), priority setting criteria could be set 
according to those used by the WHO ad hoc committee (156). 
 Size of the disease burden 
 Reasons that the disease burden persisted 
 Adequacy of the current knowledge base 
 Cost-effectiveness of interventions and the probability of successful 
development of new tools 
 Adequacy of the current level of ongoing research and funding 
2. Funding of evidence synthesis and decision modeling to address questions about whether 
research should be conducted or the intervention should be adopted. In India, the 
evidence base available for modeling for many conditions can be expected to be thin, 
with disproportionate amounts of research targeted towards global priority diseases. That 
said, WHO-CHOICE and DCP2 models could serve as starting points for making 
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country-specific models (as in Chow et al (2007) (147)), with parameters that lack 
adequate data tested in sensitivity analyses. 
3. Formal research priorities should be set based on the modeling. Expected value of Perfect 
Information (EVPI) Analysis could be conducted to establish the key interventions to be 
evaluated and parameters to be researched (182, 183). EVPI is an analytical approach that 
is seldom used in LMIC research (184, 185), but is particularly relevant for that setting 
given the incomplete knowledge base for CEA modeling. 
4. One or more primary studies can be conducted with pragmatic economic evaluation 
conducted alongside. Traditionally, this stage has focused on Randomized Controlled 
Trial (RCT) evidence (179); however, our study emphasizes the importance of non-
randomized program evaluation to provide economic evaluation evidence using 
appropriate methods for controlling for confounders (86). 
5. Previously developed models can be updated with evidence from the primary studies.   
4.5 Example of Sculpher’s progression of economic evaluation 
As may be expected, the progression of research is often not as linear as described by Sculpher’s 
(2006) model (179), particularly in the case of international public health due to the wide 
diversity of decision making bodies, funding agencies, and epidemiological settings for which 
research is conducted. An augmented version of this progression is shown in Figure 2. The 
number of economic evaluations of zinc for child diarrhea is accumulating, and can serve as an 
example to illustrate the progression of research. The decision problem of whether to advocate 
zinc for child diarrhea was recognized in the early 2000s leading up to the 2004 WHO 
recommendation. This recommendation was preceded by a small randomized controlled trial to 
evaluate zinc paired with copper in a cohort of hospitalized patients (68). This study was followed 
by a decision tree model using available evidence; cost data from four Tanzanian dispensaries, 
case fatality rates from a published meta-analysis, and crude triangular distributions to model 
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uncertainty (99). Primary research on randomized control trials were then conducted in the 
hospital setting in the Philippines (87), and community setting in Haryana India (70). Modeling 
was then conducted using the interactive Lives Saved Tool (LiST), evaluating zinc with other 
diarrhea interventions (90). In this dissertation, evaluation of the DAZT program with real world 
data of a program at scale is conducted using a net-benefit regression to test the cost effectiveness 
of the program, and different treatment providers, followed by modeling of multiple bundles of 
interventions with the LiST tool.   
4.6 Conceptual framework 
A conceptual framework to describe the occurrence of economic costs to caregivers and cost 
effectiveness can be expanded from literature describing treatment seeking processes. The widely 
cited socio-behavioral model of treatment seeking for health services by Andersen and Newman 
(1973) (119) served as the starting point for developing the conceptual framework for this study, 
with the diagrammatic form of Figure 3, expanding on Shah (151). Treatment seeking is 
dependent on several interacting variables, including predisposing, enabling, and need factors – 
and economic costs to caregivers are possible if treatment is sought. Further, the intervention that 
is provided will be associated with a level of cost-effectiveness.  
 
Predisposing factors include demographic characteristics (household size and sex of the child), 
characteristics of the social structure (education of the father, education of the mother, and caste), 
and caregiver knowledge (about ORS and zinc). Enabling factors related to the household 
included wealth quintile and being part of a financing scheme [having a Below Poverty Line 
(BPL) card], and related to the community included the main variable of interest (phase of the 
DAZT program). Need factors included the duration of each diarrhea episode, and having blood 
in the stool. The source of care (public facility based provider, public community based provider, 
and private provider) and treatment given (ORS and zinc) are also included. Evidence to justify 
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inclusion of factors both expected to have significant and not significant relationships with 
treatment seeking, cost, and cost-effectiveness were drawn from the literature and hypothesized 
directions where evidence specific to diarrhea was not found (Table 2).  
 
Household size 
It is expected that expenditures per episode of diarrhea will increase with household size as 
having more collective resources may lead to higher expenditures per person according to 
severity. A study from rural Tamil Nadu found that spending on health per capita per year 
increased with household size (186), and household size is controlled for when evaluating 
correlates of catastrophic cost and economic cost burden in Bolivia (187). Having additional 
family members may facilitate taking the child in for treatment, increasing the probability of 
incurring a cost. Having more children in the house may increase the probability of having an 
episode as children are a source of infection. However, household size is rarely evaluated when 
evaluating factors associated with treatment seeking in other literature. It is expected that the odds 
and amount of costs of the program will be higher, diarrhea frequency will be about the same, and 
cost-effectiveness will be less favorable with larger household size. 
 
Gender bias 
There is a history of preferential treatment for boy children in Asia in the allocation of healthcare 
resources and timely care seeking (188), and this trend may be exacerbated as women become 
more educated (189). NFHS-3 evidence suggests that caregivers were more likely to seek care 
from public facilities for male children, although there was no gender bias in care seeking from 
private facilities (190). In addition, there was less of a delay in care seeking for male children 
(191), which may be associated with higher priority and expenditures. An evaluation of cost to 
caregiver according to child sex in rural Chennai found that caregivers were willing to pay more 
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to protect a male child from an episode ($1.42 for males, and $1.06 for females) (192),
28
 although 
gender bias was less important in the decision to seek care further south in Kerala (193). The 
GEMS study did not find a significant difference in amount spent on girls compared to boys in 
Kolkata India (95, 194). A study from West Bengal found that boys received care from qualified 
health professionals for common illnesses more often and sooner than girls, and more was spent 
on care for boys (195).
29
 It is expected that the odds of having costs and their amount will be 
lower for female children, although the probability of having an episode would be the same, 
leading to more favorable cost-effectiveness. 
 
Education 
In the Grossman model on the demand for health, it is argued that more educated individuals are 
more efficient producers of health (196). Mosely and Chen related this concept to child health by 
suggesting that the education of the mother and father influence care seeking and health care 
practices (197). More educated parents may be more able to recognize danger signs, understand 
disease process, and recognize the importance of preventive measures. More educated people 
often live closer to facilities and are better able to access higher levels of care (198). Less 
educated people may be more likely to forgo services. Both maternal and paternal education will 
be included in the models based on the rationale below. 
 
Paternal education: Paternal education was tested as the Mosely-Chen model argues that it 
influences attitudes and preferences for consumption goods (197), and a father's education plays 
an important role in earning income. Studies have found a direct relationship between a father's 
education and access to healthcare. Education of the father was associated with seeking care from 
a trained provider in Bangladesh (199, 200), and was associated with seeking care at home, a 
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 Inflated to 2013 US$ 
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 Illnesses included acute respiratory infection, diarrhea, and fever 
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pharmacy or vendor, or at medical centers in DHS data from 11 African countries (201). In terms 
of health outcomes, a greater proportion of deaths was found among children of illiterate fathers 
than more educated fathers in Bangladesh (202), although paternal education is not associated 
with stunting (as a proxy for health and nutrition) in Uganda (203). It is expected that probability 
of incurring costs will be unaffected among fathers with primary education, but higher among 
more educated fathers. In addition, more educated fathers may influence the mother’s preferences 
to spend more rationally (less on antibiotics and antidiarrheal medicines), and health outcomes 
will be better, leading to more favorable cost-effectiveness. 
 
Maternal education: Caregivers with some education are expected to be more empowered to 
seek care and spend on health care more rationally. In India, NFHS data indicate that maternal 
education was not associated with seeking care (190), but having high school education or above 
lowered the delay in treatment seeking (204). In addition, only caregivers with higher education 
were more likely to seek care from providers in general (191). However, the amount of education 
caregivers had did not affect the proportion with cost or amount of cost in the GEMS study (95). 
Caregivers with higher education were more likely to seek higher levels of care in China (198). In 
sub-Saharan Africa, having at least primary education was associated with treatment seeking at 
home or medical centers, although these caregivers were equally likely to seek care from 
pharmacies or vendors and traditional healers as people with no education (201). The decision of 
caregivers for home treatment was attributed to their ability to use health information wisely 
(201). In Bangladesh, mother's education was not associated with treatment seeking from trained 
providers (199). Finally, maternal education was associated with more favorable cost-
effectiveness of the skilled care initiative in Burkina Faso (111). It is expected that the odds of 
incurring a cost will be unchanged for mothers with primary education, but those with more 
education will be more likely to incur costs. More educated mothers will be able to manage costs 





The Indian caste system consists of scheduled castes, scheduled tribes, and ‘other backwards 
classes’.
30
 Scheduled castes are referred to as Dalits (untouchables), scheduled tribes are referred 
to as Adivasis and are thought of as the original inhabitants of regions of India, and ‘other 
backwards classes’ is a term used for other socially and educationally disadvantaged groups that 
do not belong to the first two categories. Individuals from these marginalized population groups 
may incur higher costs and have worse health outcomes due to discrimination and other physical, 
financial, and social constraints to accessing care. For example, children in scheduled castes are 
less likely to receive immunizations, and mothers are less likely to deliver in an institution (205). 
Caregivers of children of scheduled caste and other backward classes were more likely to seek 
treatment for diarrhea and tend to seek it earlier than the other children, although there was no 
effect for children from scheduled tribes (204). Given that there were differences in significance 
across these three categories in Malhotra’s analysis (204), they will be included as separate 
variables in the regression analyses. It is expected that scheduled castes and other backwards 
castes will be less likely to incur a cost and have worse health outcomes, although it is more 
difficult to predict the effect on the amount of cost or cost-effectiveness. If these caregivers seek 
care less frequently but have higher expenditures due to the severity of the episode, the average 
cost per episode could be either higher or lower than the average. 
 
Knowledge of ORS and zinc 
Knowledge of ORS and zinc is included as a proxy for program exposure, and may be a factor 
influencing a caregiver’s decision to seek care. NFHS-3 data indicated that lack of knowledge 
about ORS was associated with seeking care, but did not affect delays in seeking care (191), and 
it was assumed that the association of knowledge of zinc on care seeking or costs to caregivers 
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 There was no overlap in these three categories in DAZT data 
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would be similar. It is expected that knowledge of ORS and zinc will be associated with an 
increased probability of incurring a cost, more rational expenditures by caregivers, and a 
favorable impact on cost-effectiveness.  
 
Study phase 
The DAZT program was expected to lower expenditures on antibiotics and antidiarrheal 
medicines, and be cost-effective based on a model using cost data from dispensaries in Tanzania 
(99) and a trial from a community setting in Haryana India (70). An early study from a hospital 
setting did not find that zinc significantly reduced costs although the expected value for cost-
effectiveness was that it was cost saving in terms of reducing the incidence of diarrhea lasting less 
than or equal to four days (68). A recent study found that zinc and copper were not cost-effective 
in this setting (85). Since care seeking for diarrhea was predominantly from community settings 
in the DAZT program, it is expected that the program will show higher odds of incurring a cost, 
lower total costs, and more favorable cost-effectiveness through time.  
 
Below poverty line card 
It is expected that possession of a below poverty line (BPL) card was associated with lower costs 
and favorable cost-effectiveness as it can defray some of the expense and encourage caregivers to 
seek treatment. NFHS-3 data indicated that possession of a below poverty line (BPL) card was 
associated with care seeking for diarrhea (191), although the same dataset indicates that being 
part of a health scheme or insurance plan was not associated with seeking care from a public or 
private facility (190). A two-part model on NFHS data found that having a BPL card was 
associated with lower probability of expenditure for institutional delivery compared to families 
without one, although differences in the amount spent were not significant (206). Having a BPL 
card was included to represent financing mechanisms for diarrhea care, and was not considered 
redundant with wealth quintile as only half of caregivers in the poorest wealth quintile had a BPL 
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card. It is expected that having a BPL card will be associated with a reduced odds of cost, and 
exempt caregivers from paying fees at public facilities (207), although have little or no effect on 
amount at private providers. In addition, it may be associated with a higher likelihood of diarrhea 
episodes, having an unfavorable association with cost-effectiveness. 
 
Wealth quintile 
It is expected that wealth quintile would be favorably associated with treatment seeking and cost-
effectiveness of the program, although a mixed effect with amount of cost. NFHS-3 data indicate 
that wealthier caregivers were more likely to seek care and waited less time than those of the 
poorest quintile (191, 204). A more detailed analysis indicates that wealthier caregivers were 
more likely to seek care in the private sector, although care seeking from public facilities shows 
no difference relative to the poorest quintile (190). Wealth quintile had an upside down U-shaped 
relationship with cost in India in the GEMS study (95). The only available evidence on wealth 
quintile and cost-effectiveness in LMICs indicates that it has an effect for a skilled delivery care 
initiative in Burkina Faso (109). Wealth quintile will be included as a series of four variables 
generated by principal components analysis. The upside-down U shaped pattern observed in 
Rheingans et al (2012) is expected as households of higher wealth quintiles are more likely to 
spend more per episode as willingness to pay for treatment is associated with ability to pay, and 
households of the highest wealth quintile may have mechanisms for saving money. However, it is 
less clear whether cost-effectiveness is expected to be more favorable as they may also be more 
effective at preventing episodes from occurring. 
 
Duration of episode 
It can be expected that treatment seeking is associated with longer duration of diarrhea as 
caregivers recognize the need for help in alleviating symptoms. Longer duration of diarrhea was 
associated with seeking care outside the home in Burkina Faso (208) and Bangladesh (209). 
43 
  
Duration of diarrhea will be included as a continuous variable, and is expected to be associated 
with a higher probability and amount of cost. As all children with diarrhea have an episode by 
definition, an unfavorable impact on cost-effectiveness is expected. 
 
Symptoms 
It is expected that caregivers of children with symptoms indicating severity will be more likely to 
seek external care. Number of symptoms of severe illness was associated with seeking care in the 
Bondo district of Western Kenya (210). In Burkina Faso, clinical symptoms were associated with 
treatment seeking (fever, vomiting, anorexia) (208). Evidence from Bangladesh indicated that 
caregivers had the highest likelihood of seeking care when child had respiratory distress, rapid 
breathing, or had several symptoms at the same time (209). In India, blood in the stool was 
associated with treatment seeking from private providers (190). Number of symptoms, difficulty 
in breathing, and fast breathing were tested in our models, although were excluded as they did not 
lead to convergence. Therefore, blood in the stool is used to represent symptoms as a proxy for 
severity, and is expected to be associated with higher probability and amount of cost, and less 
favorable cost-effectiveness. 
 
Place of care seeking and type of care provider 
It is expected that higher costs will be associated with private providers since 80% of spending in 
the private sector is out of pocket (67), where only nominal fees are charged by public providers. 
In addition, it is expected that costs will be higher at public facilities than public community 
health workers since transportation costs will be higher and there will be more wages lost. A 
variable representing seeking care from public facilities will include primary health centers and 
auxiliary nurse midwives. A variable representing public community based providers will include 
Accredited Social Health Activists (ASHAs) and Anganwadi workers (AWWs). Finally, a 
variable representing private providers will include private doctors, nursing homes or private 
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hospitals, mobile clinics, chemists, traditional healers, and charitable, non-governmental 
organization, and trust hospitals. It is expected that seeking care will have increased odds and 
amount of cost, and less favorable cost-effectiveness as all children will have diarrhea and incur 
cost. 
 
Treatment with ORS and zinc 
It is expected that being given ORS and zinc will be associated with a higher odds of cost, a 





It is possible that maternal age would have an important impact on cost or cost-effectiveness as 
older households may have more financial stability, and that older mothers may be more skilled 
in managing diarrhea leading to less treatment seeking outside of the home. Indeed, evidence 
from the National Family Health Survey third edition (NFHS-3) indicated that older mothers 
were found to have less of a delay in seeking care for their child than mothers under 20 years old 
(204). However, this data also indicated that age of the mother did not matter for whether care 
was sought for diarrhea (190), which was confirmed in a survey of four rural subdistricts of 
Chittagong and Jessore districts (199). No direct evidence exists on the cost of treating diarrhea 
by maternal age. If good practice can be assumed, it can be expected that prescriptions will be 








Studies have found that child age is an important factor in cost of seeking care for diarrhea. 
Caregivers were less likely to seek care (190) although equally likely to incur direct costs (95) for 
younger children in India. A study from Nepal found that child age was not significantly 
associated with treatment seeking (211); and evidence from Bangladesh was mixed between 
showing no association (209) and caregivers being more likely to seek care from trained health 
providers for young infants (200). Care seeking from higher level providers was observed for 
children of younger ages in China (198). In the context of the DAZT dataset, the direction of the 
effect of child age on cost and cost-effectiveness is not clear. It may not be significant as all 
patients were infants and it is not expected that older infants will be different from younger 
infants (similar to ‘truncation by Vyas and Kumaranayake 2006) (212). Given this rationale, child 
age wills be excluded from the model. 
 
Relevant variables that were impossible to evaluate 
Breastfeeding 
Mothers that breastfed their children were more likely to take them to higher level sources of care 
relative to those that did not (198). Breastfeeding is associated with incidence and severity of 
diarrhea (213) and is associated with reduced mortality (4). It is expected that breastfeeding 
would reduce costs as well as number of episodes, leading to improvements in cost-effectiveness. 
 
Perceived severity of diarrhea 
Caregivers can be expected to spend more on episodes of diarrhea perceived to be severe. In 
Nepal, perceived illness severity was associated with seeking appropriate care, but not timing of 
care (211). Illness severity was also found to be associated with treatment seeking in Nairobi 
slums (214). It is expected that our data would show worsened cost-effectiveness with disease 
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severity as more would be spent on more severe episodes, and no analysis will be done on 
probability of death or long term sequelae. 
 
Distance to health provider 
Distance to a health provider can affect a caregiver’s decision to seek care due to time, energy, 
and financial constraints. NFHS-3 data indicated that if distance to a health facility was a major 
problem, caregivers were less likely to seek care from a public provider (190), although distance 
was not associated with the timing of care seeking (204). It is expected that the program would be 
less cost-effective for people living further from health providers. 
 
Living in a rural area 
It can be expected that living in a rural area, where health providers are more sparsely distributed, 
would affect the probability and costs of seeking care. NFHS data indicate that living in a rural 
area was not associated with the decision to seek care, but rural caregivers wait longer than urban 
caregivers before taking their child to a provider (190, 204). However, it is not possible to 
evaluate urban versus rural households as urban villages were excluded from the survey. It is not 
expected that urban or rural differences would have an effect both in terms of transportation and 
wages lost as well as user fees. 
 
Living in a deprived neighborhood 
It may be expected that caregivers that live in deprived neighborhoods will be less able to access 
health services, have less money to spend on care, and be engaged in fewer practices to limit the 
incidence and severity of episodes. Evaluating Demographic and Health Surveys from 11 
countries in sub-Saharn Africa, living in a deprived neighborhood was found to be associated 
with a lower likelihood of seeking care (201). The DAZT study area was chosen as it was 
underserved by the health system overall; however, the degree of deprivation of individual 
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villages and neighborhoods was not assessed. It is expected that the program would be more cost-
effective for individuals in deprived neighborhoods from the perspective that fees may be waived 
or reduced, although these people may be less receptive to messages about preventing diarrhea or 
less able to implement them. 
 
Birth order 
Birth order can be expected to be associated with treatment seeking and costs as parents may be 
willing to spend more on their firstborn, and more efficient with their spending for subsequent 
children. Evidence is mixed about whether birth order is associated with treatment seeking. 
NFHS data indicate that birth order was not associated with the decision to seek care, or with the 
timing of care seeking (204). However, caregivers were more likely to seek care from trained 
providers for firstborn than higher order children in Bangladesh (199). It is not possible to include 
this variable in our study as information was not collected beyond limiting the survey to the 
youngest child in the household. It is expected that caregivers would incur lower costs, although 
diarrhea episodes would be more prevalent for higher order births. 
 
Antenatal care of the mother from trained providers 
It is expected that antenatal care of the mother from trained providers makes them more receptive 
to public health messages such as those from the DAZT program. In Bangladesh, women who 
received antenatal care were more likely to seek care from trained providers (199). It was not 
possible to include this variable in regressions as data were not collected in the DAZT program, 
but would be expected that costs would be lower and cost-effectiveness would be more favorable 






Place of child delivery 
Place of child delivery might be expected to be associated with cost or cost-effectiveness, as 
mothers that deliver in the home may be less likely to seek external care for diarrhea treatment. In 
India, being born in a public hospital was associated with seeking care from a public or private 
source (190). It would be expected that the program would be more costly, but also more cost-
effective for caregivers that deliver in facilities. 
 
Caregiver working away from the home 
Caregivers working away from the home may be less able to take their child to see a treatment 
provider for diarrhea every time that it is needed, particularly since diarrhea is a frequent 
occurrence. In the NFHS-3, a caregiver working away from the home was less likely to seek care 
outside of the home for a child with diarrhea (191). It was assumed that all categories of caregiver 
occupation except self-employed were away from the home to approximate this binary variable 
for the regression analyses.   
 
Other variables 
Three variables speculated by Gao et al (2012) (198) as being associated with treatment seeking 
for diarrhea including expected cost of care according to perceived diarrhea status, timing of care 
seeking, and frequency of diarrhea episodes in the previous two weeks. It is expected that people 
will spend more for episodes perceived as being more severe, although amount spent will depend 




Evidence of the association of religion and care seeking is mixed. NFHS data revealed that 
Muslims were marginally more likely, Christians were less likely, and Sikhs were equally likely 
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to seek care as other caregivers; although religion did not matter in the timing of care (204), and 
religion was not associated with choice of public or private care (190). Other studies from India 
(211) and rural Bangladesh (199) indicate that religion is not expected to be associated with 
treatment seeking, cost, or cost-effectiveness. 
 
Number of antenatal visits 
It might be expected that number of antenatal visits may be related to the value that a caregiver 
places on medical care. However, evidence from Nepal indicates that number of antenatal visits is 
not associated with appropriate or prompt careseeking for childhood illness (211).  
 
Number of siblings 
It may be expected that number of siblings would be associated with treatment seeking and cost 
as larger households may have more collective resources to be able to afford care, and older 
children may be able to supervise younger children while the parent is seeking care for an ill 
child. However, NFHS-3 data showed that number of siblings was not associated with the 
decision to seek care, or the timing of care seeking (204). Data on number of siblings was not 
collected, and it is also expected that this variable would be redundant with household size. 
 
Birth order 
Birth order may be expected to be associated with cost or cost-effectiveness as more experienced 
mothers may be more effective in preventing episodes of diarrhea, and more efficient in 
managing them. However, the association of this variable with treatment seeking was not 
significant in India and Bangladesh (199, 211). In addition to data not being collected in the 






History of death of a sibling 
Having a history of death of a sibling may indicate a lower capacity of being able to care for a 
child with diarrhea. However, a learning curve may also be possible. No association was found 
between this variable and treatment seeking in a study in Bangaldesh (199), and no data were 





5.1 Study information 
5.1.1 Setting and study design 
Gujarat is in the ‘tribal belt’ of the north of India which, along with Madhya Pradesh and Uttar 
Pradesh, contributes to half of the diarrhea burden in India (215). 57% of people in Gujarat live in 
rural areas (20), and most people who live there have no access to a toilet (215). In 2010, the 
DAZT program was introduced in the 6 districts of Gujarat and 12 districts of Uttar Pradesh 
(216). Given that the intervention is implemented on a system-wide level, a ‘before and after’ 
study design was chosen (217), which compares the costs and health outcomes associated with 
the DAZT intervention with those that preceded the intervention. Outcome indicators include 
caregiver knowledge, prevalence of diarrhea, treatment seeking, source of care, use of ORS and 
zinc, cost, and cost-effectiveness. 
5.1.2 Data collection 
Data collection for the household survey involved surveys at the starting point, midpoint, and 
endpoint of the study; which were administered to clusters of random samples of households. 
Each survey elicited information on caregiver’s knowledge of diarrhea management, illnesses in 
the past two weeks, socioeconomic status, and household data (218). Surveys were administered 
by community health workers to caregivers in the caregiver’s home. In addition, a provider 
assessment survey was conducted in 2012 at a random sample of primary health centers (PHCs) 
to characterize the knowledge and practices of providers with regard to diarrhea and diarrhea 
treatment. Data on economic costs were obtained prospectively throughout implementation, based 
on financial records of international non-government organizations working with public and 
private sector partners to promote and improve access to zinc.  
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5.1.3 Sampling  
The primary sampling unit for the surveys for the cluster randomized sampling strategy was the 
village. Villages were identified from a 2001 census, excluding urban villages. A village was 
randomly selected using an index finger, and villages were chosen moving through the list of 
households until 33 villages were chosen in total. 50 households were interviewed in each cluster, 
assuming that half would have a child under 5.
31
 All households that had a child between 2-59 
months old with diarrhea were eligible for the intervention. 
5.1.4 Ethical approval 
For the main study, ethical approval was obtained from the JHSPH Institutional Review Board to 
assess scientific merit and allow contact with human subjects. Economic evaluation activities 
were deemed to be ‘not human subjects research’.  
5.2 Cost analysis 
In Paper 1 of this dissertation, economic costs to caregivers were evaluated with descriptive 
statistics accounting for the clustered survey design. Principal components analysis was 
conducted to facilitate evaluation according to wealth quintile in both descriptive statistics and 
regression analysis. Regression methods were characterized according to a two part model, with 
logistic regression evaluating the odds of incurring an economic cost, and generalized linear 
modeling evaluating the amount of economic cost.  
5.2.1 Descriptive statistics 
Descriptive statistics were calculated according to medians, means, confidence intervals, and p-
values reflecting the extent of difference between study phases. Stata svy commands were used to 
account for clustering with F-tests to evaluate significance in differences between groups. 
                                                          
31
 Average cluster size was 59 in the starting point survey, and 25 in the endpoint survey 
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5.2.2 Principal components analysis 
Principal components analysis was used to categorize caregivers according to wealth quintile 
using established methods (212, 219). While specific rules do not exist for selecting variables for 
this analysis, broad categories included durable asset ownership, housing characteristics, and 
access to basic services based on precedent (219). To avoid illogical rankings (220), only 
variables with a prevalence between 5%-95% were retained. While these thresholds are arbitrary, 
they are consistent with rules of general inference to define a value with low probability. 
Eigenvalues were generated in Stata, which finds linear combinations of variables that capture the 
maximum amount of remaining uncertainty in the data for each component. The component with 
the greatest eigenvalue was selected for creating a wealth index, as Filmer and Pritchett argue that 
higher order components are not important and convention has become to create wealth indices 
on only one component (219). Factor loadings were assessed to determine what variables aligned 
the most closely with the principal component, and evaluate whether its representation of wealth 
had face validity. Caregivers were divided into quintiles, which were used as dichotomous 
variables for regression analyses. The scale was validated according to a Cronbach’s alpha greater 
than 0.6. 
5.2.3 Regression methods  
To evaluate economic costs to caregivers, a two-part modeling approach was taken. The first 
equation used a logistic specification, with a binary variable representing the occurrence of cost 
as the response variable. Logistic was chosen over probit as its coefficients are more interpretable 
and the first and second equations are not explicitly linked, which usually requires a normally 
distributed error term. Coefficients ( were calculated according to included parameters (x). This 












          (1) 
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Equation 1 was paired with a linear regression to model the amount of cost to caregiver. As 
various transformations did not achieve a normally distributed error term,
32
 and costs had a right 
skew, the second-part equation on amount of cost used a generalized linear model (GLM) with a 





All regression equations account for clustering as testing data indicated that inferences were 
affected (significance for some coefficients disappeared when clustering was accounted for), and 
sampling was conducted according to a cluster design. 
5.3 Steps to conducting a cost-effectiveness analysis 
The cost-effectiveness analyses for the second and third papers were conducted according steps 
drawn from Drummond et al (2005) (133), Gold et al (1996) (155), and Consolidated Health 
Economic Evaluation Reporting Standards (CHEERS) guidelines (221) – adding calculations of 
statistical power using equations defined in Glick (2011) (135). 
1. Define objectives of the cost-effectiveness analysis 
2. Identify audience for the study 
3. Determine statistical power 
4. Choose analytical approach 
5. Define perspective of analysis 
6. Describe intervention components 
7. Define the counterfactual 
8. Define the implementation period 
9. Define time horizon 
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 Transformations tested include natural log, reciprocal, square root, and inverse cube root.  
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 Zero inflated Poisson regression is ruled out as costs in econometric modeling are a continuous variable 




10. Choose discount rate  
11. Define cost components 
12. Define effectiveness measures 
13. Choose methods for accounting for uncertainty 
14. Define sensitivity analyses 
15. Define threshold for cost-effectiveness 
16. Describe presentation of results 
5.3.1 Objectives of the cost-effectiveness analysis 
The research question for the Paper 2 of this dissertation is whether the DAZT program is cost-
effective relative to the status quo represented by initial conditions in the area, which is classified 
by Gold as a ‘what is’ study (155). Paper 3 evaluates whether bundled diarrhea interventions are 
cost-effective relative to initial coverage levels in conservative and universal scale up scenarios, 
representing a ‘what if’ study (155). These questions will be answered with an aim to inform 
decisions faced by the Indian Ministry of Health and international funding organizations (154, 
222) about strategies for scaling up zinc supplementation for child diarrhea relative to other 
investment options. 
5.3.2 Audience for the study 
The audiences for the study include the Indian MHFW, essential drug list and formulary 
developers, non-governmental organizations, and international funding agencies. The MHFW is 
developing a HTA organization (169), and these studies will contribute to the body of knowledge 
available for broadly assessing the public health system. The 2011 National Essential Medicines 
List currently includes zinc sulfate syrup (58), but dispersible zinc tablets are recommended by 
the MHFW (59), and the DAZT program used the latter. In addition, zinc is not listed in the 
National Formulary of India for the treatment of child diarrhea (223). Micronutrient Initiative and 
FHI-360 may promote the program in other areas with results from this study. Economic 
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evaluation can also guide budget allocation decisions of international funding agencies such as 
the BMGF, Global Fund, or other overseas aid programs (222). 
5.3.3 Power calculation 
Equations to determine statistical power and sample size requirements for economic evaluation 
have been established (134, 135), although are rarely used in the literature. In the case of the 
DAZT program, as is common for clinical trials literature, sample sizes were calculated for the 
effectiveness outcome rather than for cost-effectiveness, leaving the option of determining the 
power with which a meaningful difference can be detected. A distinction between calculating 
these indicators for a clinical endpoint and for calculating them for a cost-effectiveness endpoint 
is that instead of comparing outcomes across study arms or phases, the incremental cost-
effectiveness ratio is compared to a ceiling ratio. With no established rules about levels of the 
ceiling ratio for Incremental Cost-Effectiveness Ratios (ICERs) measured in natural units, a wide 
range of ceiling ratios were considered in sensitivity analysis. In addition, sensitivity of results to 
variations in other parameters in the formula was tested. Formulas were used to calculate power 
with different sample sizes and different standard deviations for costs and effects in each phase 
(adapted from Glick et al (2011) (135) supplementary material) (Box 1). Cost and effect 
differences and associated standard deviations were drawn from a previous study conducted in 
Haryana India (70). 
5.3.4 Analytic approach  
Of the types of economic evaluation available, cost-effectiveness analysis was used to be 
consistent with other studies in the literature and avoid controversial valuations of health 
outcomes in monetary terms. For Paper 2, a net-benefit regression was calculated according to 
methods developed by Hoch et al (2002) (86). The outcome variable in this analysis was the 
absolute net benefit statistic for each individual patient (i) using cost and effectiveness data from 
individual patients. To calculate net-benefit, effects (E) were multiplied by the ceiling ratio (), to 
57 
  
which costs (C) were added. This modification of the net benefit statistic was made since effects 
were measured in terms of an unfavorable health outcome (episodes of diarrhea), instead of 
favorable health outcomes that are conventional in the literature to this point. 
iii CE*)NMB(E            (2) 
Program costs were distributed across patients in the intervention phase, and were scaled 
according to population size and time frame. Using a reference case and series of plausible 
estimates for  (section 6.6), columns of net benefit statistics were calculated as the dependent 
variables for a series of regression analyses.  
 
The next step was to calculate simple regression results for each covariate. The distribution of net 
benefit statistics was tested for normality, and generalized linear model specifications were used 
to satisfy regression assumptions since normality did not hold. Covariates included a binary 
variable (t) to represent treatment (the intervention phase), with its associated coefficient () 
representing the incremental net benefit of the program. 
iii tNMByE   )( 3         (3) 
Additional predictors () were added to equation 3 to calculate incremental net benefit controlling 
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       (4) 
Next, a fully-interacted multiple linear regression was formulated, with incremental net benefits 












      (5) 
In all of these equations estimating net-benefit, the p-value can be used to construct a CEAC. 
Since p-values given in regression analysis are two-tailed, and one-tailed p-values are needed for 
constructing CEACs, p-values were divided by two (111). Unadjusted and adjusted CEACs were 
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presented together in the same figure to show the impact of controlling for confounding. These 
curves were accompanied by tables that present incremental net benefits with p-values showing 
the significance of the difference from different values of the ceiling ratio. Survey data from the 
starting point and endpoint of the study were compared as program costs are not available for 
costs at the midpoint. 
 
Analysis in Paper 3 was conducted using an ingredients approach for costing, outcomes generated 
with the Lives Saved Tool, and uncertainty accounted for using probabilistic sensitivity analysis. 
Each of 11 interventions was evaluated independently, as well as in bundles of interventions that 
could be provided together in the health system. 
5.3.5 Perspective of analysis 
The cost of the DAZT program is calculated from the societal perspective according to Saving 
Newborn Lives (SNL) guidelines and standard textbooks (133, 155, 224), to inform broad 
decisions about the allocation of resources in the health sector. The societal perspective reflects 
all of the costs and effects affected by the intervention, regardless of who receives them. The 
main reason for using the societal perspective is that it makes results comparable to others in the 
literature (155). Costs included are those incurred by implementing agencies, government 
providers, and households. DALY weights used in the third analysis of this dissertation reflect the 
valuations of experts at the WHO (225).
34
  
5.3.6 Intervention components 
Zinc was introduced and ORS use was scaled up to treat diarrhea in children 2-59 months through 
the Diarrhea Alleviation through Zinc and ORS Therapy (DAZT) program over four years in six 
districts of Gujarat (Table 1). Health workers and managers in the public sector and pharma reps 
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 Weights according to diarrheal severity have become available in the most recent edition of the GBD 
study, although our survey did not classify diarrhea according to severity 
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in the private sector were trained in diarrhea epidemiology, treatment, and product advocacy; and 
incentives were established to stimulate prescribing and generate demand. Pharmaceutical 
companies and key stakeholders were convinced to finance and produce zinc, and supply chains 
were developed to ensure availability of zinc and ORS within communities (226).  
 
Public sector management was provided by Micronutrient Initiative, an international non-
governmental organization (NGO) based in Canada. MI worked with the government of Gujarat 
to develop policies to support the introduction of zinc, and procured zinc using its own tender 
scheme until the state developed the capacity to procure zinc and ORS on its own. MI organized 
and managed training of government cadres of health workers including medical officers (MO), 
auxiliary nurse midwives (ANMs), ASHAs, and Anganwadi workers on use of zinc and 
appropriate diarrhea management. 
 
Private sector support was led by FHI-360, an international NGO based in North Carolina. The 
principal providers targeted in the private sector were drug sellers/chemists and rural medical 
practitioners (RMPs) in rural areas. At facilities, DAZT corners were a key feature of private 
sector provision, which were staffed informational booths to create awareness and remind 
providers to prescribe zinc. Key opinion leaders in the medical community and pharmaceutical 
representatives of local NGOs were trained and supplied with zinc and ORS to enhance further 
changes in prescribing practices. 
 
In both sectors, each packet of ORS and zinc and referral to higher levels of the health system 
was recorded by providers, results were communicated to supervisors through SMS messaging, 
and program reports were validated against data registers. Supportive supervision was provided 
through monthly meetings, monitoring of field visits, and working with new staff due to high 
levels of attrition. 
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5.3.7 Counterfactual scenario 
Different approaches to defining counterfactual scenarios have been advocated for economic 
evaluation including a ‘do nothing’ strategy for ‘generalized cost-effectiveness analysis’ (gCEA) 
to allow the WHO to compare different interventions free from health systems constraints (227). 
However, a gCEA approach is less useful in a national context as it assumes that budgets can be 
reallocated easily, which is often not the case. Investment decisions are also made by comparing 
an intervention to the status quo or next best alternative. The most comprehensive approach to 
economic evaluation of a single intervention is to compare all pairs of possible interventions 
(including a ‘do-nothing’ approach) in an investment algorithm, although this is rarely done in 
practice (155). The counterfactual for this dissertation was status quo conditions existing at the 
starting point of the study. 
5.3.8 Implementation period 
The implementation period for the DAZT program was two years to reflect changes between 
initial conditions and the program when it was fully scaled up.  
5.3.9 Time horizon 
The time horizon in the second analysis was assumed to be the same as the implementation period 
since long term sequelae (cognitive deficits, stunting, obesity, and associated conditions such as 
cardiovascular disease and diabetes (28)) are not considered due to time constraints of the 
research. The third analysis had a five year time horizon, reflecting previous work (90), funding 
cycles such as for the Global Fund (228), election cycles such as for the Lok Sabha,
35
 and to be 
consistent with conventions in other evaluations (90). 





5.3.10 Discount rate  
Discounting is defined as ‘reducing the value of each variable in each future year by an amount 
that increases the further in the future each year is’ (130). The rationale for discounting is that 
people prefer to receive benefits in the present rather than in the future. All standard texts 
recommend a 3% discount rate (88, 130, 133, 155), which is the rate of return on ‘riskless’ 
investments such as government bonds. Both costs and health outcomes should be discounted at 
the same rate based on two main arguments: 1) the consistency argument of Weinstein and 
Stason, and 2) the Keeler and Cretin paradox (155). The consistency argument is that the discount 
rate for costs and health outcomes should be the same to be consistent with each other, and 
because it is possible to translate health into wealth and vice versa at any point in time. The 
Keeler and Cretin paradox states that if benefits are discounted at a lower rate than costs, then 
implementation of a program will be delayed indefinitely (155). For paper 2, a discount rate of 
3% was used to annualize capital costs, and was used to discount recurrent costs projected into 
the future in Paper 3.  
5.3.11 Cost components 
Cost components included both program costs for public and private sector NGOs, and economic 
costs to households. Program costs were divided into capital costs and recurrent costs, with data 
derived from program records, primary sources, and interviews with individuals responsible for 
implementation. Capital costs were annualized using figures from Drummond et al (2005). 
Consumer price indices from the International Monetary Fund (IMF) were used to inflate costs to 
the current year (229), which were converted to US$ using exchange rates from OANDA.com 
(230). Incremental government provider costs were derived using reported estimates of time spent 
on the provision of diarrhea treatment services by public sector providers. Economic costs to 
caregivers for diarrhea treatment of the episodes in the last two weeks were determined according 
to data collected through household questionnaire, and consist of direct medical costs of 
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treatment, direct non-medical costs (transportation), and indirect costs (wages lost by caregivers) 
(95). 
5.3.12 Effectiveness measures 
In the second analysis, effectiveness was measured in terms of episodes averted as it was 
impossible to determine which specific children would die given the lack of follow up. In the 
third analysis, health outcomes were derived from incremental changes in coverage based on 
DAZT achievements and levels of DPT vaccine coverage expected for other vaccines. These 
values were inputted into the Lives Saved Tool to estimate the incremental number of lives saved 
from the study’s start in 2011 and linearly extrapolated to 2015 (90). The years of life lost (YLL) 
component of Disability Adjusted Life Years DALYs was calculated using the standard formula 
from the Global Burden of Disease study (231). A life expectancy estimate was taken from WHO 
life tables representing the midpoint between 1-4 years old (232). A discount rate of 3% was 
used, excluding age weighting to be consistent with the DCPP second edition (130).  
5.3.13 Methods for accounting for uncertainty 
Methods for accounting for uncertainty include parametric inferences for Paper 2, and 
probabilistic sensitivity analysis for Paper 3. The first step in probabilistic sensitivity analysis 
involved defining probability distributions for each input parameter. Beta distributions were 
appropriate for parameters representing probabilities as they were bounded by zero and one. 
Gamma distributions were used for cost parameters as they are bounded by zero and have a 
positive skew. Random samples were drawn from the set of distributions, calculating the total 
cost, and repeating this process a large number of times. The number of iterations was set at 1,000 
according to WHO guidelines, with the rationale that this number of resamples would adequately 
fill the tails of the outcome distribution (233). Confidence intervals were determined using non-
parametric bootstrapping using these stochastic outputs. 
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5.3.14 Sensitivity analyses 
Sensitivity analyses were performed according to different values of the ceiling ratio, and 
different model specifications in Paper 2 of this dissertation. Paper 3 presented scenarios 
according to each intervention evaluated individually, the complete bundle of interventions 
provided together, bundles delivered according to different delivery channels, and different 
formulations of DALYs. 
5.3.15 Threshold for cost-effectiveness 
Use of the ceiling ratio is discouraged by some researchers as it can lead to recommendations for 
uncontrolled growth of new interventions approved in the health sector (234). In addition, cost-
effectiveness acceptability curves have been promoted as a means for presenting cost-
effectiveness results according to a spectrum of thresholds, allowing decision makers to choose 
which is the most appropriate for their context (235). However, the case has been made for an 
explicit definition of the ceiling ratio, and several approaches exist for its formulation (163). Per 
capita Gross National Income, or some multiple thereof, is a common threshold used in existing 
literature. Drake has proposed a universal threshold to enhance equity in funding decisions that 
accounts for the globalization of funding in public health, although a specific definition of this 
threshold has not yet been attempted (222). Drake proposes that this value could be based on 
humanitarian principles, a review of historical spending and gains from international aid, a 
consensus list of widely accepted services, or the per capita GDP of the world’s poorest countries 
(222). 
 
Definitions of the ceiling ratio are only based on weak rationale when cost-utility analysis is used 
(163), and become even more difficult when cost-effectiveness analysis is conducted using 
natural units as outcomes. For Paper 2 of this dissertation, an approach to defining the ceiling 
ratio was taken using outputs from the LiST tool. The per capita GNI of India was multiplied by 
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the number of DALYs per death averted and the number of deaths averted per episodes averted, 
producing a value of $14.80 per episode of diarrhea averted. 
5.3.16 Presentation of results 
Results were presented as regression coefficients, net-benefit statistics, and incremental cost-
effectiveness ratios with bootstrapped confidence intervals. Cost-effectiveness acceptability 
curves (235), which plot the probability that an intervention is cost-effective according to 
different levels of the ceiling ratio, were presented using p-values from regression equations.  
5.3.17 Software  
Three software packages were used including Stata for descriptive statistics, principal 
components analyses, and regression analyses; Microsoft Excel using a macro written in Visual 
Basic for Monte Carlo Simulations; and the Lives Saved Tool to project deaths averted from 
coverage levels. The Visual Basic macro was adapted from one written by Chris Bombardo for a 
separate model (236), which has been used in subsequent research (237). There was no need to 
validate this macro as it relies on standard Excel formulas to perform the Monte Carlo 





6. Paper 1 
Economic costs to caregivers of zinc and ORS treatment of diarrhea among children under 
5 in rural Gujarat India: findings from the Diarrhea Alleviation through Zinc and ORS 
Treatment program at scale 
Introduction: Diarrhea is a leading cause of mortality among young children in India although 
few receive the recommended treatment. The Diarrhea Alleviation through Zinc and ORS 
Therapy (DAZT) program was initiated in Gujarat to increase coverage of these interventions 
through public and private providers at scale. This study evaluates the economic impact of the 
DAZT program on caregivers of children with diarrhea in the past two weeks.  
Methods: The DAZT program evaluation took a before-and-after study design using a two-stage 
cluster cross-sectional survey. Factors associated with the odds of caregivers incurring economic 
costs and their amounts were evaluated in a two-part modeling approach.  
Results: The DAZT program lowered unadjusted economic costs to caregivers from $3.71 to 
$2.26 assuming the two years of the study. Per million people, costs of diarrhea treatment were 
lowered by 53% to $595,898. Controlling for covariates, the program was not associated with a 
change in odds of incurring an economic cost, and was associated with a reduction in economic 
cost of $1.49 (95%CI $0.17-$2.80). Cost per person that sought care from private providers was 
reduced by 40%, particularly among private doctors.  
Discussion: Introduction of zinc reduced the economic burden of diarrhea treatment on 
caregivers in underserved rural areas of Gujarat. Treatment seeking from public community based 
services both saved money to caregivers and took pressure off of higher levels of the health 
system. In addition, care was sought more efficiently from the private sector, with an increase in 
use of private doctors.  




Diarrhea is the fourth leading cause of mortality in children under five (238), accounting for an 
estimated 700,000 deaths globally each year (5). The burden of disease for diarrhea across all 
ages totals 282,982,000 Disability Averted Life Years (DALYs), which is 11.8% of the total 
Global Burden of Disease (6). If priority interventions are scaled up to 80% coverage, and 
immunizations are scaled up to 90% coverage, 95% of diarrhea deaths could be eliminated by 
2025 at a cost of $6.715 billion, where no action would result in an additional 1.5 million child 
deaths per year (239, 240). However, little evidence exists on the economic costs of diarrhea 
treatment to caregivers in settings where it is needed most. 
 
India accounts for 29% of deaths due to child diarrhea worldwide (5), where one in ten children 
experience an episode in any two week period (16). However, India is lagging behind in coverage 
of essential treatments for addressing this burden. Oral Rehydration Salts (ORS) have been 
available since the 1970s and their use could eliminate 93% of diarrhea mortality (34); however, 
coverage in India remains low at 26% in 2005/6 (16). National (59) and global (41) guidelines 
call for the therapeutic use of zinc for the management of acute diarrhea in children under 5, and  
several meta-analyses indicate that zinc reduces diarrhea duration, severity, subsequent episodes, 
treatment failure, hospitalizations, incidence, prevalence, and probably mortality (44, 50, 51, 63, 
241, 242). However, zinc has yet to be widely introduced and coverage remains at less than 1% in 
most areas of India (16).  
 
Part of the problem is that there is little investment in health care in India. Average annual public 
and private health expenditures per capita are $59-$61 (excluding investment in water and 
sanitation interventions) (14, 243), with 86% of private expenditure being out of pocket (244). In 
Gujarat, only 3.8% of total household expenditure is spent on out of pocket payments for health 
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services (245). Despite the fact that zinc and ORS cost very little, low expenditures may be 
indicative of the low priority that caregivers place on seeking care for medical problems, and this 
neglect can affect households economically.  
 
Prompt and appropriate treatment is important to avoid high costs associated with hospital care 
and adverse health outcomes. Few studies exist to estimate the costs of diarrhea management and 
treatment to caregivers in India (95, 246), which may exact substantial economic burden to 
households when full direct and indirect expenditures are taken into account (inpatient and 
outpatient medical costs of rotavirus diarrhea are between $41-72 million in India each year 
(247)). These costs are particularly important among the 68.8% of people living below I$2 
purchasing power parity (PPP) adjusted dollar per day who have difficulty financing health care 
(14). Using a more conservative threshold, 22.3% of people in Gujarat live in poverty, adjusted 
for health expenditure (245). Even small costs are important to people living in this level of 
poverty, affecting the economic status of a household and, and having population-level effects 
given the frequency of diarrheal episodes. In 2004-5, the catastrophic headcount, or percentage of 
households incurring catastrophic payments (over 10% of monthly income) for healthcare in 
Gujarat, was 16.76% (CI 15.64%-17.88%) (248). 
 
Several studies exist for comparison of estimates of the costs of managing and treating diarrhea 
episodes.
36
 The Global Enteric Multicenter Study (GEMS) (95) was a community based study 
conducted across seven countries and included a site in urban Kolkata, which found that 
caregivers spent an average of $3.65 per diarrhea episode including both direct and indirect costs. 
Notably, the overall amount of expenditure is lowest among the poorest and richest caregivers. 
Diarrhea episodes among adults in an urban slum of Mumbai cost $6.89 including transportation, 
avoidance costs, wages lost, and homemakers’ productivity losses (246). In Haryana, caregivers 
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spent $0.83-$3.38 per diarrhea episode in Faridabad district (70), and $7.48 in Yamuna Nagar 
district (249).  Zwisler et al (2013) found that caregivers spent an average of $2.29 per episode 
out of pocket for diarrhea treatment, mostly for private health worker fees and antibiotics, 
although it is not clear in which Indian states their study was conducted (73). While data are 
necessary to better approximate costs at a macro level, assuming a range of  $0.83 - $6.89  per 
episode (63, 95) and 312.22 million episodes per year nationwide (5), the economic burden of 
diarrhea treatment to caregivers in India  could range from $259 million - $2.34 billion. 
 
Widespread diarrhea management with zinc and ORS has the potential to lessen the economic 
burden borne by households in India. Evidence the Haryana trial (covering 6 primary health 
center catchments areas) suggests that these interventions may reduce out of pocket payments by 
over half through more rational use of medicines and improved health outcomes (70). Work is 
necessary to better understand the economic burden on caregivers that is associated with diarrhea 
treatment and the costs of efforts to scale up ORS and zinc at the population level in countries 
where the burden of diarrhea is high (40). 
 
The Diarrhea Alleviation through Zinc and Oral Rehydration Therapy (DAZT) program was 
started in 2010 to facilitate the delivery of zinc and ORS through public and private sector 
providers in Gujarat India (Table 1). In this study, it is hypothesized that the DAZT program 
lowered the economic burden of diarrhea care to caregivers due to two main factors. Firstly, it is 
possible that zinc replaced more expensive treatments such as antibiotics and antidiarrheal 
medications. Antibiotics are prescribed to 80% of patients whether they are needed or not as 
providers are overly cautious about not neglecting to treat a relevant infection (38), 
complemented by demand among caregivers for the strongest possible medicine for a potentially 
deadly episode (73). Secondly, program advocacy may have stimulated caregivers to seek care 




6.2.1 Study setting and context 
This study uses data from the DAZT program conducted between 2010-2013 in 6 districts of 
northeast Gujarat India (Banas Kantha, Dohad, Panch Mahals, Patan, Sabar Kantha, and 
Surendranagar – total population 13 million) (20). This area consisted of underserved rural 
populations in the ‘tribal belt’ of northern India, which had an infant mortality rate that had 
declined to 58 in 2005/6 (26).
37
 Study sites were chosen due to the high prevalence of diarrhea 
(13% of children in 2 weeks prior to the 2005/6 NFHS-3 survey (16)), near absence of zinc 
prescribing, evidence indicating the feasibility of introducing zinc at scale in the two states 
through collaboration with two international NGOs, and priorities set by the Government of 
India. Households were included if they were caring for a child of 2-59 months. 
6.2.2 Program 
The DAZT program was started in 2010 to introduce zinc and ORS through public and private 
sector providers for treatment of diarrhea in children under five years old. After a decade of 
negotiations of convincing pharmaceutical companies to produce zinc and building alliances with 
key stakeholders, policies were developed and supply chains were established to scale up 
coverage (226). Health workers at each level of the health system were trained in diarrhea 
epidemiology, treatment, and product advocacy; and incentives were established to generate 
demand and stimulate prescribers to recommend ORS and zinc. A key feature of private sector 
provision was the use of DAZT corners, which were staffed informational booths to create 
awareness and remind providers to prescribe zinc. In both sectors, each packet of ORS and zinc 
(and referral to higher levels of the health system) was recorded by providers, results were 
communicated to supervisors through SMS messaging, and program reports were validated 
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against data registers. Supportive supervision was provided through monthly meetings, 
monitoring of field visits, and working with new staff due to high levels of attrition. 
6.2.3 Data analyses 
Descriptive statistics were calculated accounting for clustering of data by villages using the svy 
commands in Stata, using a finite population correction according to the number of total episodes. 
F-tests were used to evaluate statistical significance between phases for continuous variables and 
proportions not relating to cost. Bootstrapped confidence intervals were calculated for costs since 
assumptions of normality were violated. Principal components analyses was used to categorize 
households according wealth quintile using variables including durable assets, housing 
characteristics, and sources of drinking water (219). The internal consistency of the index, or 
measurement of whether variables represented entities that were legitimate to combine, was 
assessed with the Cronbach’s alpha coefficient (250), with the threshold for acceptable defined at 
0.6. Multivariable logistic regression was used to estimate the effect of covariates on the odds of 
the average caregiver incurring an economic cost. As opposed to Rheingans et al (2012) (95), this 
analysis was followed by multivariable linear modeling to assess the influence of these factors on 
the amount of economic cost. This two-part modeling approach was appropriate as economic 
costs to caregivers have an excess of zero values (38% at the beginning survey and 40% at the 
endpoint). Models were specified according to how well they fit the data, compatibility with 
model assumptions, and ease of interpretation of coefficients.  
 
Covariates tested were chosen from an adapted form of the Andersen and Newman (1973) 
conceptual framework on treatment seeking behavior (119), as it is expected that economic costs 
to caregivers will be closely related to treatment seeking, and this model has had influence on 
several studies in South Asia (251-253). Predisposing factors include demographic characteristics 
(family size, and sex of the child), characteristics of the social structure (education of the father, 
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education of the mother, and caste), and caregiver knowledge (about ORS and zinc). Enabling 
factors related to the family included wealth quintile and being part of a financing scheme 
(having a BPL card), and related to the community included the main variable of interest (phase 
of the study). Need factors included the duration of the episode and presence of blood in the stool. 
Theory to support specific variables was based on their significance in previous studies, using 
treatment seeking as a proxy for cost where literature was lacking. Variables thought to be 
important were included regardless of whether the coefficient was significant in our data to 
ensure accurate estimation of variance in coefficients. Parameters where we lacked data were 
identified as potential sources of omitted variable bias including breastfeeding (198), perceived 
severity (211, 214), distance to health provider (190, 204), living in a rural area (190, 204), living 
in a deprived neighborhood (201), birth order (199, 204), antenatal care of the mother from 
trained providers (199), place of child delivery (190), caregiver working away from the home 
(191), timing of care seeking (198), and frequency of diarrhea episodes in the previous two weeks 
(198).  
 
Covariates were assessed according to caregiver report. Maternal education was categorized 
according to primary (1-8 years), secondary (9-12 years), and tertiary education (13+ years) 
according to the British structure adopted by the Indian school system (254). Duration of diarrhea 
was calculated as the difference between the date of onset and date of recovery as reported by the 
caregiver.  
 
Sensitivity analysis was performed testing the set of covariates affected by the program, including 
knowledge or ORS and zinc; seeking care outside the home at a public facility, public community 
based provider, or private provider; and receiving ORS and zinc. Further sensitivity analyses 
were performed collapsing education and caste variables to single variables, and excluding 
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education. Finally, a sensitivity analysis was performed using only variables included in the 
GEMS study analysis (95). 
6.2.4 Model specification 
For the first part of the model, logistic was chosen over probit specification as odds ratios are 
more interpretable than z-scores, and it is not necessary to link model equations through an 
inverse Mills ratio (255). Hosmer Lemeshow tests were chosen over Pearson’s to assess the 
goodness of fit of the multivariable logistic model as the number of unique covariate patterns was 
equal to the number of observations. Results from this test were indistinguishable between logit 
and probit models, both with p-values < 0.000.  
 
For the second part of the model, several measures were taken to address the positive skew in the 
response variable. Hospitalized children were excluded due to their high average costs and the 
influence this had in preventing model convergence. Transformation of outpatient expenditures 
was tested using natural log, reciprocal, square root, and inverse of the cube root. As quantile-
quantile plots (Figure 4) and Shapiro-Wilk tests indicated that none of these transformations 
normalized studentized residuals, generalized linear modeling was employed.
38
 The gamma 
family was chosen as the distributional form using the Park test (256), and identity link was 
chosen to represent a direct association between independent and dependent variables (257).  A 
zero-inflated specification was ruled out (257); despite there being two processes – one where 
caregivers decided whether to seek care, and another whether those that sought care incurred a 
cost – the interpretation is difficult because some caregivers that decided not to seek care (treated 
the child at home) incurred costs (e.g. purchase of special food, wages lost).  
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Visual inspection of the residuals versus fitted values plot indicated heteroskedasticity (Figure 5), 
which was confirmed by a Breusch-Pagan / Cook-Weisberg test (p<0.000). In addition, a 
clustering adjustment was necessary based on the complex survey design of the study. To account 
for these factors, models were estimated using the vce(cluster vill_code) option. Linearity of the 
regression line according to continuous variables was tested using Locally Weighted Scatterplot 
Smoothing (LOWESS) curves in Figure 6, which indicated a potential knot at 6 days of diarrhea 
duration. As the AIC was lower in the GLM gamma specification with the spline compared to the 
specification without the spline, the specification with a knot at 6 days was used. Continuous 
variables were centered at their means to make regression intercepts more meaningful. All 
calculations were performed in Stata 13 (258).  
3.1.1 Power calculation 
The main trial was powered to detect differences in coverage of ORS and zinc (assumed to be 
equal) across trial phases (216, 259, 260). Given a total sample size of 409 that was available 
from starting and endpoint surveys for GLM gamma regression, power was computed to detect 
meaningful differences in the economic burden to households across study phases. Data for the 
calculation was drawn from a previous trial in Haryana India (70) using the standard formula for 
testing the difference between continuous means (261). The difference in costs between trial arms 
() was $0.67, with a standard deviation of $0.85 in the intervention arm (1
2
), and $4.17 in the 
control arm (2
2
). With a two sided Z/2 critical value of 1.96 for a 95% confidence interval, and 
sample sizes taken from the Stata outputs, the Z/2 score that resulted was 0.39 for GLM Gamma 





Overall, there were 1,312 episodes of diarrhea among 10,352 children in the two weeks prior to 
the surveys, although only 486 individuals were included in the analysis. Factors associated with 
prevalence of diarrhea and seeking treatment will be covered in a separate paper.  
6.3.1 Population characteristics, prevalence, care seeking, and wealth indices 
All children included in these samples were infants, born to mothers averaging 27 years old, 
within families of over six people (Table 3). Descriptive statistics indicate some imbalance 
between study phases, highlighting the importance of controlling for covariates. There may have 
been a significant reduction in diarrhea prevalence among study infants from 14%-11% from 
Spring 2011 to Autumn 2013 (p < 0.000) (Table 4), suggesting a potential impact of the program, 
secular trends, Hawthorne effect, or regression to the mean (262, 263). Overall, use of private 
sources of care decreased with marginal significance from 80% to 74% over the two and a half 
year period (p < 0.089), particularly for nursing homes / private hospitals (p < 0.000). Increases 
were seen in care seeking from community based public sources of care such as ASHAs and 
Anganwadi workers, which quadrupled their market share by the endpoint of the study (p < 
0.000). Care seeking from private doctors increased to 64% (p < 0.067), in keeping with the 
overall trend of an increased use of close to client services. In principal components analysis, the 
distribution of wealth showed a positive skew (Figure 7), and variables selected showed good 
internal consistency with a Cronbach’s alpha of 0.80. 
6.3.2 Baseline costs 
Before the start of the program, the average cost of diarrhea treatment was $3.71 (95% CI $3.03-
$4.39), and the average positive cost was $5.61 (95% CI $4.72-$6.50) (Table 5). The average cost 
of outpatient visits was $5.11 (95% CI $4.26-$5.95), with the largest components being wages 
lost, purchase of drugs other than zinc and ORS, and dispensing fees (Table 6). Average cost of 
inpatient treatment was $33.09 (95% CI $10.52-$55.66) – with the largest components being 
75 
  
purchase of other drugs and hospitalizations – and the wide confidence interval resulting in part 
from being based on only 6 patients. Average cost of home care was $0.04 (95% CI -$0.01-
$0.08), with the main components being purchase of special foods and wages lost.  
6.3.3 Costs by source of care seeking 
The source of care seeking was an important factor associated with economic cost to caregivers. 
Compared to the average total economic cost at the endpoint of the study, private doctors, and 
nursing homes and private hospitals were particularly costly at $3.81 and $8.27 per caregiver 
respectively (p < 0.000) (Table 7). Costs among caregivers consulting Anganwadi workers were 
significantly less than average expenditure at both starting point and endpoint surveys. Caregivers 
in the poorest quintile incurred lower costs than other quintiles (p < 0.013 at the endpoint of the 
study), suggesting either progressive financing or inefficient patterns of forgone treatment when 
costs were expected to be high. 
6.3.4 Variables associated with the odds of incurring a cost 
The DAZT program was not associated with a change in the odds of a caregiver incurring an 
economic cost from the starting point to endpoint of the study (p<0.75) (Table 8), which held 
when tested according to covariates included by Rheingans et al (2012) (Table 10) (95). 
Important influences on the odds of incurring an economic cost to caregivers included duration of 
diarrhea, treatment by a public community based provider, and treatment by a private provider. 
Each additional day of diarrhea under 6 days was associated with 76% higher odds of an 
economic cost (95% CI: 19%-159%). Receiving care from a public community based provider 
was associated with a 92% lower odds of incurring a cost (95% CI: 76%-97%). Receiving 
treatment from a private provider was associated with higher odds of a caregiver incurring an 
economic cost by a factor of 37.8 (95% CI: 12.0-119.3). In sensitivity analysis, duration of 
diarrhea <6 days was robust at the p<0.02 level, and receiving care from a public community 
based provider or private provider were robust at the p<0.01 level (Tables 9 &10). Paternal 
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primary education and being given zinc were marginally associated with odds of incurring a cost 
in reference case calculations, but these results were not robust to all sensitivity analysis.  
6.3.5 Changes in cost over time and influences on amount of cost 
A reduction in economic costs to caregivers from $3.71 to $2.26 was achieved across all children 
that had diarrhea in the past two weeks from starting point to endpoint surveys (Table 5). For 
caregivers with a positive cost (as a proxy for seeking treatment outside of the home), a larger 
reduction was achieved ($5.61 to $3.73). The cost of outpatient care decreased from $5.11 to 
$2.98 per caregiver (Table 6), or by $1.49 (95% CI: $0.17-$2.80) for the average caregiver 
controlling for other covariates in GLM Gamma regression (Table 9). Reduction in indirect costs 
(wages lost) was the most important reason for this decline, although reductions in transportation 
costs and expenditures on drugs besides zinc and ORS were also observed (Table 6, Figure 8). 
Dispensing and purchase of drugs other than ORS and zinc accounted for the largest share of 
direct costs. Notably, expenditures on ORS and zinc were very small fractions of the total.  
 
Each additional day of diarrhea and seeking care from a public facility or private provider were 
associated with an increased cost (Table 11), which was robust to sensitivity analysis (Tables 10 
& 12). Knowledge of ORS among caregivers improved (p<0.000), interpreted as a proxy for 
exposure to program messages, and was associated with a decrease in cost in most model 
specifications.  
 
Unadjusted analysis indicated that the largest reduction in cost among provider types was among 
private providers across the span of the program (Table 5). However, the relative importance was 
not seen when adjusted for covariates (p < 0.196). Instead, a reduction in costs across the trial 
among public community based providers relative to those among other caregivers was observed 




Mothers having lower costs may have been associated with lower costs, although significance 
depended on the model specification. Knowledge of zinc had no effect on amount of cost 
controlling for other covariates, and administration of zinc was only marginally associated. In 
addition, this study did not find evidence of gender bias in terms of expenditures on diarrhea 
treatment. 
 
Results according to wealth quintile suggest that expenditures were reduced across study phases 
in all but the least poor quintile (Table 5). These quintiles were defined by variables that had the 
strongest correlations with the unrotated first principal component (assumed to represent wealth). 
Variables positively associated with wealth included piped water (factor loading = 0.2231), pit 
slab latrine (0.2437), cooker (0.2483), and color television (0.2466). Variables with the strongest 
negative correlations were open space latrine (-0.2360) and dung floor (-0.2874). However, while 
these factors deserve attention when assessing the equity impact of the program, universal 
coverage should be emphasized over using these factors to define targeted financing schemes or 
provision of these inexpensive and potentially life-saving medicines. 
 
6.3.6 Costs of hospitalized patients 
Among the 13 hospitalized patients that were observed across surveys, there was a significant 
difference in economic costs to households between the starting point and endpoint of the study 
(Table 6). A particularly expensive patient increased the cost of admission/hospitalization at the 
midpoint of the study, costing 9,968 rupees ($167.89). The top 10% of caregivers incurred a cost 
of $10.31 at the starting point (95% CI $8.45-$11.91), $9.86 at the midpoint (95% CI $8.05-
$12.98), and $6.96 (95% CI $6.23-$7.75) at the endpoint of the study; indicating that the 
intervention may have reduced the burden of high cost patients. Boxplots suggest that outliers 
78 
  
may have been reduced at the study endpoint, and occurred mainly at private sources of care, 
specifically private doctors and nursing homes/private hospitals (Figures 9 & 10), although the 
significance of this result is not confirmed with hypothesis testing. Outliers were also observed 
among higher wealth quintiles, suggesting a possible association with ability to pay, although this 
finding also was not tested for significance.  
6.3.7 Costs among caregivers that provided home treatment 
Costs among caregivers that treated their child at home mainly consisted of wages lost. No 
expenditures were made on zinc or ORS, and no changes in economic costs were observed across 
study phases among these caregivers. 
6.3.8 Population level costs 
Overall, diarrhea treatment seeking cost caregivers between $595,898-$1,777,522 per 1 million 
people across one year (Table 13). An increasing preference for outpatient care was observed 
across phases, contributing to a reduction in cost per million. In total, outpatient care accounted 
for the bulk of the economic burden to caregivers, although infrequent but expensive 
hospitalizations can have a substantial impact on total costs, as seen in the hospitalization costs at 
midline. These outliers are important enough to interrupt the downward trend suggested in Table 
6. 
6.4 Discussion 
Studies evaluating economic costs to households of health interventions are essential for setting 
priorities in public decision making, predicting levels of demand, and providing data necessary 
for subsequent cost-effectiveness calculations from a societal perspective. This study assessed 
direct and indirect economic costs associated with diarrhea treatment before and after the 
introduction of the DAZT program in Gujarat India, finding reductions in indirect costs (wages 
lost), transportation costs, and amount spent on medicines besides ORS and zinc. While it was not 
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possible to assess whether delays in care seeking were reduced, results support the hypothesis of 
this study that cost savings would be achieved through reduced antibiotic and antidiarrheal use, 
and also suggest reductions in expenditures due to more efficient care seeking in the health 
system. Use of community based services increased (ASHAs and Anganwadi workers), use of 
efficient private sector providers increased (private doctors), and use of higher level sources 
decreased (nursing homes and private hospitals). These findings are both plausible and amenable 
to intervention. Besides findings from this study, evidence supporting the feasibility of a 
community based health systems strategy for treating diarrhea is proliferating through the 
Strengthening Health Outcomes through the Private Sector (SHOPS) initiative in a variety of 
settings, highlighting Sierra Leone, Guyana, Malawi, and Bangladesh (40). 
 
Results suggest that the proportion of caregivers that incurred an economic cost at the initial 
survey (62%) and endpoint survey (60%) was lower than that found in another study from rural 
India (79%) (73). A pilot study from Haryana found that the percentage of caregivers incurring a 
financial cost decreased from 97% to 70% (96), possibly reflecting a setting with greater potential 
for reduction in the occurrence of these costs. However, reducing the proportion of caregivers that 
incurred a cost may not be favorable from a policy perspective as an increase in the proportion 
may indicate that more caregivers are seeking and receiving appropriate care for their child. The 
desired trend was seen in Bangladesh, where an increase in the proportion of caregivers that 
incurred a cost per episode of diarrhea was observed, with a decrease in the amount spent (95). 
 
Putting economic costs into context, $2.26-$3.71 for average economic costs is a bit more than 
the daily minimum wage in Gujarat (133 rupees, or $2.24).
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 Results compare to similar studies 
reviewed in the introduction of this chapter, and related studies have been conducted in Pakistan 
and Mali. In a comprehensive program introduced in Pakistan in 2005, a training, provision, and 





marketing strategy was implemented through facility and community based levels of both the 
public and private components of the health system (71). This program lowered household costs 
by 12.8% ($0.50) (71). In a program in Mali introduced in 2006, zinc and ORS were provided at 
first level facilities which distributed drug kits to community health workers. This program 
increased ORS use rates by 10% to 43%, doubling sales levels in the community, at minimal 
mean total cost to households (72). 
 
The difference in proportions of children who were hospitalized across phases was not 
statistically significant. The average total cost for these inpatients ranged from $8.32-$77.16 
across phases, which is 0.56%-4.67% of per capita GNI (14). These results compare to $25.18 per 
patient in a hospitalized cohort in Nagpur, although the estimate from that study includes costs to 
the government in the total (85). The small number of datapoints in our sample produces large 
standard errors, and there is a scarcity of studies in the literature, making precise comparisons 
difficult. 
 
Diarrhea prevalence may be an overestimate as all children in this analysis were infants, and 
incidence peaks between 6 to 11 months (4, 8). In comparison to published estimates, prevalence 
was comparable to levels reported in the 2005-6 National Family Health Survey – 13% in Gujarat 
(26) – however this estimate precedes our study by half of a decade, and state wide prevalence 
levels may be falling due to secular trends and economic development. Total costs including non-
drug components are affected by low probability, high cost episodes, which were not seen in the 
endpoint survey of the DAZT program. While outliers appeared among caregivers of higher 
wealth quintiles, these results may have been due to chance, and should not mask the fact that 
people of lower wealth quintiles may be forgoing treatment of serious cases and bearing the 
burden of premature mortality. Nasrin et al (2013) suggest that reasons that caregivers do not seek 
care is usually because they don’t consider the illness to be severe enough to warrant treatment 
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(92%), and 100% of those that do think that care is needed cite cost as a reason for forgoing 
treatment (264).  
 
In agreement with our findings, the GEMS study highlighted the importance of the influence of 
diarrhea duration on odds and amount of economic cost per episode (95). This result is logical as 
duration and severity may be correlated, leading to treatment seeking and increased amount of 
care. The finding that private providers are associated with higher costs is relevant as nearly 62%-
74% of caregivers seek care from private or unqualified providers in Gujarat and 80% of 
spending at private providers is in the form of out of pocket payments (67, 246). As opposed to an 
evaluation of NFHS data by Malhotra et al (2013) (191), and a contingent valuation study 
evaluating differential willingness to pay for treatment among caregivers of male and female 
children in Chennai (192), no evidence of gender bias was found in our study. This finding is 
corroborated with the lack of evidence for gender bias in Kolkata in the GEMS study (95). 
 
A strength of this study is in the level of detail on economic costs to households in a rural area, 
which is unique except for a previous study from Haryana India (63). A similar dataset is being 
generated from a site in Uttar Pradesh, and being conducted in two study sites with important 
epidemiological and health systems differences will allow questions of generalizability to be 
addressed. Finally, significant differences in adjusted cost were detected despite being 
underpowered to detect meaningful changes in cost at the 80% level, assuming values from the 
Haryana trial. This finding adds strength to the result that a significant change exists. 
 
It was difficult to assess severity of episodes directly, and principal components analysis to 
summarize information from symptoms interfered with the convergence of the maximum 
likelihood estimation of our regression equations. Similarly, the generalized linear model (GLM) 
regression with a gamma distribution failed to converge for midpoint to endpoint comparisons. 
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Pregbion’s link test was significant for both the multivariable logistic and GLM gamma reference 
case models, although variables justified in the reference case were included to ensure that 
variance was not underestimated.
40
 Caregivers were not asked to identify the types of 
antidiarrheal medicines or antibiotics given, and dosages were not assessed to account for 
changes in prescribing patterns or adherence. Demographically, only rural areas are represented; 
however, these are the main areas where zinc availability should be improved (38), and universal 
coverage is recognized as priority by the Indian Government (42). The long term impact of the 
program on households or the epidemiological profile of the study area are not assessed, and the 
series of cross-sectional surveys does not capture reasons why costs changed through time or if 
changes occurred with repeated episodes.  
 
No information was collected on the sources of financing, although 48% of households used 
savings in the GEMS study, and other major sources included borrowing (21%), cutting other 
expenses (21%), and reducing the number of meals (19%) (95). Information on the use of coping 
strategies (aka distress financing (265)) would be helpful to develop solutions to address 
questions about affordability. To calculate the proportion of households that incur catastrophic 
health expenditures (266), information on monthly household expenditure on food and non-food 
items is necessary. Finally, information was not collected on the use or cost of any diagnostic 
tests, costs of obtaining or purifying additional water, or the monetized value of household tasks 
left undone while caregiving (95, 246). 
6.5 Conclusions 
This study evaluates the impact of the DAZT program on economic costs of treatment of child 
diarrhea to caregivers in rural Gujarat India using a two-part modeling approach that has not yet 
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 Sensitivity analysis using the set of variables specified by Rheingans et al (2012) gave a non-significant 
coefficient for y-hat squared in Pregbion’s linktest for logistic regression, but the coefficient remained 
significant for GLM gamma in this specification.  
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been applied to this area of research. It is important to understand these costs as the burden of 
diarrhea is high, both in terms of frequency of episodes and in terms of mortality, and since even 
the low costs of treatment can be problematic for people living in poverty. The main finding was 
that costs were reduced both through improving rational drug use and through improving rational 
access of the health system. Antibiotics, which are appropriate only with bloody diarrhea or 
shigellosis, and antidiarrheal medicines, which can be harmful and should not be prescribed, were 
prescribed more frequently but expenditures on them were reduced. Use of public sector 
providers increased, with care seeking from community based providers increasing four fold. In 
addition, care seeking from private providers was reduced, the amount caregivers paid who 
accessed them fell, and caregivers that used the private sector were more likely to access private 
doctors. Despite the fact that diarrhea treatment is usually not expensive, the frequency of 
episodes and reduction in prevalence translate to a large overall cost savings to the health system 
through effective treatment. Episodes of long duration, and caregivers that access private 
providers should be targeted by intervention programs, particularly with an aim to strengthen 
close to client services. Despite adding a small cost to diarrhea treatment programs, scaling up 




7. Paper 2 
Economic evaluation of the Diarrhea Alleviation through Zinc and oral rehydration 
Therapy (DAZT) program in rural Gujarat India: an application of the net-benefit 
regression framework  
 
Introduction: Net benefit regression is a valuable analytic technique for economic evaluation of 
nonrandomized study designs; however, it has been rarely applied in a low- and middle-income 
country context. The purpose of this study is to evaluate the Diarrhea Alleviation through Zinc 
and oral rehydration Therapy (DAZT) program for scaling up treatment of child diarrhea in rural 
northeastern Gujarat India relative to status quo conditions.   
Methods: Data was drawn from starting point and endpoint surveys of an evaluation with an 
uncontrolled before and after study design. The power of detecting a significant difference in net 
benefit in this dataset was calculated using published methods. Costs were evaluated from a 
societal perspective, including program costs for both public and private sectors and economic 
costs to caregivers, with effectiveness assessed in terms of episodes of diarrhea averted. Three 
model specifications were tested including simple regression with the phase variable alone, 
multiple regression with the complete set of covariates, and regression with the full set of 
covariates and each interacted with the phase variable. To account for non-normal error terms, 
models were specified with generalized linear modeling with a gamma distribution. Cost-
effectiveness acceptability curves were calculated for all three specifications. Subgroup analysis 
was not emphasized due to policy reasons why targeting zinc is not advocated as a health systems 
strategy.  
Results: The DAZT program had sufficient power to detect a meaningful difference in 
incremental cost effectiveness relative to the expected policy maker’s valuation of averting an 
episode of child diarrhea (). The fully implemented program was dominant (lower cost with 
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fewer episodes of diarrhea) relative to status quo conditions with 100% certainty in the 
unadjusted and adjusted models, and was cost-effective with over 95% certainty in the fully 
interacted model. 
Discussion: This analysis indicates that the DAZT program is likely to be cost-effective relative 
to the status quo condition depending on which covariates are included in the model. However, 
results should be interpreted cautiously given the lack of control group in the program evaluation. 
Net benefit regression is a promising analytical technique for evaluating studies with non-
randomized designs evaluating interventions relevant to low- and middle-income country health 
systems. Modifying the net benefit statistic to allow for ‘health gap’ measures makes possible the 
use of econometric specifications not yet applied to net-benefit regression such as Generalized 
Linear Models (GLMs) with a gamma distribution. 
 




7.1.1 Cost-effectiveness analysis  
Cost effectiveness analysis (CEA) is a useful tool for improving allocative efficiency in the health 
sector (133), and has been widely applied, particularly in publicly financed health systems. In 
India, public sector spending is particularly low, although has been expected to increase (67, 
147),
41
 and evaluation is necessary to ensure that resources are employed efficiently to help 
achieve goals for universal access to health care (267). In addition, economic evaluations of 
interventions delivered mainly through the private sector can improve health systems where 
private provision is predominant (268), even if the set of evaluations are not considered in a 
systematic way. Further, India is a recipient of large amounts of international development aid, 
and despite the absence of formal prioritization mechanisms, donors face pressures to fund and 
help implement interventions that are cost-effective (154). Finally, economic evaluation of health 
systems models found to be cost-effective in India may help its government prioritize investments 




Economic evaluation in countries with strong traditions of health technology assessment often 
follows a general continuum from modeling studies to evaluations alongside clinical trials, which 
can in turn inform revisions to make models more comprehensive (179). Less attention has been 
paid to economic evaluation in the context of implementation science and non-randomized study 
designs. Methods have been developed recently which combine econometric and economic 
evaluation techniques through transforming incremental cost-effectiveness ratios into net benefit 
statistics (86). Net benefit regression allows analysts to control for variables that may confound 
cost-effectiveness when allocated unevenly across scenarios being compared.  
                                                          
41
 The goal of the Indian government is to increase health spending to 2% of GDP (Berman et al 2010) 
42
 India allocated $680 million in 2010 to foreign assistance programs and is a net-exporter of 
pharmaceuticals (Watt et al 2013) 
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7.1.2 Diarrhea in India and DAZT program 
The Diarrhea Alleviation through Zinc and oral rehydration Therapy (DAZT) program in Gujarat 
India is an example where net benefit regression is applicable in a low- and middle-income 
country (LMIC) context. The objective of the DAZT program was to scale up coverage of oral 
rehydration salts (ORS) and zinc for treating children with diarrhea, and reduce the irrational 
prescription of more expensive antibiotics and antidiarrheal medicines. Program evaluation took a 
before and after study design across 2010-2013, and the intervention consisted of a complex 
health system wide approach through which zinc was introduced and ORS was scaled up through 
both public and private sector providers. This design allows for the evaluation of zinc itself as an 
intervention, as well as evaluation of the health systems delivery strategy. 
7.1.3 Literature review 
The application of net benefit regression in a LMIC context is relatively new. Hounton and 
Newlands (2012) (109, 111) conducted the first two studies to evaluate public health 
interventions in a LMIC context, including programs for skilled attendance at childbirth and 
community based insurance in Burkina Faso. Shih (2009) published a net-benefit regression 
analysis in 2009 relevant to Taiwan (269), which is technically a LMIC since it is part of China, 
although is considered a high income region by the World Bank (270). In addition, cost-
effectiveness analyses of before and after studies are emerging (102-107); however, these studies 
are not well established in the literature. 
 
Cost-effectiveness studies relevant to the introduction of zinc to treat child diarrhea include a 
model based analysis (99), hospital based studies that use patient level data (68, 85, 87), and a 
community based study based on patient level data (70). Consistent with WHO recommendations 
(271), zinc has been found to be cost-effective for treatment of non-severe cases based on 
modeled evidence (99), a community based cluster randomized trial evaluation (70), and an 
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evaluation of a social franchise program (132); but not cost effective (85), or without significant 
differences in effect (68, 87) in the hospital setting. Further work should be done to evaluate cost-
effectiveness in real world sector-wide conditions to inform decisions about scaling up zinc to 
achieve high levels of coverage. This information is particularly relevant in the Indian context 
where the government has set policy for a national program to provide zinc to all children over 
three months old with diarrhea (42), and diarrhea was the third leading killer of children under 
five years old nationwide in 2010 (272), although its rank has fallen from second to fourth 
worldwide in the last few years (238). 
7.1.4 Study hypothesis and rationale 
The hypothesis of this study is that the DAZT program was cost-effective relative to status quo 
conditions for treating diarrhea in rural Gujarat. The DAZT program was designed according to 
lessons learned from similar successful programs, such as the SUZY program in Bangladesh, and 
the ‘status quo’ counterfactual was chosen to inform marginal investment decisions (155). 
Chapter 6 found that the prevalence of diarrhea among infants may have been reduced from 14% 
to 11%, in addition to lowering the economic burden borne by caregivers across the span of the 
program (273). Consistent with economic evaluations of other interventions delivered at the 
community level (274, 275), it is expected that program costs will be distributed thinly enough 
across beneficiaries of the program to make economic costs per person good value for money 
when considered alongside health benefits. 
 
Reviews of effectiveness literature suggest that zinc efficacy is modified by a variety of variables 
(51, 131), and interventions delivered at scale may benefit some subpopulations more than others 
given inequities in coverage of child health services. In Gujarat, coverage of maternal, newborn, 
and child health is 32.4% among people in the poorest wealth quintile, and twice that in the 
richest quintile (276). For the effectiveness of zinc, Patel et al (2009) recommend that ‘a 
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reexamination of all available trial results … is needed to dissect out the potential contributions of 
heterogeneity of trial results before Zn can be recommended universally’ (131). Lazzerini and 
Ronfani (2013) have addressed this question recently in terms of efficacy and effectiveness (51), 
and the question exists whether similar work should be conducted on cost-effectiveness. Given 
the standards of the National Institute of Health and Care Excellence (NICE) for subgroup 
analysis (277), and plans of the Indian Government to develop a similar organization (169), the 
case can be made that evaluation of the cost-effectiveness for different subgroups is particularly 
relevant from a policy perspective. However, countering this rationale is that zinc should not be 
targeted to specific subgroups as it is likely to slow the development of drug resistance to 
antibiotics instead of contribute to drug resistance through widespread use as has been seen for 
malaria and pneumonia programs (278). In addition, taking a targeted approach rather than 
universal coverage may introduce inefficiencies in trying to administer the rationing strategy in 
the health system (67).  
7.2 Methods 
7.2.1 Study setting 
The DAZT program was implemented in the context of India’s largely private health system, 
utilizing community health workers, dispensaries, chemists, primary health centers, hospitals, and 
other sources of health care. The study area consisted of six districts in northeastern Gujarat 
(Banas Kantha, Dohad, Panch Mahals, Patan, Sabar Kantha, and Surendranagar – total population 
13 million (20)) which are currently underserved by India’s health system. The study area was 
chosen for its low coverage of zinc, availability of non-governmental organization partners, and 
priorities set by the Government of India. Evaluation of the DAZT program consisted of 
household surveys spanning two years comparing 5,080 caregivers of children 2-59 months in the 
final survey to 4,200 children assessed at the beginning (Table 14). These surveys assessed only 
the youngest child in the household, and the latest episode per child within the last two weeks. 
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While it was not possible to extrapolate long term outcomes from patient specific data on 
episodes of diarrhea, data was sufficient to perform cost-effectiveness analysis in terms of natural 
units.   
7.2.2 Power calculation 
The main trial was powered to detect differences in coverage of ORS and zinc (assumed to be 
equal) across trial phases (216, 259, 260). Given the sample sizes that were collected in program 
activities (Table 14), power was computed to detect meaningful differences in cost-effectiveness, 
translated to incremental net-benefit (Box 1).  
 
Power associated with cost-effectiveness was calculated merging two formulas from Glick et al 
(2011) ((135) supplemental material) to account for different sample sizes across study phases, 
and different standard deviations in costs and effects across phases. Alternative hypotheses were 
tested against a null hypothesis of no difference of net benefit from a ceiling ratio (), or a policy 
maker’s willingness to pay for diarrhea treatment. A novel calculation was conducted for the 
reference case of  based on outputs from the Lives Saved Tool (LiST) by multiplying per capita 
GNI ($1,653) by DALYs averted per death averted (27.06), and deaths averted per episode 
(1,082/3,269,219). This calculation produced an estimate of  = $14.80 per episode averted. 
 
The reference case power available by the study sample size and sensitivity analyses are given in 
Tables 15 & 16. Values for C, Q, and their standard deviations were taken from a trial on zinc 
conducted in Haryana India (70). The expected correlation (between incremental cost and 
effect was assumed to be 0.2 based on convention for sociological studies. The standard Z score 
for 95% confidence was used for a two-tailed alpha (1.96), with sensitivity analyses on 99%, 
90%, and 80% confidence. Results indicate that halving effectiveness reduces power, and 
reducing effect to 0 provides power to detect a difference in the direction of not being cost 
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effective. Reducing cost increases power to 100%. In addition, Z scores reach their lowest point 
where net benefit equals zero (when the ceiling ratio equals $7.64). Power reaches its lowest 
point () at the same point (Figure 11). The correlation coefficient has little influence on power, 
and power decreases with increasing Figures 12 & 13 show the relationship between  and 
power. 
7.2.3 Costs and effects 
Economic costs were assessed from the societal perspective, consisting of those to the caregiver 
and program costs borne by the NGOs and government. Program costing was performed 
according to Saving Newborn Lives (SNL) costing guidelines for capital and recurrent costs 
(224). Data were drawn from program records. Costs to caregivers were assessed according to 
caregiver report through the household surveys, and included direct medical costs, direct non-
medical costs (transportation), and indirect costs (wages lost).  
 
Program costs were combined for public sector and private sector activities (Table 17), and were 
divided evenly across caregivers in the endpoint survey. A full year of program costs at the 
midpoint survey were not available, limiting capacity to evaluate cost-effectiveness at that stage 
of the program. Allocation of program costs across caregivers was scaled to the population of 
children in the study area (n = 1,188,634), and according to time frame (2/52 weeks) to consider 
coverage of children beyond the scope of the surveys. Program costs components included capital 
costs (start up and sustainability, furniture and equipment, and training), and recurrent costs 
(personnel, vehicles, buildings, zinc and supplies). Capital components were annualized using 
factors from the WHO-CHOICE study discounted at 3% as the rate for a risk-free investment 
(155) and recommendations for economic evaluation in LMICs (88). In the absence of other data, 
items were assumed to last the duration of the program. Currency was inflated using consumer 
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price indices from the International Monetary Fund (IMF) and converted using factors from 
OANDA.com. 
 
In the absence of data on mortality and long term sequelae from diarrhea, outcomes were assessed 
in terms of episodes averted. No attempt was made in questionnaires to define diarrhea according 
to official WHO definition (279). Evaluation was limited in its scope to the most recent episode 
per child within the two weeks prior to study to limit recall bias. 
7.2.4 Traditional cost-effectiveness calculation 
The cost-effectiveness of the program was calculated according to the costs and episodes averted 
observed in the trial. In a separate study (280), uncertainty around these estimates will be defined 
using a non-parametric bootstrap according to established methods for cost-effectiveness analysis 
(133). 
7.2.5 Cost-effectiveness according to net benefit regression 
All children evaluated by starting point and endpoint surveys of the study were included. For each 
individual, a modified version of the net benefit statistic was calculated by multiplying the 
variable representing whether a child had an episode of diarrhea by the value of averting an 
episode (), then adding the economic costs associated with that individual. 
iii CENMByE  *)(          (6) 
A modified version of the incremental net benefit can therefore be represented by the number of 
episodes averted between the study starting point and endpoint, and by the same difference for 
costs. 
)()(* CeCbEeEbNMB          (7) 
This analysis was different from the typical net benefit statistic of most net-benefit regressions 
(86, 109, 111) in that episodes of diarrhea are an unfavorable outcome, where other outcomes 
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used (e.g. days of stable housing (86), enrollment in community based insurance (109), 
institutional delivery (111), successful diagnosis (110)) are favorable outcomes. To ensure that 
the incremental net-benefit statistic had the appropriate sign, individuals assessed in the initial 
survey were coded 1 and those assessed in the endpoint survey were coded 0. Coding of other 
variables was inverted in the same way. As both episodes and costs are unfavorable, adding them 
within trial phases was appropriate before taking the incremental difference between the two. 
With more episodes observed at the starting point of the survey, the value of incremental benefits 
was positive in this formulation. The sum of program costs and economic costs to caregivers was 
observed to be higher at the endpoint than starting point of the survey, so the resulting 
incremental cost was subtracted from the incremental effects. When the sum of costs and 
outcomes converted to dollar values are higher at the starting point than endpoint of the survey, 
incremental net benefits are positive, producing the correct interpretation for policy. 
  
The net benefit statistic was used as the dependent variable in a series of simple and multivariable 
linear regressions. In these formulations, the coefficient on the treatment variable () represented 
incremental net benefit of the program relative to the initial survey. Simple linear regression on 
the  alone, representing study phase, was conducted to show that the incremental net benefit is 
the same when calculated in this approach as when calculated in the standard deterministic 
approach. 
iii tNMByE   )(         (8) 
Multiple linear regression was then conducted to evaluate net benefit when controlling for 
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)(       (10) 
Different values of  were tested in sensitivity analysis, including the extreme case of 0 to test 
negative costs as the response variable. An effects only regression to represent the scenario where 
 equals infinity was not conducted as the outcome is binary and logistic regression coefficients 
would not be comparable to other model specifications. 
7.2.6 Cost-effectiveness acceptability curves 
Cost effectiveness acceptability curves (CEACs) were constructed to depict the probability that 
the DAZT intervention was cost-effective according to different levels of  using p-values on the 
treatment variable. Stata outputs for results above the threshold were subtracted from 1 and all 
outputs were divided by two to convert them to one-tailed tests. Similar to comparisons of 
coefficients, results from simple linear regression and multiple linear regression were compared 
to assess the effect of controlling for covariates on the position of the CEAC.  
7.2.7 Regression modeling 
It was expected that ordinary least squares estimation would not be a good fit given the skewness 
in the outcome variable, although it is difficult to test normality of residuals in large datasets.
43
 
Therefore, a quantile-quantile plot was generated, which illustrated this right skew (Figure 14). 
Breusch Pagan / Cook Weisberg tests indicated that the residuals did not have constant variance 
at different points along the regression line, and visual inspection of residual versus fitted plots in 
Figure 15 a-c confirmed heteroskedasticity.   
 
As another check on these model assumptions, models were specified comparing OLS, negative 
binomial, and GLM gamma with Akaike’s Information Criterion (AIC) and the Bayesian 
                                                          
43
 The Shapiro Wilk tests performs well in sample sizes up to 2000, the Shapiro Francia test performs well 
in sample sizes up to 5000, and the Jarque Bera test does not perform well in large sample sizes. The 
skewness and kurtosis test did not produce results in this dataset. 
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Information Criterion (BIC), which indicated that GLM Gamma was clearly the best fit, even up 
to  of $1 million.
44
 Of the generalized linear model options for error term distribution (257), 




 Identity link was prioritized to preserve correct interpretation of the coefficient on the treatment 
variable, although suffered from convergence problems. Therefore, relationships in the full model 
were tested using the log link to provide coefficients interpretable as the ratio of net benefits, 
which can be termed ‘relative net benefit’.
47
 Huber White robust standard errors were added to 
address heteroskedasticity using the cluster option to account for the effect of complex survey 
design. A finite population correction was incorporated according to the number of episodes in 
the study area. 
 
Continuous variables including household size and duration of diarrhea were checked to see if 
model fit could be improved with the use of spline terms. The importance of highly influential 
points was checked by calculating DFBETAs for fully interacted models, excluding caregivers 
with the top 10 DFBETA scores. Comparison of AIC / BIC scores indicated that omitting these 
points slightly improved model fit, although little difference was seen in the significance of the 
treatment variable. Since these extreme cases were considered important to the analysis to make 
results comparable to the CEA according to bootstrapping, reference case calculations were 
performed on the full dataset. 
                                                          
44
 The influence of the skew in the cost component of the net benefit statistic is lower at lower levels of . 
Increasing  often makes the distribution more normal as effects have more influence.  
45
 3,840 children had no cost and no episode, and 3608 had no cost alone, indicating an excess of zero 
values. However, a zero inflated model was not implemented to preserve the interpretation of cost-
effectiveness of the intervention across the entire dataset. 
46
 The Park test indicates chi-square values for Gaussian, Poisson, Gamma, and Inverse Gaussian 
distributions. Although p-values do not indicate a clear choice, the chi square statistic is lowest for the 
Gamma distribution. 
47
 The ratio of net benefits is useful to provide evidence about whether the intervention is cost-effective, 
even if not represented on the monetary scale as with incremental net benefits. 
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7.2.8 Covariates tested  
Covariates for the model were chosen according to an adapted form of the Andersen and 
Newman (1973) conceptual framework for treatment seeking (119), to be consistent with Chapter 
6. A sensitivity analysis was performed testing the set of variables affected by the program.
48
 To 
construct a wealth index for assessing the effect of assets on net benefit, principal components 
analysis according to standard methods  (212, 219), using the component with the highest 
eigenvalue to construct a scale for classifying caregivers into quintiles. Descriptive statistics and 
regression analyses were performed in Stata 13, with program costing and generation of 
acceptability curves performed in Microsoft Excel. 
7.3 Results 
7.3.1 Power calculation 
Given the available sample size, power calculations indicate that the study had over 95% power 
to detect a significant difference in incremental cost-effectiveness from  if  was below $5.50 or 
above $9.75 (Figure 11). Given our calculation for the reference case  being $14.80, this study 
was expected to have sufficient power to detect a meaningful difference in cost-effectiveness, and 
this result was robust to most sensitivity analyses (Tables 15 & 16).  
7.3.2 Descriptive statistics and program costs 
Comparison of covariates across study phases indicated that many of them were unevenly 
distributed (Table 18). Program costs are presented in Table 17. Expenditures on both capital and 
recurrent costs were higher in the public sector [managed by the NGO, Micronutrient Initiative 
(MI)], despite the fact that most people sought care through the private sector [managed by the 
NGO, Family Health International (FHI-360)]. This finding is explained by the fact that MI was 
responsible for the block, district, and state level review workshops to launch the program; for 
                                                          
48
 This set included knowledge of ORS and zinc, seeking treatment outside of the home (public facilities, 
public community based providers, and private providers), and being prescribed ORS and zinc 
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paying for its own personnel and travel expenses, and for the procurement of zinc and ORS 
(initially). Importantly, this costing did not include the salaries of health providers themselves, 
who were remunerated according to the status quo functioning of the health system. The most 
significant component of costs to FHI-360 were for subcontracts to other NGOs and West Coast 
pharmaceutical company, for training of pharmaceutical representatives in zinc and the SMS 
system to monitor sales, and managing of promotional booths called ‘DAZT corners’.  
 
Sample statistics for costs and health outcomes are presented in Table 19. Cost per average 
person in the sample decreased by $0.25, and diarrhea prevalence was reduced by 3.25%, leading 
to a dominant cost-effectiveness ratio not dependent on . 
7.3.3 Regression outputs 
In simple linear regression, the magnitude of the coefficients on the phase variable and their 
standard errors increased with higher values of except for in two specifications
49
 In simple 
linear regression, the coefficient on the phase variable was equal to the result when net benefit 
was calculated according to standard methods (-$0.25 compared to when  = $0/episode averted). 
For all simple linear specifications tested, the intervention was dominant across values of in the 
unadjusted analysis (Table 20). These results were confirmed by the unadjusted CEAC, which 
shows that the intervention was cost-effective with 100% certainty for all values of  tested 
(Figure 16). Results were robust to sensitivity analysis testing negative binomial and ordinary 
least squared specifications and the inclusion and exclusion of robust standard errors and 
adjustments for clustering (Table 20). Adjusting the model for the full set of covariates revealed a 
pattern of dominance according to study phase (Table 21, Figure 17). When interaction terms 
were added to the model, results remained cost-effective with over 95% certainty up to very high 
                                                          
49
 This trend held except for the simple generalized linear regression model with a log link, robust standard 
errors, and accounting for clustering; and the negative binomial model with the same adjustments 
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levels of , with declining levels of cost-effectiveness according to increasing levels of the ceiling 
ratio (Table 22). This finding indicates that the program is an inferior good, averting fewer 
episodes and costing less controlling for covariates for a small proportion of individuals (Table 
22, Figure 18). This result was robust to sensitivity analysis using the set of covariates evaluated 






 and duration of 
diarrhea) (Table 23) (95). Subgroup effects were observed with being given zinc showing reduced 
cost-effectiveness, and improved maternal education, being from a scheduled tribe, having 
knowledge about zinc, and diarrhea duration showing improved cost-effectiveness. No subgroup 
effects were seen for the specification using variables aligned with the GEMS study (95). 
 
Diagnostic tests were conducted to check linear regression model assumptions. Variance inflation 
factors indicated that there was not collinearity between covariates. Breuch-Pagan / Cook 
Weisberg statistics confirmed that error terms around the regression line were highly 
heteroskedastic, with no signs of losing significance with ceiling ratios between extreme 
specifications of net-benefit with a  = $0 and  = $1,000,000. However, chi-squared statistics 
showed a declining trend, indicating that results were increasingly homoskedastic with the ceiling 
ratio. Omitting the top ten influential points identified through DFBETA made little difference to 
model outputs (Table 24). Testing results according to the set of parameters affected by the 
program revealed the same pattern of dominance seen in other model specifications.  
7.4 Discussion 
Net benefit regression provides a useful framework for evaluating the cost-effectiveness of the 
DAZT program, adjusting for imbalances in covariates. Results indicate that the program was 
dominant relative to conditions at the starting point of the survey before adjusting for covariates, 
                                                          
50
 I included both maternal education and paternal education with primary and secondary education cut-offs 
51
 Despite the small range of child ages found in our dataset, age was included to be consistent with 
Rheingans et al (2012)  
52
 I used blood in the stool as a proxy for severity to facilitate convergence  
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with unadjusted and adjusted estimates without interaction terms being comparable to those from 
a standard deterministic calculation. Adjusting for covariates and interaction terms did not have 
an important impact on conclusions, still recommending the program with 95% certainty.  
 
Subgroup effects were observed, but should not be emphasized. Improved cost-effectiveness with 
each level of maternal education is not policy relevant as medical treatment should not be 
targeted according to socio-demographic characteristics (281).  Little evidence was available in 
the literature on the impact of caste on amount of cost or diarrhea outcomes with which to pre-
specify hypotheses. Being given zinc was associated with a reduced cost-effectiveness relative to 
not being given zinc as expected by the data structure as there was no reduction in episodes 
among children given zinc, although there was a reduction in episodes among children overall. 
Unadjusted costs among children that received zinc across the course of the program were 
reduced, but this trend disappeared in adjusted analysis with expected values actually showing an 
increase. Knowledge about zinc was consistent with the hypothesis that caregivers with 
knowledge would be able to spend more rationally, and represents a program attribute that may 
be targeted in further expansion of DAZT. However, targeting zinc by prescribers should not be 
done to promote rational prescription of antibiotics (278), and avoid costs associated with 
rationing medicine (67).  
7.4.1 Policy relevance 
Currently, only around 30 English language cost-effectiveness analyses evaluating interventions 
are available on PubMed in the Indian context indicating key gaps in the evidence base. Therefore 
results from this study are likely to be considered in an ad-hoc fashion by program managers and 
policy makers (282). In the near future, with the formation of a health technology assessment 




The proliferation of large scale public health programs in the developing world, and the non-
randomized nature of their data, provide increasing opportunities to conduct net-benefit 
regression when undertaking economic evaluation. In addition, this methodology is useful for 
randomized trials that fail to produce a balanced allocation of covariates.  
7.4.2 Strengths and limitations 
A natural limitation of the net-benefit statistic is the requirement to make an assumption about  
(86), for which definitions are only loosely defined (163), and are particularly unknown in the 
case of cost-effectiveness analysis in terms of natural units. However, this analysis provides a 
novel method for defining in terms of natural units using outputs from the LiST tool. A strength 
of the net-benefit framework is that it makes it unnecessary to quantify uncertainty around ICERs 
according to bootstrapping, which can be problematic due to the ambiguity of negative ICERs 
across quadrants (86). 
 
The uncontrolled before and after study design limits the measurement of effectiveness. 
Imbalances between before and after phases were controlled for through the regression approach; 
however, no mathematical adjustment can control for unobserved characteristics in non-
randomized study designs. In the case of this study, secular trends may have influenced results 
such as changes in living standards, source of water, and hygiene practices. In addition, the 
Hawthorne effect may have magnified effects (283). To some extent these effects may have been 
countered by secular trends in costs, which may have been expected to increase given current 
trends of economic development in Gujarat.  
 
The fact that this analysis evaluates cost-effectiveness analysis defined in natural units limits 
capacity to compare results to cost-utility analyses of other interventions. However, outcomes 
measured in terms of natural units are often used in net-benefit regression (86, 109, 111), and 
101 
  
outputs of this analysis are important in other ways. The finding that controlling for confounders 
and sets of those included did not have an important effect on cost-effectiveness strengthens the 
robustness of conclusions from calculations performed according to non-regression based 
methods. 
7.4.3 Steps further 
Statistically, non-parametric methods may be tested as a robust alternative to ordinary least 
squares to improve fit, in addition to the specifications tested in this analysis. The ‘wild 
bootstrap’ is appropriate given the heteroskedasticity in the residuals (284); however, goodness of 
fit tests and post estimation commands are not currently available in Stata.
53
  A more flexible 
approach to modeling regression based cost-effectiveness analysis with separate equations for 
incremental costs and outcomes, linked together by their error term in seemingly unrelated 
regression (285).
54
 This approach is useful for specifying models with different covariates for 
costs and outcomes, although makes several assumptions (286).
55
 Alternative methods of 
accounting for clustering may also be tested, such as a two-stage non-parametric bootstrap or 
other methods (287).  
7.5 Conclusions 
This study evaluated the cost-effectiveness of the DAZT program to treat child diarrhea in 
Gujarat using a new formulation of the net-benefit statistic to accommodate calculation with 
‘health gap’ measures. The main finding was that it is likely to be cost-effective according to a 
cost-effectiveness threshold derived from per capita GNI. This result is robust to the sets of 
covariates tested to adjust results, with unadjusted and adjusted results being dominant, and the 
                                                          
53
 It is necessary to write out manually the commands to perform the wild bootstrap itself, although 
Cameron and Trivedi provide the appropriate code which works for my data. 
54
 Conditional mixed processes are an option for combinations of probit and linear regressions with 
correlated error terms 
55
 Assumptions include that parameters are normally distributed, that there are constant variances between 
study phases, and that the correlation between costs and effects are the same in each study phase (Nixon 
and Thompson 2005). 
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fully interacted specification remaining cost-effective with 95% certainty. Recognizing the 
impossibility of controlling for unobserved factors, the program should be recommended for scale 
up given consistency with cost-effectiveness evidence from previous literature, and cost savings 
described in Paper 1. Methodologically, net-benefit regression is a valuable tool for evaluating 
non-randomized programs, and has promise as an analytic tool in the LMIC setting. Modifying 
the net-benefit statistic to accommodate ‘health gap measures’ has promise to make new 





8. Paper 3  
Cost-effectiveness of bundling diarrhea services in Gujarat India: A probabilistic analysis 
based on OneHealth and the Lives Saved Tool 
Introduction: Bundling health interventions is a health systems strategy for exploiting synergies 
between interventions with joint inputs or complementary effects, and has been applied 
frequently in maternal and child health programs. The purpose of this study is to evaluate the 
cost-effectiveness of different bundles of interventions to prevent and treat diarrhea and 
pneumonia. 
Methods: A league table was evaluated to define a bundle of services in the context of six 
districts of Gujarat, with component bundles defined according to service delivery channels. 
Coverage levels were defined according to conservative and universal scale up scenarios. Costs 
were calculated using an ingredients approach, with outcomes modeled using the Lives Saved 
Tool (LiST). Incremental cost-effectiveness ratios were calculated in 2013 US$ according to 
deaths and Disability Adjusted Life Years (DALYs) averted. 
Results: The evidence base on the cost-effectiveness of interventions for pneumonia and diarrhea 
is currently incomplete in the Indian context. League table evaluation revealed that investment in 
health is strikingly low in Gujarat relative to what is recommended by cost-effectiveness 
evidence, with the current budget able to finance less than 8% coverage of zinc treatment for 
diarrhea. Calculations indicate that the full bundle of interventions is cost-effective, with a cost 
per DALY averted of $155.02 (95%CI: $128.58-$183.33) and $180.38 (95%CI: $149.86-
$213.73) in the conservative and universal scenarios.  
Discussion: Investment in the health system in Gujarat should be increased to scale up cost-
effective interventions to prevent and treat child diarrhea and pneumonia. A pattern of expected 
synergies in adding further interventions to the bundle was not seen, although all bundles were 
well below a cost-effectiveness threshold of per capita GNI in Gujarat (US$1,653). Further cost-
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effectiveness analyses would strengthen the evidence base for rational policy making and health 
systems planning in the health system of Gujarat.  
Key words: Diarrhea, Pneumonia, Cost-effectiveness, Zinc, Oral Rehydration Salts, India, 




8.1 Introduction  
Bundling services is a health systems strategy in which several interventions are delivered at once 
to minimize costs to the patient and health system and maximize favorable health outcomes 
(288). Synergistic effects between treatment and prevention interventions can enhance benefits 
realized by the health system, and generate economies of scale that minimize joint production 
costs and reduce total costs. For example, health provider time per patient can be minimized, 
patient time in seeking care can be reduced, facility space can be utilized more efficiently, and 
medical records and administrative procedures can be standardized (118). Specialized resources 
can be used more efficiently by screening patients at lower levels of the health system and 
allowing treatment of conditions earlier in development when they are less expensive and more 
amenable to cure (288). Determining what interventions are essential for the bundle can be 
helpful from a health systems perspective, informing which should be provided by the public 
sector, and which should be left to the private sector or external assistance (288). The process of 
defining bundles can protect financing for cost-effective and equitable services from being 
diverted to services that are more intensely demanded such as hospital services (81). In addition, 
it can shift the mindset of policy makers from inputs to outputs, improving the effectiveness of 
the health system (81). 
 
However, bundling also has potential drawbacks. A common concern among community health 
worker programs is the possibility of overburdening them with an excess of responsibilities (289), 
and the added need for prioritization within a recommended package can lead to inefficiencies 
(290). Bundles may be bundled out of logistical convenience, donor directives, organizational 
expertise, or specific lines of scientific inquiry, not lending to effectiveness and sustainability 
(83). In addition, the process of defining bundles of services can be used as a delaying tactic, with 
policy stagnating in discussion for long periods of time (81). The experience in Andhra Pradesh 
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provides an example where bundling services was problematic – the bundle of services was 
defined by disengaged international representatives and academics (81), and a large amount of 
time elapsed between study completion and presentation of results (291), both hindering the 
implementation of the policy.  
 
Bundling services in international health has roots in Alma Ata and the 1993 World Development 
Report (WDR) (288, 292). The latter defined an essential national package of cost-effective 
health services to which low and middle income countries could aspire to scale up coverage. This 
package focused on interventions that benefited poor people and addressed major sources of 
disease burden, and was designed through a league table approach (288). However, many 
approaches are available to defining service bundles. For example, UNICEF defined bundles of 
services for diarrhea based on a prevention and treatment classification (9). Bundling can also be 
done according to diseases that share diagnoses, medicines, and treatment protocols, such as 
diarrhea and pneumonia (239). Similarly, interventions can be bundled according to a risk factor 
that is amenable to intervention – although determining attributable risk by risk factor can be 
difficult (288). Bundling can be done by delivery channel, specifically by what one cadre of 
provider can reasonably offer. Interventions that target a particular patient group can be bundled 
together, such as neonatal care interventions (83, 89). Services can be bundled according to those 
that should be delivered through the public and private sectors respectively (288), or by economic 
sector (health versus other non-health sectors) (293-295). A final approach to bundling is 
according to which services can be delivered through the community versus facility levels of the 
health system. 
 
There are many examples in public health where maternal and child health programs have 
combined interventions to provide packages of services. GOBI-FFF was an early package from 
UNICEF that included growth monitoring, oral rehydration therapy, breast feeding instead of 
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early weaning or bottle feeding, immunization, family spacing, food supplements, and female 
education (296). More recent examples of bundling health services in LMICs include the 
expanded program on immunization (EPI) (297), and Integrated Management of Neonatal and 
Child Illness (IMNCI) (298). Integrating perinatal services delivered by Community Health 
Workers in Bangladesh, India, and Pakistan has proven to be feasible, resulting in significant 
reductions in neonatal and perinatal mortality (299-302). Bundling immunization and maternal 
and child health interventions (such as micronutrient supplementation or preventive malaria 
treatment (292)) has been found to increase coverage of child health interventions when 
interventions are carefully selected for compatibility and receive adequate support, but do not 
achieve levels of immunization coverage (303). A systematic literature review found insufficient 
evidence for improving efficiencies of resource use through bundling, and benefits were mostly 
not evaluated (304). The child health days strategy for delivering multiple interventions provides 
another example of bundling health services, and is particularly useful in areas where 
infrastructure is weak (116). The World Health Organization’s CHOosing Interventions that are 
Cost-Effective (WHO-CHOICE) initiative evaluated bundles of child health interventions 
relevant to LMICs including: oral rehydration therapy, case management of pneumonia, 
supplementary food and nutrition counseling, vitamin A, zinc supplementation, vitamin A 
fortification, zinc fortification, and measles immunization (102). 
 
Modeling studies make conflicting assumptions about whether bundling leads to efficiencies. 
Darmstadt et al emphasize the benefits of delivering services as bundles according to delivery 
channel (89). However, WHO-CHOICE found increasing incremental cost-effectiveness ratios as 
additional services were added to a bundle of child health interventions (102). The Lives Saved 
Tool (LiST) considers bundling efficiencies in terms of incremental time needed to provide 
services and in indirect costs. LiST has been used to evaluate diarrhea interventions from the 
UNICEF package of diarrhea interventions (9) for 68 priority countries according to conservative 
108 
  
and universal coverage scenarios between 2011-2015. This study found additional costs of $0.80 
per capita in 2015 for non-WASH interventions to achieve universal coverage, and found that the 
number of diarrhea deaths in these countries declined from 1.39 million in 2010 to 334,000 in 
2015 (90). 
 
The objective of this study is to evaluate the cost-effectiveness of bundles of interventions to 
prevent and treat diarrhea in six districts of Gujarat including Banas Kantha, Sabar Kantha, Patan, 
Surendranagar, Dohad, and Panch Mahals. Implementation was considered in the context of the 
the health system of India (Figure 19). This study draws on methods from Fisher-Walker et al 
(2011) (90), expanding the set of interventions to include those for pneumonia (239), consistent 
with those evaluated by Tam and Friberg in a recent UNICEF report (305). Re-analysis is 
relevant as the burden of disease estimates considered by Fischer Walker et al (2011) were too 
high at 1.4 million and 1.1 million deaths in 2010 and 2011 (subsequent studies have found 
751,000 (114) and 700,000 (5) deaths for these years).  In addition, Fischer-Walker et al (2011) 
did not calculate cost per death averted using the rationale that outcomes only include diarrheal 
deaths averted and do not account for the full impact, although only accounting for disease 
specific mortality is common in cost-effectiveness analysis (306-309). They did not translate 
deaths averted to DALYs averted, limiting comparison of results to the majority of cost-
effectiveness literature in international health. Methods for determining coverage levels are not 
presented, and at-scale data are becoming available to inform more realistic targets for scaling up 
relevant interventions. Finally, only one previous project has used probabilistic sensitivity 
analysis (PSA) to evaluate uncertainty around estimates of the cost-effectiveness of multiple child 
interventions based on outcomes from the LiST tool (132). Our study uses a similar method to 
PSA, although models scaling up various sets of interventions through two hypothetical scenarios 




8.2.1 Selection of interventions 
Eleven diarrhea and pneumonia interventions were considered for each package including 
vitamin A supplementation, oral rehydration salts, therapeutic zinc supplementation, 
breastfeeding promotion, antibiotic treatment of dysentery, treatment of severe diarrhea, 
antibiotics for treatment and management of pneumonia, treatment of severe pneumonia, 
rotavirus vaccine, pneumococcal conjugate vaccine, and HiB vaccine. Prophylactic use of zinc 
was excluded based on the rationale that these programs will be difficult to introduce given the 
problems in implementing less intensive programs of zinc for diarrhea treatment, although efforts 
to promote these programs are recognized (125). Complementary feeding programs were 
excluded due to the lack of coverage data. While Water, Sanitation, and Hygiene (WASH) 
interventions are sometimes evaluated in cost-effectiveness analysis (140, 310, 311), they were 
excluded as Hutton et al (2004, 2007) argue that WASH interventions are better assessed by cost-
benefit analysis (293-295) since they are not delivered through the health sector (WASH 
interventions are delivered by the Ministry of Drinking Water and Sanitation in India). In 
addition, Cairncross et al (2010) (312) emphasize the limitations of data parameterizing the 
effectiveness of WASH interventions and the need for caution when interpreting results from 
LiST (313). These interventions include improved water sources, water connection in the home, 
hand washing with soap, hygienic disposal of children’s stools and improved sanitation – 
utilization of latrines or toilets. 
8.2.2 Literature search 
Each intervention was evaluated individually, a full package was tested (justified with a league 
table exercise), and interventions were tested according to delivery through a common service 
delivery channel (Table 25). The package of interventions tested in the league table was defined 
according to coverage levels that fit within the budget of the Gujarat Ministry of Health. PubMed, 
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Scopus, Embase, and Google Scholar were searched for cost-effectiveness analyses evaluating 
interventions to address diarrhea and pneumonia in the Indian context using the search terms 
‘[intervention name] cost-effectiveness‘. Inclusion criteria were 
1. Being from India, South Asia, or a LMIC, with priority given to articles identified from 
studies in that order.  
2. Appropriate service delivery channel – for example, a mix of community and facility 
based channels for breastfeeding promotion is appropriate (4) instead of hospital based 
programs alone (314) 
3. Presenting results in terms of incremental costs per death or DALY averted 
4. Disaggregating costing data to facilitate calculation of the budget requirements 
8.2.3 Decision making criteria 
In addition to cost-effectiveness, other decision making criteria defined by Musgrove (1999) were 
considered (175). These included economic efficiency and ethical criteria. 
 
Economic efficiency criteria 
1. Whether the intervention is a public good 
2. Whether positive or negative externalities are associated with the intervention 
3. Whether the intervention can avert catastrophic health expenditures to households 
4. Whether the intervention is cost-effective relative to the status quo, or a null comparator 
Ethical criteria 
5. Whether the intervention addresses diseases of poverty 
6. Whether the intervention improves horizontal equity 
7. Whether the intervention improves vertical equity 




Costs were calculated from a societal perspective consistent with textbook recommendations for 
economic evaluation (88, 133, 155). This calculation assumed a well-functioning health system, 
with adequate infrastructure and human resources, and that only the incremental costs of 
providing the additional services would be of interest to policy makers. 
 
Program costs were drawn from a variety of sources due to the large number of interventions 
considered. Start-up costs consisted of training alone, assuming that no recruitment was necessary 
of new health workers. Levels of training included master training of trainers (1 event), training 
of supervisors in each of the six districts, and training of health workers. Lump sums were taken 
from the Haryana trial data [Lefevre et al, unpublished data], and scaled up to six districts. No 
international consultant or field testing costs were assumed due to lack of data, despite 
conventions to include them (224), and this may underestimate the true costs.  
 
Facility costs consisted of those for administrative buildings, and were derived from DAZT 
program records assuming a headquarters in Delhi, and separate offices for public and private 
sector operations in Gujarat. Costs of health facilities were assumed to be the same across trial 
phases as no new building of facilities was anticipated, and facilities were not anticipated to 
remain open an additional number of hours. Expenditures on rent represented the value of 
facilities, which was also assumed to include the costs of utilities (electricity and gas, telephone 
and mobile phone, water) and maintenance. 
 
Vehicle costs included one vehicle for the program supervisor and a vehicle for each of the 
program offices based on data from the Haryana trial [Lefevre et al, unpublished data]. No 
additional vehicles were assumed for health worker use, as it was assumed that these were 
provided by the existing health system. However, transport and storage was assumed for costs of 
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the cold chain, for which costs were scaled to the population size of the six districts (315). It was 
assumed that distribution costs of medicines were included in their price. 
 
In-service training of pharma partners in diarrhea epidemiology and benefits and use of zinc was 
based on DAZT program records. Additional training for each of the new vaccines was assumed 
to require seven modules lasting half of a day in total (316), with an additional half day on 
vitamin A administration. No additional training was assumed for breastfeeding counselling as 
ASHAs already provide this service. Also, it was assumed that health workers were already 
trained in providing antibiotics for dysentery and pneumonia, and in treating severe cases. No 
account was made for governance, management information systems, monitoring and evaluation, 
or overall health system strengthening. 
8.2.5 Cost-effectiveness  
Cost-effectiveness was calculated according to incremental cost-effectiveness ratios (ICERs), 
defined as the incremental cost divided by the incremental effects of each bundle of interventions 
(133). Both costs and effects were calculated according to coverage levels of the interventions in 
each bundle. Initial coverage levels were defined according to NFHS and Multi-Indicator Cluster 
Survey (MICS) data for rural areas (16), assumptions made by Fischer-Walker et al (2011) (90), 
and set to zero for vaccines considered as they have not yet been introduced. Conservative and 
universal coverage scenarios were modeled (90) according to a variety of criteria. Coverage 
levels for zinc and ORS were defined according to levels observed in the DAZT program 
between 2011-2013 (Chapter 6), and were assumed to follow linear trends to 2015. Increases in 
coverage of antibiotics for dysentery and pneumonia were assumed to occur proportionally. 
Vaccine and Vitamin A coverage levels achieved were defined according to existing levels of 
Diphtheria-Pertussis-Tetanus (DPT) vaccine coverage as they may be delivered together (16). 
Levels of breastfeeding were set according to values used in Fischer-Walker et al (2011) (90). 
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The number of severe diarrhea cases observed in each study phase was about 1%, consistent with 
OneHealth assumptions. While only half the number of severe diarrhea cases was seen at the end 
of the study as compared to the start, it was assumed that the program did not have a detrimental 
effect on treatment of severe cases, and that 100% were treated through the duration of the scale 
up.  
 
The universal scale up scenario was defined using existing estimates from Fischer-Walker et al 
(2011) (90), which were based on expert opinion stemming from discussions between Christa 
Fischer-Walker and Nancy Binkin. Further assumptions were made for pneumonia interventions 
not covered in that paper. Coverage levels for the HiB vaccine were set at 96% in this scenario 
based on levels that were achieved in Bangladesh (14). Coverage levels for the pneumococcal 
vaccine were set to be the same as the HiB vaccine since they have the same dosing schedule 
(317), and no estimate was available from Fischer-Walker et al (2011) (90). Coverage of 
antibiotics for pneumonia was scaled up to 90% consistent with antibiotics for dysentery (90). 
 
Outcomes were modeled using the Lives Saved Tool (LiST), which is a software program used to 
predict the impact of increases in intervention coverage achieved by large scale programs in terms 
of child lives saved (318). LiST is part of the Spectrum policy modeling system, which 
incorporates data from Demographic Health Surveys and Child Health Epidemiology Reference 
Group (CHERG) reviews of the effectiveness of interventions on disease specific mortality. 
Modules in Spectrum include demographic modeling, HIV modules, and the LiST tool. LiST 
calculates impact by attributing effectiveness to preventive interventions before curative 
interventions. Parameters were modified to reflect setting specific conditions such as 
demographic characteristics, initial coverage of interventions, and extent to which they were 
scaled up. However, as LiST is a deterministic model, effectiveness results were not given with 




LiST projections were generated using established methods (318). The time frame was set 
according to the starting year of the DAZT trial (2011) extended to five years to be consistent 
with funding cycles (228), election cycles, and previous work (90). Conditions in India were 
described in terms of five categories of variables including maternal, neonatal, and child mortality 
including stillbirths; exposure to plasmodium falciparum, or zinc and vitamin A deficiency; risk 
factors for child illness; intervention coverage; and demographic data from the National Family 
Health Survey (318). 
 
Resource requirements were drawn from the OneHealth manual, which is based on WHO clinical 
protocols. Costs were drawn from a variety of sources, outlined in Table 26. Personnel salaries 
and amount of time required were drawn from the LiST tool, which uses data from WHO-
CHOICE (90). Costs of medicines were drawn from the Management Sciences for Health (MSH) 
International Drug Price Indicator Guide (319). Vaccine prices were taken from GAVI alliance 
sources (320, 321), and published literature (166, 167). Costs of materials were taken from the 
UNICEF supply catalogue (322), and other online vendors. Prices per intervention were 
multiplied  by the population in need, or percent of the population that should be receiving the 
intervention annually (323). Resource requirements for each intervention are listed in Table 27. 
 
Incremental cost-effectiveness ratios were converted to 2013 US$ using consumer price indices 
from the International Monetary Fund for national level estimates, or percent change in average 
consumer prices for regional level estimates (229). Currency conversion for one study was 
performed using the mid-year exchange rate from OANDA.com (324). International dollars were 
converted to United States dollars using a purchasing power parity index from the World 
Databank (14). Uncertainty around ICERs was quantified using non-parametric bootstrapping 
(133), with simulations generated with Monte Carlo Simulation using a visual basic macro for 
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Microsoft Excel. Beta distributions represented probabilities given that they are bounded by zero 
and one, and gamma distributions represented costs given that they are bounded by zero and have 
a positive skew (139). Alpha and beta parameters for these distributions were defined using the 
‘method of moments’ according to the mean and variance of a triangular distribution, defined by 
the best estimate, low, and high values drawn from the literature (325). Calculation of costs and 
probabilistic sensitivity analyses were performed in Excel using a Visual Basic for Applications 
macro. 
8.3 Results 
8.3.1 League table results 
For the league table exercise, the literature search revealed 19 studies with ICERs eligible for 
consideration, although most were excluded from analysis. Two studies on vitamin A fortified 
mustard and rice were excluded as outcomes were not assessed with respect to diarrhea (326, 
327). Dabral (2009) evaluating measles vaccines was excluded as measles deaths due to diarrhea 
are classified as measles by international conventions (90). An analysis of ORS and 
recommended home fluids by Islam et al (1994) was excluded due to its date (328). Gupta et al 
(2013) was excluded as it was conducted for a Haryana state perspective (329), and Gujarat 
specific data was available from Clark et al (2013) (166). Other studies excluded are listed in 
Table 28. 
 
Disaggregated cost data was available for five studies which could be included, listed in Table 29. 
If a ceiling ratio of per capita Gross National Income for Gujarat is used (US$1,653), the 
necessary budget would be $47,283,301 to finance all five interventions listed at full coverage. 
However, given that the total public and private expenditures for health in Gujarat was 
$1,261,866 in 2008-9 (330), and with 18.1% of people living in the study districts, the budget 
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would be $228,538 if allocated proportional to population. Within this budget, only zinc 
supplementation could be financed, and at less than 8% coverage. 
8.3.2 Other criteria 
Other diarrhea interventions were considered for inclusion, but there was reason to omit them 
from the league table, as indicated in Table 28. Therefore, the set of interventions evaluated with 
CEA was incomplete, limiting the scope of the league table. However the case was made to 
include these interventions in the recommended package based on the following rationale 
according to Musgrove (1999) criteria (175). 
 
Both herd immunity and interventions that lower disease incidence are public goods as their 
benefits are spread across the entire community whether or not individuals choose to consume 
them (331). Unvaccinated individuals enjoy the benefits of immunity despite not choosing to 
receive the vaccine. In addition, breastfeeding reduces incidence of both diarrhea and pneumonia 
(5, 332). These goods are non-excludable and non-rivalrous (333) in that individuals cannot be 
excluded from use, and consumption by one person does not preclude consumption by another. 
Since all of the other interventions in the league table reduce incidence, they all can be considered 
public goods. 
 
Many externalities, or costs and benefits beyond the scope of the analysis, are associated with 
these interventions. Breast milk diminishes the adverse effects of diarrhea on nutritional status 
(4), contains many immunobiological components which confer protection to diseases beyond 
just pneumonia and diarrhea (332), confers protection against post-partum depression (334), and 
helps mothers provide adequate space between births (335). Vaccines, as discussed, confer herd 
immunity, which protects unvaccinated people from illness (167). Zinc confers protection beyond 
diarrhea and pneumonia treatment and prevention, including general benefits to the immune 
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system (336), and contribution to child growth. From a health systems perspective, scaling up 
zinc can increase uptake of ORS (337). Both zinc and vaccines can slow the development of 
antimicrobial resistance in affected organisms by reducing the amount of antibiotics prescribed 
for bacterial infections (4, 338, 339). Vitamin A provides protection against night blindness and 
xerophthalmia (340). Antibiotics can treat subclinical infections, although their overuse can lead 
to unintended negative consequences such as drug resistant strains of bacteria. At a macro level, 
control of diarrhea and pneumonia has external benefits to other sectors, such as transportation, 
tourism, and manufacturing (338). 
 
Hospitalization for both diarrhea and pneumonia can have serious financial implications to 
caregivers.  Alamgir et al (2010) showed that hospitalization for pneumonia can become 
catastrophic for poor families in Bangladesh (341). While Sheih et al (2013) conclude that 
diarrhea hospitalization was unlikely to cause catastrophic expenditure in Ho Chi Minh city 
(342), Rheingans et al (2012) highlight the importance of rare, expensive events (95).  
 
Despite being common enough to affect everyone – rich and poor, old and young, and people in 
developed and LMICs – diarrhea particularly affects people living in poverty due to its 
association with unhygienic environments (4). In addition, the incidence of pneumonia 
disproportionately affects the poor (305, 332, 343). Breastfeeding has the potential to reduce 
inequalities in health (344) and is possibly progressive – mothers in the richest wealth quintile 
were less likely to exclusively breastfeed in India (345) and Pakistan (346). With diarrhea 
affecting the poor preferentially, mothers of the highest priority are doing more breastfeeding. 
Treatment with zinc, however, is regressive, with DAZT data showing caregivers in the least poor 
quintile being nearly twice as likely as giving zinc as those in the poorest two quintiles [Lefevre 
et al, unpublished data]. The distribution of vaccination across wealth quintiles improved between 
the first and second rounds of the National Family Health Surveys in urban areas, but not in rural 
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areas (347). Antibiotics are widely prescribed, even in rural areas, which has the semblance of 
equity but poses the risk of antibiotic resistance (348).  
 
All of these interventions prevent or treat diarrhea or pneumonia, the two leading causes of child 
death worldwide (5), which gives the semblance of addressing the ‘rule of rescue’. However, 
‘rule of rescue’ refers to interventions that can be visibly observed to save an identifiable life 
(349). As the interventions considered for the full bundle address treatment of non-severe cases, 
or are preventive measures, they do not satisfy the ‘rule of rescue’.  
8.3.3 Cost and cost-effectiveness results 
Figure 20 shows the number of lives that can be expected to be saved each year with 
implementation of the full package of interventions according to the coverage levels used in the 
study (Table 30). Number of child deaths declined from 7,503 in 2011 to 4,749 in 2015 in the 
conservative coverage scenario, and from the same initial number to 3,499 in the universal 
coverage scenario. The total recurrent cost over five years was $48.3-$62.9 million, with the 
largest component being for oral rehydration salts due to the frequency of episodes and high 
coverage, and the smallest component being antibiotics for dysentery (Table 31). Program costs 
totaled $640,899 per year (Table 32). Assuming that program costs were distributed evenly across 
interventions, the most cost-effective intervention was breastfeeding promotion due to its low 
cost, which became cost-saving when discounted at 3%. The least cost-effective (Table 33) was 
zinc supplementation due to the high frequency of episodes, low number of deaths averted 
relative to ORS (66% lower), and high costs (33% higher). For treatment of severe diarrhea and 
pneumonia, cost-effectiveness was undefined as it was assumed that the program did not have an 




For the total package, incremental cost effectiveness ratios were found of $159.85 (95%CI: 
$134.86-$192.27) per DALY (3,0) averted in the conservative coverage scenario, and $185.50 
(95%CI: $156.65-$221.80) per DALY (3,0) averted in the universal coverage scenario (Table 
34). Considering a 3 dose regimen of rotavirus vaccine did not have an important effect on 
results, raising the cost-effectiveness of the package in the conservative scenario to $159.85 (95% 
CI: $134.86-$192.27).
56
 Results were sensitive to alternative DALY scenarios using variations in 
the discount rate between 0% and 6%, although were robust to formulations with and without age 
weighting. By delivery channel, cost varied according to comprehensiveness of the package 
(Table 35), and cost-effectiveness ranged from $95.49/DALY (3,0) averted (95%CI $75.99-
$117.72) for community based interventions to $208.53/DALY (3,0) averted (95%CI $196.87-
$233.49) for the outreach package in the conservative scale up scenario (Table 36). Differences in 
cost-effectiveness between scenarios were significant for the outreach and clinic bundles.  
8.4 Discussion 
Results from this study emphasize the cost-effectiveness of community based care relative to 
facility based services. However, which package is optimal for implementation will depend on 
the setting (292), including factors such as infrastructure, geography, cultural barriers, utilization 
patterns, financing systems, and budgets. In each context, the process of designing or adapting a 
package will allow health systems to use a degree of rationality in decisions made about what 
interventions are given the highest priority. This process will facilitate health systems planning in 
terms of coordination with manufacturers, purchasing, and training of human resources. 
However, assumptions of the process should be recognized, including that the system operates 
with technical efficiency, referral systems are well-functioning, vehicles and equipment are in 
good condition, sufficient staff exist where they are necessary, drugs are available, and facilities 
are open (288).  
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One of the main messages from the league table exercise is that there is a lack of cost-
effectiveness evaluation of key interventions to address diarrhea in the Indian context. More work 
should be done to evaluate complementary feeding, antibiotics for dysentery, and vitamin A 
supplementation with a focus on diarrhea to fill gaps in the evidence base and shift attention away 
from interventions sometimes seen as ‘magic bullets’ such as vaccines (166-168). These studies 
are expected to be of increased relevance with the formation of a health technology assessment 
organization in India to guide decision making in the public sector, which is expected to increase 
in importance in the Indian health system (180). 
 
The literature based league table that resulted from this analysis suggests that all interventions 
should be adopted in Gujarat based on cost-effectiveness evidence alone from an aspirational 
perspective (81) using per capita Gross National Income (US$1,653) to define cost-effectiveness  
(Table 29). The total budget necessary to introduce these interventions in the six DAZT districts 
is $43 million, indicating that budgets for health care must be dramatically increased or 
reallocated to address the disease burden in ways that are cost-effective, anticipating the rapidly 
growing population. This process can be difficult due to the inertia of historical factors (spending 
patterns, distribution of infrastructure, skill mix of healthcare providers and their locations, 
socioeconomics of the country, and demographic and geographic factors), political pressures and 
ideologies, and administrative procedures as allocation of government budgets not usually 
organized by type of intervention (although donor investment sometimes funds programs this 
way) (154, 288). In the case of diarrhea interventions, balance must be found between allocation 
to the Ministry of Health and Ministry of Drinking Water and Sanitation, professional 
organizations, manufacturers, government sponsored insurance schemes for the poor (Rashtriya 
Swasthya Bima Yojna), and other governmental and non-governmental organizations – 
particularly if WASH interventions are to be compared to those delivered by the health sector. 
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Budgets may also be organized according to input categories including personnel, supplies, 
maintenance, training, transport and other factors.  
 
Zinc is the least cost-effective intervention in the league table based on our model, but is the most 
cost-effective in the league table based on published literature. This discrepancy stems in part 
from the fact that zinc was evaluated alongside ORS in the Haryana study [Lefevre et al, 
unpublished data], but these interventions are evaluated separately in our model. When evaluated 
together, fewer DALYs were averted, although the joint cost-effectiveness was more favorable 
than the cost-effectiveness of the interventions evaluated individually due to synergies in staff 
time and treatment seeking costs. From a programmatic perspective, it can be argued that 
programs to scale up zinc can stimulate progress in scaling up ORS coverage (337), which is the 
intervention that averts the most DALYs due to diarrhea (Table 33). 
 
Breastfeeding counselling is also noteworthy as results between the league table approach and 
cost-effectiveness calculation are discrepant. In the literature based league table, breastfeeding 
promotion is the least cost-effective intervention, although our study argues that it is the most 
cost-effective, with low budgetary requirements relative to other considered interventions 
(discounted at 3%, the program would have negative incremental costs in the conservative 
scenario due to modest levels of expected scale up). The age specific evidence base for the LiST 
tool for averting mortality was different (350, 351) from the estimates used in the DCP2: 10.5% 
(range 4%-17%) (4). In addition, breastfeeding has many externalities, benefits the poor, and is 
equitable. Our study found that breastfeeding promotion is the most cost-effective intervention 
evaluated due to its potential to save 67-578 lives at a negative or low incremental cost to society.   
 
Increases in funding alone will not have an impact if health system capacity does not exist to 
respond to the new incentives. The level of infrastructure in the six districts of the study area is 
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comparable to other districts in Gujarat (Table 37); however, also comparable is the fact that only 
78%-92% of positions in the public health sector are filled (352). Health care in rural India often 
suffers from high levels of absenteeism, callous attitudes of providers, shortages of medicines, 
and inadequate supervision and monitoring (353). Low levels of managerial capacity and lack of 
demand due to low quality services pose additional challenges to absorptive capacity (354). There 
is some evidence that rural providers have had success in using increased investment to stimulate 
demand for family planning and vertical programs such as polio vaccination, however, scaling up 
absorptive capacity for channeling money to provide other services is a health systems challenge 
that requires long run solutions (355). 
 
As can be indicated through this analysis, decision makers face the choice between expanding the 
number of interventions included in packages, or extending coverage to new geographic regions 
and non-poor parts of the population. Literature indicates that as less accessible populations are 
targeted, increasing coverage may raise marginal costs above average costs (288, 292). However, 
an important finding from this study is that increasing coverage did not significantly worsen cost-
effectiveness, despite arguments that reaching populations located remotely from urban centers is 
more costly for less return in terms of health. The pattern associated with increasing the number 
of services in the package is less clear, although it has the risk of reducing equity in the delivery 
of services (292). Children in LMICs have been cited as an example of inequitable distribution of 
health services as most rich children have access to several life-saving interventions at the same 
time, where poor children may have access to 1 in 10 (292). An alternative is for financing bodies 
to pay for certain inputs, and let the healthcare providers determine what services will be 
provided (81) – but this approach often leads to delivery of services of questionable value (288). 
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8.4.1 Engaging the private sector 
Delivery of the interventions discussed was balanced between the public and private sectors, 
although conceivably, the program could have been conducted exclusively through the private 
sector. This assertion can be supported by health financing patterns in India – 80% of health care 
is financed privately in India, and 80% of private spending is through out of pocket payments 
(67). Specific considerations for league table analysis within the context of the private system are 
that it is less relevant whether the intervention is a public good, and the budget constraint should 
be defined to include more than just the health sector budget (adding out of pocket and insurance 
expenditures). Upon implementation, the government can engage the private sector through 
reimbursement mechanisms, best practice formularies, drug pricing guidelines, contracts with 
non-governmental organizations, monitoring mechanisms, and the requirement that insurance 
schemes and private providers provide a minimum number of interventions included in the 
package (180, 288). 
 
Vitamin A supplementation has been promoted through the private sector using social marketing 
(356), although the public sector has substantial control over Vitamin A programs (357). ORS 
may be more effectively provided through the public sector as evidence suggests that for-profit 
providers are 15% less likely to provide ORT than public providers, corroborated by several 
studies from the 1980s and 90s (358). Pharmacies are privately owned and are less likely to 
provide ORS than other facility types. There is no evidence about whether breastfeeding 
promotion is more effectively provided through the public and private sector, although advice 
could be delivered by both.  
 
Vaccines may be more effectively delivered through the private sector as the cold chain is better 
maintained than in the public sector (359). Private sector manufacturers in India are the major 
supplier of vaccines to UNICEF, and a large number of them are administered through the private 
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sector in India (360). However, vaccine deployment is also part of the National Rural Health 
Mission (360), which is public and subsumes the Universal Immunization Program (UIP). The 
central government makes all of the decisions about vaccine introduction, and is responsible for 
procuring all of the vaccines in the country. State governments in India execute vaccine programs 
(360).  
 
Antibiotics for dysentery and pneumonia can be delivered through both sectors, although might 
be prescribed more rationally through the public sector. 80% of antibiotics that were prescribed in 
DAZT were by private providers, but there is no indication about what percentage of this was for 
dysentery. Pediatricians in New Delhi working in the private sector were more than twice as 
likely to prescribe antibiotics for diarrhea as those working in the public sector (361). The 
problem with rational use of antibiotics in the public sector is drug availability. In Delhi, the 
private sector had better availability of more expensive and popular antibiotics, where the public 
sector had problems maintaining availability of essential antibiotics (362). 
8.4.2 Strengths and limitations 
There are several strengths to this analysis. It has a setting-specific scope, which will be useful to 
policy makers in Gujarat. Translating deaths averted to DALYs averted makes results more 
comparable to other studies using the same metric, such as those evaluated through WHO-
CHOICE and the Disease Control Priorities Project (162, 363). Bundling diarrhea and pneumonia 
interventions together reflects current thinking of the Global Action Plan for Pneumonia and 
Diarrhea (GAPPD) (239), increasing its relevance to policy, and updating methods from previous 
work (90). Generating outcomes with LiST gives comprehensive consideration of the available 
data from large surveys for health outcomes, and incorporates attribution of lives saved to 




There are also several limitations to this analysis. The league table exercise is not based on a 
systematic review, and important studies may have been missed. Among those studies found, the 
full range of interventions was not represented, making a comprehensive consideration of cost-
effectiveness according to thresholds impossible. While it is possible to quantify the relative 
importance of cost-effectiveness to other decision making criteria with appropriate data collection 
and methods (282), no attempt was made at multi-criteria decision analysis in our study. 
Methodological heterogeneity affected the sample of studies used in this analysis, and it was 
difficult to assess some attributes due to lack of reporting. For example, the perspectives of the 
analyses were a mixture of the public sector (125, 166), societal (70, 167, 168), or not stated (4) – 
reflective of reviews of the cost-effectiveness literature (364). This inconsistency mainly affects 
cost, which is the element most likely to vary across settings (365). Only one study gave 
perspectives on generalizability (70), although most analyses included were already done from a 
national (166, 167) regional (4, 125), or multicountry (168) perspective. Only one study presented 
ranges of uncertainty around ICER estimates (70), which has been argued to be essential in 
league table methodology (366).  
 
There was inadequate reporting of what comparison strategy was used in included studies (4, 125, 
167), and studies were mixed between those using comparators representing a null scenario (no 
intervention) (166, 168) or status quo conditions (70). Contrary to the assumptions of generalized 
cost-effectiveness analysis (227), Drummond argues that even with no intervention in the 
comparison arm (e.g. a no-screening scenario), some costs and benefits are inevitable due to 
passive case detection or other mechanisms, and that these outcomes should be accounted for in 
analysis (366). Even in very poor health systems, some degree of health seeking behavior can be 
expected in the absence of a program, although under the assumption that the treatment is 




The discount rate has become standardized at 3% in the international health literature, consistent 
with WHO-CHOICE (88) and DCP2 guidelines (130), and was either 3% (70, 166-168) or not 
stated (4, 125) in our selection of studies. An advantage of economic evaluation in the 
international health context is that DALY weights are provided by the WHO (231), reducing the 
amount of heterogeneity in utility weights that affects the high income country literature (366), 
although the new edition of the GBD study has released disability weights to revise those based 
on expert opinions that it provided in the past – improving the empirical foundation of the 
evidence base (138). 
 
In calculated cost-effectiveness estimates, this analysis does not account for the fact that different 
children will have access to different sets of interventions – some will have access to many 
interventions, others will have access to few – affecting the effectiveness of interventions. Health 
systems strengthening costs were excluded from the analysis, which can be substantial and 
necessary to achieve technical efficiency. Data for program costs was patchy, and drawn from a 
variety of sources, although this limitation is typical of modeling exercises evaluating outcomes 
not prospectively planned before data collection (for example the World Health Report 2000 
relied on synthesized and imputed data (367)). Cost curves and coverage scale up trajectories may 
be non-linear, such as the sigmoidal trajectories for scaling up child health interventions assumed 
by the WHO (368), although it is not clear what precise shape to give these curves given the 
available data. While ranges of effect sizes for the respective interventions are available in the 
CHERG reviews informing the LiST tool (34, 50, 369-376), it is not clear how some of them 
align with the reference case chosen for the model (313), restricting these parameters from being 
included in the probabilistic sensitivity analysis. Evaluating interventions in isolation is artificial, 
and the modeling techniques used only account for sequential attribution of lives saved and some 




There are limitations in how recommendations of packages of services may be implemented. No 
consideration is given to the tradeoff between coverage and quality – whether expanding number 
of health workers includes those of lower competencies, or whether programs functioning under 
tight deadlines can avoid taking shortcuts that affect effectiveness (292). Alternative delivery 
strategies are not considered, or their effect on costs or effectiveness, although their cost-
effectiveness should be considered along with that of the interventions themselves (292). A 
constraints analysis could be done to assess these and other barriers to scaling up. 
8.4.3 Further research 
 
The model should be further developed to account for synergies between the costs of each 
intervention, and to better reflect the realities of the health system in Gujarat. Consultation with 
health officials in Gujarat is needed to determine the face validity of results, fill missing program 
cost components, and better define assumptions. The emergence of the new Rotavac vaccine in 
India (377), and the controversy surrounding its approval for the Universal Immunization 
Program (378), indicate that it should be studied once estimates exist on its impact on mortality. 
As the costing component of the LiST tool develops, parameterization can be selected according 
to the translog functions that it uses to generate costs. Further development to make the LiST tool 
probabilistic could be done on its underlying spreadsheets using the VBA macro used in this 
chapter.  
8.5 Conclusions 
This study evaluated the cost-effectiveness of scaling up zinc and other interventions to prevent 
and treat diarrhea and pneumonia in the context of rural Gujarat India, using outcomes predicted 
by the LiST tool. The analytic approach is new to this area in that it uses probabilistic sensitivity 
analysis to evaluate uncertainty around ICERs. The main finding is that investing in diarrhea and 
pneumonia interventions is highly attractive in the six districts of Guajrat included in the DAZT 
program, although increases in investment and health systems strengthening are necessary to 
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ensure adequate coverage and realize the full benefit. A clear pattern of efficiencies in bundling 
increasing numbers of interventions was not seen in this analysis, although may be revealed with 
more sophisticated modeling and operational research. In addition, inefficiencies in expanding 
services to greater proportions of people may not be inevitable, with further costs balanced by 
further health gains.   
129 
  
9. Policy implications 
9.1 Introduction 
This main objective of this dissertation was to evaluate the economic case for the DAZT program 
in rural Gujarat India, and theoretical argument for investment in the context of other diarrhea and 
pneumonia interventions. Paper 1 evaluated the costs to caregivers of providing diarrhea 
treatment to children under 5, changes in these costs over the course of the DAZT program, and 
factors associated with costs. Paper 2 evaluated the cost-effectiveness of the DAZT program and 
the importance of controlling for covariates given the uncontrolled non-randomized study design 
of the program evaluation. Paper 3 examined the cost-effectiveness of the DAZT program when 
bundled with other interventions to prevent and treat diarrhea and pneumonia, and compared 
modeled cost-effectiveness estimates of these interventions with results found in the literature and 
current health expenditures in Gujarat. Main themes are summarized in Figure 21. The goal of 
this research is to inform investment decisions that will increase the effectiveness of the health 
system in rural Gujarat given limited resources. Given that the health system in this area is largely 
private, this research is expected to inform decisions faced by formulary developers, clinical 
practice guideline developers, and social franchises deciding which services to provide – in 
addition to a benefits package provided by the public health system. 
9.2 Summary of chapters  
The analysis in Paper 1 showed that costs to caregivers were reduced in the two years of the 
program. The main drivers of costs were wages lost, purchase of other drugs such as antibiotics 
and antidiarrheal medicines, and transportation costs. Unadjusted analysis indicates that the 
biggest decline in costs was among private providers, although these providers remained the most 
expensive sources of care. Costs were lowest at community based public providers (ASHAs and 
AWWs). The program was not associated with a change in the odds of incurring a cost, but was 
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associated with a lower overall economic cost to caregivers across the course of the study 
controlling for confounders. Per million population, the program was associated with a cost 
savings to society of $687,572. In future development and in scaling up to other areas, the 
program should focus on service delivery through private providers, where most care was sought, 
and develop strategies for encouraging increased use of public community health workers. These 
findings emphasize the importance of the health systems component of the intervention as giving 
zinc was not associated with lowering the cost of treatment to caregivers controlling for other 
covariates. 
 
In paper 2, the cost-effectiveness of the program was evaluated using a net benefit regression 
framework building on methods of Hoch et al (2002) (86). A novel adjustment to these methods 
is introduced in reformulating the net-benefit statistic to accommodate health gap measures, 
which opens the scope of net-benefit regression to new econometric modeling techniques. 
Unadjusted analysis indicated that the program was associated with fewer episodes and lower 
costs to the health system from a societal perspective, and adjusting for covariates did not alter 
the recommendation in favor of the program. Costs to caregivers were the main driver of costs, 
which were reduced by over half across the span of the program, and exceeded program costs by 
an order of magnitude at study completion. More work is necessary to determine why the 
prevalence of diarrhea was reduced as it could have been due to secular trends unrelated to the 
program such as improvements in living conditions, access to safe water, and sanitation practices; 
or due to other factors such as the Hawthorne effect or regression to the mean. 
 
In paper 3, the review of studies evaluating interventions for diarrhea and pneumonia revealed 
that all are cost-effective, although public and private expenditures are currently insufficient to 
provide them at any reasonable level of coverage. The set of interventions evaluated in the 
literature is incomplete, and further work is necessary to evaluate complementary feeding, 
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antibiotics for dysentery, vitamin A supplementation, and antibiotics for treating and managing 
pneumonia. The case can be made for all interventions considered using criteria from Musgrove 
(1999) (175), although some degree of prioritization is expected to be inevitable given current 
budgets and health system capacity.  
 
Modelled results from paper 3 indicate that incremental costs of scaling up the full package of 
services are expected to be between $12-$20 million in the study area, and are expected to avert 
2,754-4,004 deaths. Calculations suggest that the total package was highly cost-effective at 
$155.02 (95%CI: $128.58-$183.33) per DALY averted in the conservative scenario, which is 
well below the per capita GNI in Gujarat of US$1,653. The most expensive and least cost-
effective intervention was zinc supplementation due to the frequency of episodes, its higher per 
unit cost, and modest DALY reduction relative to ORS. The least expensive and most cost-
effective intervention was breastfeeding promotion due to its low incremental cost, which was 
negative in the conservative scenario with a 3% discount rate. Cost-effectiveness of any 
intervention or bundle of interventions never exceeded the per capita GNI threshold. The main 
message from this analysis is that health sector budgets should be increased, ensuring that 
absorptive capacity exists to deliver the services, and that diarrhea and pneumonia interventions 
are a good investment. 
9.3 Policy and implementation context 
Basing decisions about what interventions to provide through the health sector on cost-
effectiveness is consistent with objectives of making both national and donor investment more 
efficient. International aid and avertable disease burden are not well aligned in many cases, with 
the exception of some multilateral donors such as the Global Fund and GAVI, and some bilateral 
agreements between the UK, Germany, Denmark, and recipient countries (154). Child health 
interventions are some of the most cost-effective available to low- and middle-income country 
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health systems (102, 379), and saving child lives is consistent with Millennium Development 
Goal 4, which is due to be replaced by Focus Area 3 of the Sustainable Development Goals (380). 
Making services available close to client minimizes travel expenses and time lost from paid 
employment, which is consistent with Alma-Ata article VI to make services universally available 
to individuals and communities at a cost that they can afford (381). Given these mandates, it 
matters how diarrhea programs are promoted to policy makers. Based on an analysis using Policy 
Maker software (similar to stakeholder analysis), Bump et al (2012) advocate promoting diarrhea 
programs as part of a technology and vaccine implementation strategy, or as part of a health 




From a national level policy perspective, zinc and ORS are already advocated by the Indian 
government for the treatment of child diarrhea (42); however, scale up has been slow given the 
policy constraints and supply and demand side challenges mentioned in the introduction that have 
inhibited widespread coverage. To address these obstacles, DAZT partners have committed $1.5 
million to support the state government in training 97,000 health workers in the proper use of zinc 
and ORS to scale up coverage to all 26 districts of Gujarat (382) and further areas of Uttar 
Pradesh (383).  This policy is consistent with the constitution, which recognizes the importance of 
serving marginalized groups. 
 
Whether scaling up zinc coverage nationally is feasible depends on manufacturing capacity, 
which currently includes a limited number of national and international companies (61). The most 
notable is Bharat Immunologicals and Biologicals Corporation Limited (BIBCOL), which is a 
government owned corporation with the capacity to produce 240 million tablets of 20mg scored 
tablets of zinc sulfate per year (59). At least five other companies (brands) exist in India, 
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 Bump et al (2012) acknowledge that promoting diarrhea programs as a child health strategy is more 
feasible now than it was in 2008, when support for child health programs had waned. 
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including Zuventus (Zinconia), Dr Reddy’s (Z and D), Wallace (ZN), USV (Trustim), and 
Emcure (Emzinc) (61). Sales in India have increased dramatically since 2005 (61), with some 
companies selling exports. In addition, Gitanjali and Weerasuriya argue that production capacity 
to address the burden of diarrhea in India appears to exist (56).  
 
Feasibility also depends on the presence of infrastructure and human resource availability and 
receptiveness to decision making based on cost-effectiveness evidence. There are more private 
doctors and community health workers than other cadres of health worker in Gujarat (352), with 
the National Rural Health mission aiming to establish 400,000 ASHAs (384) that can provide 
close to client care for the frequent occurrence of episodes. Having the appropriate skill mix of 
cadres in each geographic area is important to ensure widespread coverage of zinc and ORS, 
coupled with appropriate referral and management of severe cases. 
 
Economic evaluation has been criticized as politicians tend to approve interventions that affect 
themselves and their own families, and generally do not like to acknowledge explicit rationing as 
it is always associated with a bad outcome for some group, incurring costs to decision makers 
who do not stand to benefit from the decision (385). In addition, policy makers may not 
understand methods and jargon, and study results may not always be produced in a timely manner  
(385). There are identifiable methodological problems in many evaluations, and results from 
studies are not always transferrable to the relevant jurisdiction (385). In defense of economic 
evaluation, it offers a useful means to structure thoughts about both costs and benefits, and is 
rarely considered as a sole decision making criterion (175, 385, 386). Priority setting is 
particularly important in emerging markets where budgets are limited (154), and to identify new 
priorities as these countries progress through the demographic transition, experience economic 
growth, and confront a ‘triple burden of disease’  (10, 11).  
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9.4 Amount of investment recommended 
Results from this dissertation promote the continued scaling up of zinc to similar areas with a 
high burden of diarrhea and limited access to appropriate treatment. Diarrhea treatment costs 
caregivers $7.6 million in the six survey districts per year, and $1.5 billion scaled up to the 
country level.
58
 Results from these analyses indicate that zinc is expected to save caregivers 
money and be cost effective with >95% certainty controlling for other factors. Based on program 
cost data, the amount of investment recommended by this analysis would be $88,328,946 
nationwide. With universal coverage, this investment could be expected to provide caregivers 
with an savings of an order of magnitude at $818,916,895 (387). Politicians might justify this 
investment with projections with how the resulting savings might boost economic development, 
and devise strategies for channeling some of the savings into tax revenues so that the program 
pays for itself.  
9.5 Importance of close to client services 
The most favorable cost of service provision through ASHAs and AWWs emphasizes the 
importance of community based delivery. The case has been made that CHW programs are cost-
effective health systems strategies that reach underserved populations with effective, low-cost 
interventions (388). However, evidence on the cost and cost-effectiveness of CHW programs is 
only recently emerging to make informed discussion of the economic case for these programs 
possible (89, 274, 389-392). Our study makes the case for the DAZT program in terms of cost, 
although it was not possible to evaluate the relative cost-effectiveness of different service 
providers since observed outcomes were the same across all of them.  
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Health systems may be able to support scaling up the DAZT program to other areas with 
emphasis on close to client providers. A 2011 report indicates that only 10% of sanctioned ASHA 
positions were vacant in the study area, which is comparable to other districts in Gujarat (352). 
However, there is a shortfall of 12% of the required 7274 auxiliary nurse midwives (ANMs) at 
subcenters in Gujarat, and a shortfall of 23% of the required 8432 ANMs at PHCs (393). National 
trends for scaling up CHW numbers are encouraging, with an increase in female health workers 
of 56% between 2005-2012 (394), changes in policy to post two female health workers at each 
subcenter, and the commitment of the National Rural Health Mission (NRHM) to provide human 
resources in underserved areas (395). However, producing more CHWs cannot be expected to 
automatically scale up appropriate diarrhea treatment. Historically, community health worker 
programs in India have suffered from various problems, such as conflicts about remuneration, ill-
defined definitions of responsibilities, and lack of community ownership; although these issues 
are being addressed in current CHW programs (396). In addition, knowledge retention among 
health workers needs assessment before they are allowed to work in the field, as well as refresher 
training (397). Further challenges to scaling up services to new areas include absorptive capacity, 
management constraints, lack of regulation, and absenteeism (354). An alternative strategy is to 
increase the work hours and responsibilities of existing ASHAs as they currently only work 25 
hours per week (397). 
3.1 Bundled services 
This study also indicates that bundling can be an attractive health systems strategy for scaling up 
priority services efficiently. Several countries have attempted provision of bundled services, 
particularly through the Minimum Care Packages, although with mixed results (290, 398, 399). 
These findings emphasize that the method that services should be bundled depends on the 
financing capacity, drug supply, human resources, working conditions, and the health systems 
structure of the area. Conversely, Salam (2009) discusses implementation of services with 
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greatest impact (400), implying that health systems should adapt to fit recommendations based on 
the published literature. Whether a normative view or consideration of existing conditions is 
taken, the bundling framework is useful to consider decisions in a framework more representative 
of how interventions will be implemented, rather than the individual context in which 
interventions are usually evaluated in cost-effectiveness analysis. 
3.2 Gender bias 
Gender bias is a commonly recognized problem in India, which ranks 101 out of 134 nations 
worldwide in level of gender equity in health and survival (401).
59
 However, the lack of evidence 
of an influence of child sex on costs and cost-effectiveness in our analysis is notable. In literature, 
there was an absence of evidence of inequality for care seeking in the more developed state of 
Kerala (193), although an absence of evidence is not evidence of absence in scientific analysis. A 
contingent valuation study in Chennai indicated that parents were willing to pay more for diarrhea 
treatment for a male child than for a female child when adjusted for duration and severity of the 
illness, particularly among more educated households (189, 192). NFHS-III data showed 
evidence of gender bias in diarrhea care seeking nationwide in 2005/6 (191), and gender bias has 
been found in other child health indicators (402). Gujarat is already a state where gender bias in 
child health is a recognized problem (402), and the problem may worsen as the state develops and 
people become more educated. However, rewards for ‘whistle-blowers’ on sex selection is cited 
as a priority by the Gujarat Ministry of Health (403), suggesting that efforts are likely to promote 
gender equality. 
3.3 Link to literature 
Findings from this dissertation are consistent with previous work that zinc and ORS are likely to 
be cost-effective for treating acute diarrhea in children under 5 in a community setting (70). It 
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emphasizes the importance of a delivery strategy that uses a variety of service providers, and in 
its innovative engagement of the private sector. The cost-effectiveness of DAZT was more 
attractive than what was found in the Haryana trial, despite a smaller incremental increase in zinc 
coverage, because program costs per million people were much lower ($70,542 in DAZT and 
$477,034 in Haryana), and cost savings per caregiver were higher ($1.45 in DAZT and $1.32 in 
Haryana).
60
 A model by Robberstad et al (2004) did not account for transportation for caregivers 
or wages lost, as well as assumed fixed prescribing patterns (99). Likewise, the ORASEL trial 
evaluation did not account for these factors (132). 
 
The impact of studies evaluating the cost-effectiveness analysis of zinc in the academic literature 
has remained limited, with around 30 citations of the most-cited study in the last ten years (99), 
and even fewer citations of other studies (10 citations for Patel et al (2003) (68), 16 citations for 
Gregorio et al (2007) (87), and 2 citations for Patel et al (2013) (85)). However, sufficient 
political support has been achieved to create the POUZN, SUZY, and DAZT programs, all of 
which have been successful in scaling up zinc. Findings confirm that increased levels of coverage 
are attainable when activities extend beyond one year, although did not achieve levels attained in 
the Haryana study (70). An intensive trial in Bangladesh attained over 80% coverage after 7 
months of implementation (242), and further research is necessary to examine what levels of 
coverage are achievable at scale in the long term. It is estimated that universal coverage with 
ORS would reduce diarrhea mortality by 93% (34), and that universal coverage with zinc would 
lower diarrhea mortality by 23% (50).
61
 It is relevant to consider economies of scale when 
comparing results to other community based studies, with program costs being spread across a 
larger set of individuals in the DAZT program leading to the lower cost per million population. 
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 An important methodological difference in the calculations for these two studies is that the Haryana trial 
had a control group, allowing a difference in differences calculation.  
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 LiST calculates mortality reductions sequentially, with the percent reduction on mortality from each 
intervention being calculated on the remaining cohort of individuals when interventions are evaluated 
together.   
138 
  
3.1 Economic evaluation in India 
Economic evaluation is not adequately considered in health systems planning in India, with only 
around 30 studies indicated by PubMed. However, an evaluation of evidence from the Disease 
Control Priorities project was conducted in 2007 (147), and further research is being done by the 
DCP research team in the Indian context with state of the art methods (165, 167). The formation 
of a Health Technology Assessment body based on the model of the National Institute of Health 
and Care Excellence in the UK is likely to increase the importance of economic evaluation in the 




Health Technology Assessment internationally has been advocated as a strategy for achieving 
universal health coverage, both directly through national HTA bodies, and through knowledge 
transfer from countries with more developed organizations (404). These organizations increase 
the relevance of cost-effectiveness evidence. As Rudolf Klein stated, ‘unless we strengthen our 
institutional capacity to analyze evidence, to clarify policy choices and to promote informed 
debate, generating more information is more likely to compound confusion than lead to better 
decision making’ (154). Importantly, evidence based policy making must take into account the 
local context. Hass argues that maximizing health may not be consistent with the objectives of 
Indian health systems planners whose decision making processes may be tied to eastern 
philosophy, where balance may take priority over maximization (180); however, people have 
been shown to value equity in a wide range of contexts (405), and research is needed to fully 
understand what factors are relevant in India.  






3.2 Strengths and limitations 
Overall, this dissertation has several strengths and limitations. The size of the dataset provided 
sufficient power to test hypotheses, although exceeded the limit required by some statistical tests 
such as tests for normality. In addition, risk of type 1 error exists when calculating regression 
coefficients in large datasets, which was particularly relevant for the net-benefit regression. The 
study design was valid given that it would not be ethical to conduct a controlled study on zinc 
given its proven effectiveness (50). In addition, introducing zinc at scale is consistent with policy 
in India to provide zinc to children older than 2-3 months. The broad case mix of the study and 
statistical methods facilitate subgroup analysis and generalizability, although from a policy 
perspective universal coverage of zinc has been advocated (278).  
 
Measures of effectiveness are complicated by intrinsic limitations of the uncontrolled before and 
after study design (262). Secular trends such as improvements in living conditions, access to safe 
water, and improved sanitation may have contributed to the decline in diarrhea prevalence in the 
DAZT study area (406).
63
 In addition, this study design is sensitive to sudden changes in the 
conditions of the study area (407). The Hawthorne effect is a potential confounder, which may 
have overstated the magnitude of the effect (262), consistent with results from a meta-analysis 
comparing controlled and uncontrolled studies (262, 407). Regression towards the mean may be 
problematic (263), which means that if a study had high diarrhea prevalence at beginning, future 
measurements will be likely to be less extreme. The DAZT study found a 14% prevalence of 
diarrhea in 2011, while levels were 13% in in 2005/6 in Gujarat (26), and were 9% nationwide 
(16). Regression to the mean predicts that the prevalence would be lower in future surveys as 
downward changes would be more frequent than upward changes. 
 
                                                          
63
 It is not possible that reductions in diarrhea were due to scaling up the rotavirus vaccine as it has only 
been approved in India – it has not been rolled out yet. 
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Data were based on self-report, which may have introduced reporting bias into our data, although 
recall bias was minimized by limiting the period of interest to the two weeks before the study, and 
the in-person questionnaire may have helped aid the memories of respondents. Only rural areas 
are represented in the sampling frame, although rural areas are the main settings in which the 
availability of zinc must be improved  (38). There are no national standards for economic 
evaluation in India, and it is difficult to target recommendations to specific bodies, although many 
characteristics of international texts (102, 133, 155) and reporting standards (221, 408) are 
similar. In addition, the extent to which policy makers will balance these recommendations with 
their own value judgments and other decision making criteria must be determined. The statistical 
methods of this analysis may be difficult for some policy makers to understand, and care must be 
taken to ensure that main messages are understandable to target audiences.  
3.1 Areas for further research 
This dissertation has contributed to the growing body of knowledge on the economics of diarrhea 
interventions in India (68, 70, 85, 95, 147), and South Asia (4). However it does not fully answer 
several important questions. An important finding is that expenditures on medicines other than 
zinc and ORS were reduced, although no investigation was made about what proportion of 
antibiotics were prescribed for dysentery and what proportion were prescribed in excess. Further, 
detail was not pursued on the specific reasons for lost wages, or types of transportation that were 
used in seeking treatment. It can be argued that explanation of these results is less important than 
observing that they occurred, although further detail could be provided to promote the program in 
specific terms to policy makers. 
 
Further research should be done to understand qualitative reasons for heterogeneity in prescribing 
practices between providers, and to what degree these practices were maintained or spread further 
after the end of the program. The question remains whether costs will be further reduced, and 
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whether coverage levels will plateau in a sigmoidal curve shape (as assumed by WHO costing of 
child health interventions (368)), and whether the level will be substantially below 100%. 
Evidence to deepen understanding of the relative merits of provision through the public and 
private sectors and what factors influenced prescription of zinc would be informative for policy 
making. 
 
The net benefit regression of this analysis required more advanced methods than the ordinary 
least squares approach used in the original Hoch et al (2002) article (86). Further methods have 
been developed that could be tested for fit and applicability. Willan et al (2004) developed a 
seemingly unrelated regression framework to allow for different covariates and functional forms 
for cost and effects regressions (285), and a similar method (conditional mixed process) could be 
used in our dataset given its binary effectiveness variable (409). However, these approaches 
assume that costs and effects are normally distributed. To relax this assumption, Nixon and 
Thompson (2005) (286) developed a set of Bayesian methods that allow for skewness in cost 
data, and consider costs and effects jointly. 
 
For the bundled cost-effectiveness analysis, additional modeling could be undertaken to represent 
efficiencies gained by providing services jointly, and cost-benefit analysis could be used to 
consider interventions not provided by the health sector (e.g. WASH interventions). The Excel 
based model could be made interactive, according to precedent (236), to allow decision makers to 
adjust parameters according to scenarios that reflect their thinking. Alternatively, the probabilistic 
modeling approach could be incorporated into the LiST tool.  
 
A systematic review of the available cost-effectiveness literature in the Indian context is 
necessary, as was performed in Thailand, with an emphasis on the quality of the evidence base 
and identification of important gaps in the literature (410). In addition, methods are necessary for 
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guiding formal consideration of this evidence in the policy process, and creation of a national 
database would be useful to guide research priorities. 
 
Modeling impact of zinc on development of drug resistance 
It has been argued that overuse of antibiotics to treat diarrhea contributes to antimicrobial 
resistance in India and similar countries (339). However, there is a lack of studies modeling the 
effect of scaling up zinc on resistance to antibiotics in terms of rational use of medicines and 
diarrhea epidemiology. Modeling resistance is more complicated for diarrhea than for other 
diseases as it can be caused by a multitude of viruses, bacteria, and parasites; and since there are 
multiple drugs that can treat it. The most important drug to be modeled is ciprofloxacin, and the 
two most important pathogens are Escherichia coli and Shigella. 
 
From the malaria literature, Coleman et al (2004) present one option for modeling the 
development of drug resistance (411). Initial levels of resistance can be measured from empirical 
studies; for example, collecting stool from a sample of children, isolating pathogenic organisms 
and culturing isolates on petri dishes containing antibiotics; or detecting resistant genotypes with 
enzyme linked assays, simple polymerase chain reactions (412), or microarrays (413). Growth 
trajectories for the proportion of pathogens (R) resistant to drug i at time t can be modeled using a 

















kR         (11) 
Ri,0  The level of drug resistance to treatment i at the start of the N-year time period 
ki  The maximum possible level of drug resistance, which cannot exceed 1 (at ki = 1, the 
entire pathogen population would be resistant to drug i) 





Levels of resistance predicted by this equation can be used to calculate treatment failure (F) 
)]m1(pm)[R1(1F iiit,iit          (12) 
mi Probability that a patient adheres to a full regimen 
pi Probability that a patient is cured despite not fully adhering to the full course of medicine 
 
This equation assumes that mi and pi remain constant over time. 
 
The case can be made that an important difference between antibiotics to treat diarrhea and 
artemisinin combination therapies is that antibiotics have been used for quite some time, and 
historical trends for drug resistance may predict future trajectories instead of modeling according 
to a logistic function. However, considerable uncertainty remains about the trajectory of drug 
scale up for zinc, which will be a key factor in the development of drug resistance. 
 
Alternatively, a more data intensive model could be constructed according to a Markov form 
including individuals in five states (Susceptible, Infected with sensitive parasites, Infected with 
resistant parasites, Immune, and Dead). 
 
Rate of infection is a key parameter that would be derived from evidence on diarrhea incidence. 
More detailed modeling of resistance can be done based on equations representing two 
mechanisms - de novo development from spontaneous mutations or the spread of existing 
pathogens to new hosts. In addition, susceptibility can re-emerge in resistant pathogens (414). 
These equations would categorize fully resistant and fully susceptible populations, and model 
mutation and amplification rates (415). It may be considered that proliferation of resistant and 
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susceptible populations may be different due to their levels of relative fitness (416). Level of 
transmission will be associated with development of host immunity to pathogens.  
 
The fraction of the population that receives treatment would be defined by levels of intervention 
coverage. Successfully treated individuals return to the susceptible state, and may lose immunity. 
From the infected states, individuals can return to susceptible, become immune, or die. Age 
structure should be modeled for its influence the trajectory of resistance as fewer children are 
born, lowering the absolute number of episodes of child diarrhea. Which factors are most 
important in increasing transmission and drug resistance would be identified in sensitivity 
analysis. Finally, the epidemiologic model would be used to predict outcomes for a cost-
effectiveness model. 
3.2 Conclusion 
This dissertation found that providing zinc and ORS at scale are likely to be cost saving to the 
health system. Expenditures by organizations to procure medicines and organize service provision 
are substantially offset by savings to caregivers. Econometric analysis indicates that the program 
is likely to be cost-effective, even when controlling for imbalances in other factors across trial 
phases, although limitations should be noted in the study design for detecting changes in diarrhea 
prevalence. The bundled analysis suggests that delivering zinc and ORS remains highly cost-
effective when accompanied by other diarrhea and pneumonia interventions. Given the evidence 
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11 Tables and figures 
11.1 Introduction 
 
Table 1. DAZT intervention components according to activity 
 
a) Public sector 
 
Micronutrient Initiative (MI) 
Alliances: Between MI and the government. Commitment from the Department of Women and Child Development 
Policy change: National Rural Health Mission (NRHM) Program Implementation Plans (PIPs) were changed to include the procurement of 
zinc and ORS 
Training: MI trained three levels of supervisors, and supported the government in training public sector providers 
Supply: Kits contained two ORS sachets and 14 taste masked zinc tablets, a measuring cup, and an informational leaflet for caregivers 
Procurement: Healthy Life Pharma provided the first procurement of kits, phase 1 (2011) MI provided ORS and zinc, phase 2 (2012) MI 
limited to zinc only (government procured ORS), 2013 state disbursed funds to all districts to purchase zinc 
Program implementation: Incentives delivered to ASHAs, Anganwadi workers (AWWs), and Auxiliary Nurse Midwives (ANMs) at monthly 
meetings  
Distribution: ANMs informed Primary Health Center (PHC) block level supervisors about needs, supplies were redistributed from areas of 
surplus to areas of shortage   
Monitoring and supervision: Each packet and referral was documented in a form, district coordinators routinely matched reports to data 
registers 
Supportive supervision - Supervisors attended monthly meetings of ASHAs, AWWs, ANMs, spent at least 18 days monitoring field staff 
visits, provided staff with hands on training when necessary, analyzed service provider knowledge and skills, stock status, and caregiver 





b) Private sector 
FHI-360 
Alliances: Memorandums of Understanding with prominent professional medical organizations (IAP, IMA). Partnered with four NGOs, West 
Coast Pharmaceutical Company, and homeopathic and alternative medicine associations  
Policy change: None 
Training: NGO and pharma field staff were trained in diarrhea epidemiology, importance of zinc and ORS, correct dosage and regulatory 
guidelines, promotional strategies, role of FHI-360, and use of an SMS MIS system. Continuing medical education was provided for 
professional organizations. Three day residential training was provided for NGO and pharmaceutical staff 
Supply: Same as public sector 
Procurement: All supplies procured through the public sector 
Program implementation: Push and pull strategy – push: changed prescription among key opinion leaders in the medical community, pull: 
NGOs created IEC materials with medical experts about diarrhea management and marketed ORS and zinc to RMPs and drug sellers   
    DAZT corners: staffed informational booths to create awareness and remind providers to prescribe zinc 
Sehat Mitra project: In Faizabad, in-home provision by RMPs on bicycles 
Monitoring and supervision: Monitor activities, validate data and reports, SMS messaging from the field 
Supportive supervision: FHI staff attended monthly meetings, district coordinators spent a lot of time in the field working with new staff 
IAP: Indian Academy of Pediatrics 





c) United Nations Children’s Fund 
UNICEF 
Alliances: Sensitization workshop for field staff and NGO partners, who sensitized Rural Medical Practitioners (RMPs) and Indigenous 
Systems of Medical Practitioners (ISMPs) to use zinc and ORS, and established mechanisms to make supply available 
-Indian Academy of Pediatrics – endorsement by the state chapter published in its bulletin 
-Indian Medical Association - state level advocacy workshop, two district level workshops on childhood diarrhea prevention and treatment 
for promoting ORS and zinc. Participation of major stakeholders - state health officials, leading pediatricians, local media, and DAZT 
partner. Endorsement in October 2012 Bulletin of the IMA. FAQs provided by UNICEF in the IMA bulletin 
Training: Nine continuing medical education (CME) workshops with private practitioners for the use of zinc and ORS (2 with 
pediatricians, 7 with RMPs) 









of cost C/E Outcome measured in literature Source 
Predisposing factors      
Demographic characteristics      
Larger household size + + + Spending (186) 
Female child - - - Care seeking from public providers 
Delay in care seeking 




Characteristics of the social structure     
Paternal primary education no change - - Care seeking (199, 200) 
Paternal secondary  
   education 
+ - - Expect an education gradient  
Caregiver primary education no change - -  (198) 
Caregiver secondary  
   education 
+ - - Higher education associated with 
seeking care in general 
(201) 




Less likely to seek treatment (204, 205) 










Caregiver knowledge      
Knowledge about ORS + - - Care seeking (191) 
Knowledge about zinc + - -   
Enabling factors      
Study phase + - - Episodes <= 4 days, DALYs averted (99) (68, 70, 85) 
Below poverty line card - no effect + Care seeking (191) 
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Wealth index - 2nd quintile + + not 
specified 
Care seeking (191, 204) 
Wealth index - 3rd quintile + + not 
specified 
Cost (95) 
Wealth index - 4th quintile + + not 
specified 
Institutional delivery (109) 
Wealth index - 5th quintile +  - not 
specified 
  
Need factors      
Duration of diarrhea <6 days + + + Care seeking (208) 
Duration of diarrhea ≥6 days + + +   
Blood in the stool + + + Care seeking (190) 
Source of care      
Public provider - facility care + + +   
Public provider - community care + + +   
Private provider + + +   
Treatment given      
Given ORS + + +   
Given zinc + + + Cost (87) 















1976 1980 1986 1990 2000 2000 2001 2001 2004 2010 2011
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Modeling of multiple decisions  or bundled analysis 
Cost-effectiveness according to subgroup 
Evaluation with real world data 
Interactive modeling 
Synthesis and updated modeling 
Primary research RCTs 
Set research priorities 
Model with available evidence 
Identify decision problem 
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- Household size 
- Child sex 
Characteristics of the social 
structure 
- Father’s education 
- Mother’s education 
- Caste 
Caregiver knowledge 
- Knowledge about ORS 







-Duration of episode 





Place of care seeking 
Home  Facility  
Type of care provider 








11.2  Paper 1 
Table 3. Population characteristics for a subsample of children under 5 with diarrhea and their caregivers interviewed in six districts of Gujarat 
*Marginally significant at p<0.10, **Significant at p<0.05 
  
Initial survey  
(N = 594) 
Midpoint survey 
 (N = 165) 
Endpoint survey 
 (N = 553) 
F-test p-values 
22 March- 21 May 
2011 
14 Sep - 8 Oct 2012 29 Sep - 18 Nov 2013 







Age of child (mo) 5.16 0.15 4.82 0.23 4.76 0.17 0.221 0.076* 0.835 
Family size 6.74 0.12 6.33 0.19 6.52 0.11 0.071* 0.206 0.388 
No of children in family < 5 yr 1.64 0.03 1.61 0.05 1.50 0.03 0.270 0.005** 0.095* 
Age of mother 26.39 0.22 26.98 0.35 26.58 0.20 1.990 0.162 0.338 
Duration of diarrhea 3.24 0.13 2.39 0.20 3.14 0.09 0.000** 0.514 0.001** 
Dichotomous variables n % n  % n  %       
Child characteristics         
  
   
  
Age categories (mo)                   
<12 594 100% 165 100% 553 100% - - - 
13-24 0 0% 0 0% 0 0% - - - 
>24 0 0% 0 0% 0 0% - - - 
Male gender 304 51% 95 58% 297 54% 0.155 0.377 0.417 





Living mother 592 99.7% 165 100% 549 99.3% 0.456 0.364 0.279 
Education of child's father         
 
     
  
No school 110 19% - - 65 12% - 0.009** - 
Primary 484 81% - - 488 88% - 0.009** - 
Secondary 243 41% - - 253 46% - 0.219 - 











Initial survey  
(N = 594) 
Midpoint survey 
 (N = 165) 
Endpoint survey 
 (N = 553) 
F-test p-values 
  
Dichotomous variables  
(continued) 







Education of mother         
 
    
 
  
No school 314 53% 104 63% 325 41% 0.069* 0.003** 0.000** 
Primary 280 47% 61 37% 325 59% 0.069* 0.003** 0.000** 
Secondary 95 16% 16 10% 104 19% 0.089* 0.293 0.018** 
Tertiary 12 2% 0 0% 11 2% 0.117 0.972 0.103 
Father's occupation         
 
    
 
  
Private service 54 9% 20 12% 58 10% 0.296 0.526 0.580 
Daily wage earner 264 44% 67 41% 208 38% 0.410 0.018** 0.506 
Self employed 63 11% 19 12% 77 14% 0.744 0.116 0.385 
Farming  202 34% 56 34% 195 35% 0.989 0.689 0.794 
Does not work 1 0.17% 0 0% 1 0.18% 0.597 0.481 0.590 
Mother's occupation         
 
    
 
  
Private service 2 0% 0 0% 6 1% 0.449 0.126 0.202 
Daily wage earner 76 13% 28 17% 59 11% 0.221 0.294 0.049** 
Self employed 2 0% 15 9% 24 4% 0.000** 0.000** 0.057* 
Farming 34 6% 32 19% 77 14% 0.000** 0.000** 0.204 
Does not work 476 80% 88 53% 384 69% 0.000** 0.000** 0.005** 
Caste                   
Scheduled caste 79 19% 31 23% 110 25% 0.370 0.105 0.370 
Scheduled tribe 200 43% 10 8% 165 36% 0.001** 0.258 0.001** 
Other backwards class 238 49% 100 65% 227 48% 0.034** 0.895 0.034** 
*Marginally significant at p<0.10, **Significant at p<0.05       
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Table 4. Diarrhea prevalence, caretaker knowledge, reported symptoms, treatment received, and source of care for children under 5 in six districts 
of Gujarat 
  
Initial survey  Midpoint Endpoint 
F-test p-values 22 Mar -21 May 
2011 
14 Sep - 8 Oct 2012 
29 Sep - 18 Nov 
2013 









Diarrhea prevalence and caregiver 
knowledge 
N = 4202 N = 1070 N = 5080       
Diarrhea in the last two weeks 594 14.1% 165 15.4% 553 10.9% 0.476 0.000** 0.005** 
Heard of ORS 2,298 54.7% 759 70.9% 3333 65.6% 0.000** 0.000** 0.041** 
Heard of zinc 211 5.0% 212 19.8% 759 14.9% 0.000** 0.000** 0.019** 
Breastfed in the previous 24 hours 2439 58.0% 610 57.0% 3043 59.9% 0.642 0.209 0.199 
Reported symptoms associated with 
diarrhea in the past 14 days 
N = 594 N = 165 N = 553       
Pass blood 44 7.4% 15 9.1% 34 6.1% 0.514 0.417 0.197 
Fever 370 62.3% 104 63.0% 318 57.5% 0.872 0.141 0.214 
Vomiting 218 36.7% 49 29.7% 199 36.0% 0.071* 0.826 0.134 
Thirsty 420 70.7% 65 39.4% 167 30.2% 0.000** 0.000** 0.024** 
Lethargic or irritable 382 64.3% 107 64.8% 245 44.3% 0.901 0.000** 0.000** 
Sunken eyes 156 26.3% 47 28.5% 48 8.7% 0.606 0.000** 0.000** 
Dehydration 268 45.1% 32 19.4% 167 30.2% 0.000** 0.000** 0.014** 
Treatment received in the last two weeks N = 594 N = 165 N = 553       
Sought external care 398 67.0% 126 76.4% 412 74.5% 0.011** 0.014** 0.626 
ORS 91 15.3% 25 15.2% 219 39.6% 0.957 0.000** 0.000** 
Zinc 15 2.5% 13 7.9% 124 22.4% 0.003** 0.000** 0.000** 
Other medication 415 69.9% 123 74.5% 326 76.3% 0.203 0.026** 0.658 
Home fluids 127 21.4% 56 33.9% 183 33.1% 0.011** 0.000** 0.883 




 Initial survey  Midpoint Endpoint 
F-test p-values 
 










Source of care† N = 398 N = 126 N = 412       
Any Facility (public or private) 118 29.6% 22 17.5% 102 24.5% 0.008** 0.194 0.075* 
Public source - facility based 59 14.8% 17 13.5% 78 18.9% 0.750 0.221 0.184 
 PHC, gov't hospital, gov't disp. 55 13.8% 13 10.3% 72 17.5% 0.411 0.271 0.098* 
 ANM subcenter 4 1.0% 5 4.0% 8 1.9% 0.029** 0.283 0.224 
Public source - community based 20 5.0% 12 9.5% 83 20.1% 0.118 0.000** 0.022** 
 Anganwadi worker/center 18 4.5% 8 6.3% 53 12.9% 0.424 0.000** 0.064* 
 ASHA 2 0.5% 4 3.2% 37 9.0% 0.016** 0.000** 0.031** 
Private source 319 80.2% 101 80.2% 306 74.3% 0.999 0.089* 0.261 
 Private doctor 227 57.0% 65 51.6% 264 64.1% 0.369 0.067* 0.023** 
 Nursing home/private hospital 64 16.1% 6 4.8% 27 6.6% 0.001** 0.000** 0.451 
 Mobile clinic 1 0.3% 0 0.0% 1 0.2% 0.575 0.981 0.582 
 Chemist 47 11.8% 31 24.6% 30 7.3% 0.009** 0.034** 0.000** 
 Traditional healer 4 1.0% 3 2.4% 5 1.2% 0.233 0.777 0.323 
 Charitable hospital, NGO, Trust 5 1.3% 0 0.0% 3 0.7% 0.356 0.507 0.345 
†Some caregivers sought care from multiple sources, so the sum of counts for individual service providers exceed totals for their category  
*Marginally significant at p<0.10 
**Significant at p<0.05  
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Table 5. Characteristics associated with economic costs of diarrhea treatment to caregiver in six districts of Gujarat 
  
Initial survey 
22 March - 21 May 2011 
Midpoint survey 
14 Sep - 8 Oct 2012 
Endpoint survey 
29 Sep - 18 Nov 2012 











Average cost 589 $0.98 $3.71 $3.08 $4.45 165 $0.59 $4.30 $2.66 $6.99 553 $0.96 $2.26 $2.01 $2.54 
Average non zero cost 353 $3.73 $5.61 $4.80 $6.53 114 $1.78 $3.44 $2.64 $4.46 327 $2.41 $3.73 $3.37 $4.09 
Cost by wealth quintile   
    
  
   
  
    
  
Poorest wealth quintile 159 $0.24 $2.63 $2.03 $3.27 - - - - - 69 $0.80 $1.58 $1.06 $2.13 
Very poor wealth quintile 132 $0.39 $3.02 $2.39 $3.68 - - - - - 94 $1.28 $2.17 $1.68 $2.70 
Poor wealth quintile 107 $1.18 $5.17 $3.06 $8.16 - - - - - 121 $0.32 $2.24 $1.65 $2.89 
Less poor wealth quintile 90 $1.40 $3.73 $2.58 $5.14 - - - - - 138 $1.24 $2.30 $1.83 $2.88 
Least poor wealth quintile 96 $0.26 $4.80 $2.89 $7.07 - - - - - 130 $0.92 $2.66 $2.01 $3.34 
Cost if exposed to messages 329 $1.18 $3.70 $3.00 $4.57 128 $1.14 $4.32 $2.29 $7.26 401 $0.80 $2.15 $1.84 $2.46 
Cost by treatment provider                               
Public facility care 59 $1.97 $3.33 $2.07 $5.29 17 $1.78 $2.28 $1.12 $3.59 78 $1.12 $2.40 $1.70 $3.30 
PHC, government hospital, 
government dispensary 55 $2.16 $3.58 $2.23 $5.42 13 $1.96 $2.73 $1.36 $4.21 72 $1.24 $2.58 $1.80 $3.48 
Auxiliary nurse midwife, 
subcenter 4 $0.00 $0.00 $0.00 $0.00 5 $0.00 $0.64 $0.00 $1.93 8 $0.00 $3.37 $0.00 $8.79 
Public community care 20 $0.00 $2.04 $0.71 $3.66 12 $1.25 $2.62 $1.03 $4.48 83 $0.00 $1.35 $0.78 $2.06 
Anganwadi worker/center 18 $0.00 $2.26 $0.79 $3.96 8 $0.42 $2.69 $0.69 $5.16 53 $0.00 $1.04 $0.55 $1.60 
ASHA 2 $0.06 $0.06 $0.00 $0.12 4 $3.11 $2.48 $0.87 $4.09 37 $0.00 $2.00 $0.87 $3.70 
Private source 315 $4.13 $6.47 $5.38 $7.66 101 $2.49 $6.80 $3.84 $10.59 306 $2.65 $3.87 $3.50 $4.27 
 Private doctor 224 $4.32 $6.33 $5.35 $7.38 65 $4.45 $7.65 $5.10 $11.03 264 $2.78 $3.81 $3.45 $4.21 
 Nursing home/private 
hospital 63 $5.70 $11.45 $7.47 $16.51 6 $6.41 $28.02 $3.44 $74.78 27 $7.74 $8.27 $6.89 $9.80 
Mobile clinic 1 $5.70 $5.70 $5.70 $5.70 0 - - - - 1 $1.61 $1.61 $1.61 $1.61 
Chemist 47 $0.39 $2.78 $1.13 $5.37 31 $0.16 $5.58 $0.52 $15.16 30 $0.88 $2.63 $1.29 $4.27 
Traditional healer 4 $0.00 $2.95 $0.00 $8.84 3 $0.07 $0.24 $0.00 $0.64 5 $0.00 $0.55 $0.00 $1.57 
Charitable hospital, NGO, 
Trust 5 $5.80 $6.11 $1.86 $11.16 0 - - - - 3 $5.62 $8.99 $1.28 $20.06 





Table 6. Economic costs for treatment of diarrhea among children under 5 in six districts of Gujarat. Results calculated across all children with 
diarrhea surveyed in the study area 
 
a) Outpatient care 
 










 N = 393 N = 122 N = 409 
Total cost in the last 2 
weeks 
$3.14 $5.11 $4.37 $6.04 $1.60 $3.21 $2.44 $4.30 $1.83 $2.98 $2.66 $3.33 
Direct medical $1.77 $2.89 $2.40 $3.56 $1.07 $1.94 $1.52 $2.48 $1.44 $2.08 $1.87 $2.33 
Consultation $0.00 $0.59 $0.46 $0.72 $0.00 $0.34 $0.19 $0.51 $0.00 $0.47 $0.38 $0.57 
Dispensing $0.00 $1.06 $0.70 $1.59 $0.00 $0.84 $0.54 $1.19 $0.00 $0.75 $0.62 $0.89 
Purchase of zinc (tablets  
   or syrup) 
$0.00 $0.01 $0.00 $0.02 $0.00 $0.00 $0.00 $0.02 $0.00 $0.01 $0.01 $0.02 
Purchase of ORS  
   (packets) 
$0.00 $0.02 $0.01 $0.03 $0.00 $0.00 $0.00 $0.01 $0.00 $0.02 $0.01 $0.03 
Purchase of other drugs $0.02 $1.09 $0.87 $1.32 $0.02 $0.66 $0.41 $0.98 $0.00 $0.72 $0.60 $0.86 
Special food purchased $0.00 $0.14 $0.09 $0.18 $0.00 $0.10 $0.05 $0.15 $0.00 $0.10 $0.07 $0.13 
Other costs $0.00 $0.01 $0.00 $0.02 $0.00 $0.00 $0.00 $0.00 $0.00 $0.01 $0.00 $0.01 
Direct nonmedical   
   
  




Transportation (round trip) $0.39 $0.89 $0.71 $1.09 $0.00 $0.46 $0.32 $0.62 $0.00 $0.39 $0.33 $0.46 
Indirect costs*   
   
  




Wages lost $0.00 $1.35 $1.06 $1.70 $0.00 $0.81 $0.37 $1.49 $0.00 $0.51 $0.37 $0.66 
















N = 6 N = 4 N = 3 
Total cost in the last 2 weeks $22.33 $33.09 $12.00 $56.88 $70.12 $77.16 $39.96 $118.21 $6.90 $8.32 $3.69 $14.36 
Direct medical $16.82 $19.86 $9.28 $30.42 $67.27 $64.40 $34.11 $94.70 $5.38 $5.06 $3.69 $6.10 
Consultation $1.08 $3.01 $0.43 $6.22 $0.53 $0.84 $0.00 $1.81 $0.00 $0.27 $0.00 $0.80 
Dispensing $0.00 $0.33 $0.00 $0.98 $0.00 $0.00 $0.00 $0.00 $1.61 $1.34 $0.80 $1.61 
Purchase of zinc (tablets or  
   syrup) 
$0.00 $0.17 $0.00 $0.50 $0.00 $0.00 $0.00 $0.00 $0.00 $0.19 $0.00 $0.56 
Purchase of ORS (packets) $0.00 $0.07 $0.00 $0.20 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 
Purchase of other drugs $3.93 $10.65 $1.64 $22.77 $22.25 $16.69 $6.02 $25.36 $1.61 $1.61 $0.00 $3.21 
Special food purchased $0.00 $0.20 $0.00 $0.52 $0.00 $0.32 $0.00 $0.96 $0.00 $0.16 $0.00 $0.48 
Admission/hospitalization $3.44 $5.11 $1.87 $9.66 $53.39 $46.55 $12.84 $80.25 $1.61 $1.50 $0.80 $2.09 
Other costs $0.00 $0.33 $0.00 $0.98 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 
Direct nonmedical   
   
  




Transportation (round trip) $2.06 $3.24 $1.08 $5.96 $3.65 $8.75 $2.29 $20.66 $0.80 $0.59 $0.00 $0.96 
Indirect costs   
   
  




Wages lost $0.49 $9.99 $0.08 $22.93 $3.56 $4.01 $0.00 $8.03 $0.00 $2.68 $0.00 $8.03 




c) Home care 













N = 195 N = 39 N = 141 
Total cost in the last 2 weeks $0.00 $0.04 $0.00 $0.09 $0.00 $0.22 $0.00 $0.64 $0.00 $0.04 $0.00 $0.10 
Direct costs only $0.00 $0.02 $0.00 $0.05 $0.00 $0.06 $0.00 $0.15 $0.00 $0.03 $0.00 $0.08 
Purchase of zinc (tablets or syrup) $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 
Purchase of ORS (packets) $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 
Purchase of other drugs $0.00 $0.00 $0.00 $0.01 $0.00 $0.00 $0.00 $0.00 $0.00 $0.02 $0.00 $0.07 
Special food purchased $0.00 $0.01 $0.00 $0.02 $0.00 $0.01 $0.00 $0.02 $0.00 $0.01 $0.00 $0.02 
Direct nonmedical   
   
  




Transportation (round trip) $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.01 $0.00 $0.03 
Indirect costs*   
   
  




Wages lost $0.00 $0.02 $0.00 $0.06 $0.00 $0.16 $0.00 $0.49 $0.00 $0.00 $0.00 $0.00 




 Table 7. Comparison of costs by source and wealth quintile to average economic costs per caregivers of children with diarrhea 
  
Initial survey 
22 March - 21 May 2011 
Midpoint survey 
14 Sep - 8 Oct 2012 
Endpoint survey 
29 Sep - 18 Nov 2012 
  n Cost t test p-value n Cost t test p-value n Cost t test p-value 
Total costs#   $3.71        $4.77        $2.26      
Public source - facility care 59 $3.33 0.4353 0.3322 17 $2.52 1.5848 0.058* 78 $2.40 -0.3318 0.3704 
 PHC, government hospital, government  
      dispensary 
55 $3.58 0.1497 0.4407 13 $3.03 1.1622 0.1243 72 $2.58 -0.6853 0.2475 
 Auxiliary nurse midwife, subcenter 4 $0.00 10.7613 0.000** 5 $0.71 2.8776 0.003** 8 $3.37 -0.4185 0.344 
Public source - community care 20 $2.04 1.9344 0.032** 12 $2.91 1.1798 0.1214 83 $1.35 2.4396 0.008** 
 Anganwadi worker/center 18 $2.26 1.5559 0.067* 8 $2.99 0.9392 0.1795 53 $1.04 3.8923 0.000** 
 ASHA 2 $0.06 10.4391 0.000** 4 $2.75 1.2376 0.1175 37 $2.00 0.3605 0.3602 
 Private source 315 $6.47 -4.0599 0.000** 101 $7.54 -1.2097 0.114 306 $3.87 -6.5375 0.000** 
 Private doctor 224 $6.33 -4.057 0.000** 65 $8.48 -1.7268 0.043** 264 $3.81 -6.4265 0.000** 
 Nursing home/private hospital 63 $11.45 -3.2186 0.001** 6 $31.07 -1.0183 0.1775 27 $8.27 -7.8231 0.000** 
 Mobile clinic 1 $5.70 - - 0 - - - 1 $1.61 - - 
 Chemist 47 $2.78 0.7494 0.2284 31 $6.19 -0.2686 0.395 30 $2.63 -0.4607 0.3241 
 Traditional healer 4 $2.95 0.2576 0.4065 3 $0.26 3.6422 0.000** 5 $0.55 3.264 0.013** 
 Charitable hospital, NGO, Trust 5 $6.11 -0.8576 0.219 0 - - - 3 $8.99 -1.1848 0.1788 
Total cost if exposed to messages 329 $3.70 0.0296 0.4882 128 $4.79 -0.0122 0.4952 401 $2.15 0.5137 0.3038 
Poorest wealth quintile 159 $2.63 2.3118 0.011** - - - - 69 $1.58 2.246 0.013** 
Very poor wealth quintile 132 $3.02 1.4091 0.080* - - - - 94 $2.17 0.2943 0.3845 
Poor wealth quintile 107 $5.17 -1.0627 0.145 - - - - 121 $2.17 0.0456 0.4818 
Less poor wealth quintile 90 $3.73 -0.0248 0.4901 - - - - 138 $2.30 -0.1311 0.4479 
Least poor wealth quintile 96 $4.80 -0.8984 0.1854 - - - - 130 $2.66 -1.0762 0.1417 
#Values against which other results from the table are compared                     





Table 8. Factors associated with the odds of economic cost of diarrhea treatment for caregivers  
Conceptual framework    Bivariable Multivariable (Pseudo R2 =  0.5583) 
category Parameter Odds ratio p-value 95% conf interval Odds ratio p-value 95% conf interval 
  Study phase 0.94 0.69 0.71 1.25 0.85 0.75 0.32 2.29 
Demographic 
characteristics 
Household size 1.00 0.88 0.96 1.05 0.93 0.29 0.80 1.07 
Child sex 0.89 0.34 0.71 1.13 1.39 0.46 0.58 3.35 
Characteristics of the 
social structure 
Paternal primary education 0.97 0.86 0.70 1.34 0.22 0.06* 0.05 1.05 
Paternal secondary education 1.11 0.41 0.87 1.41 0.81 0.67 0.30 2.17 
Maternal primary education 1.10 0.45 0.86 1.39 2.30 0.15 0.73 7.24 
Maternal secondary education 1.09 0.61 0.78 1.52 0.52 0.33 0.14 1.95 
Scheduled caste 0.38 0.00** 0.26 0.55 1.05 0.95 0.20 5.46 
Scheduled tribe 0.31 0.00** 0.22 0.45 0.50 0.44 0.08 2.94 
Other backwards caste 0.17 0.00** 0.11 0.26 0.25 0.11 0.05 1.39 
Caregiver knowledge 
Knowledge about ORS 0.99 0.92 0.78 1.25 0.57 0.23 0.23 1.41 
Knowledge about zinc 0.79 0.18 0.56 1.12 1.45 0.59 0.37 5.73 
Enabling factors 
Below poverty line card 1.01 0.96 0.79 1.29 0.48 0.11 0.20 1.18 
Very poor 1.11 0.44 0.85 1.47 1.21 0.82 0.24 6.11 
Poor 0.97 0.84 0.72 1.31 0.49 0.34 0.12 2.11 
Less poor 1.20 0.25 0.88 1.62 0.62 0.61 0.10 3.76 
Least poor 0.97 0.85 0.71 1.33 0.75 0.73 0.14 3.90 
Need factors 
Duration of diarrhea <6 days 1.40 0.10 1.23 1.60 1.76 0.00** 1.19 2.59 
Duration of diarrhea ≥6 days 0.79 0.09* 0.60 1.04 omitted    
Blood in stool 1.57 0.10 0.92 2.66 0.63 0.59 0.12 3.41 
Source of care 
Public facility provider 0.26 0.00** 0.16 0.41 0.39 0.10 0.13 1.21 
Public community based provider 0.05 0.00** 0.03 0.08 0.08 0.00** 0.03 0.24 
Private provider 45.77 0.00** 25.02 83.72 37.78 0.00** 11.96 119.31 
Treatment given 
Given ORS 1.67 0.00** 1.20 2.33 0.87 0.79 0.31 2.43 
Given zinc 1.20 0.44 0.76 1.88 0.43 0.09* 0.16 1.15 
 Constant         56.80 0.00** 6.05 533.55 
*Marginally significant at p<0.10, **Significant at p<0.05 




Table 9. Sensitivity analysis: Factors associated with the odds of economic cost of diarrhea treatment for caregivers 




















Study phase 0.95 0.91 0.37 2.42 0.62 0.32 0.25 1.57 0.72 0.49 0.29 1.81 
Household size 0.92 0.22 0.80 1.05 0.91 0.17 0.79 1.04 0.90 0.14 0.79 1.03 
Child sex 1.38 0.48 0.57 3.32 1.32 0.52 0.57 3.06 1.32 0.52 0.57 3.02 
Paternal primary education 0.25 0.06* 0.06 1.06 
        Paternal secondary education 0.83 0.70 0.32 2.15 
        Mother primary education 2.20 0.15 0.76 6.37 
        Mother secondary education 0.70 0.59 0.19 2.57 
        Any vulnerable caste 0.41 0.27 0.09 1.98 
    
0.49 0.34 0.11 2.14 
Scheduled caste 
    
1.14 0.86 0.26 5.05 
    Scheduled tribe 
    
0.58 0.54 0.11 3.24 
    Other backwards caste 
    
0.34 0.18 0.07 1.66 
    Knowledge about ORS 0.66 0.36 0.27 1.61 0.52 0.18 0.20 1.34 0.62 0.32 0.25 1.57 
Knowledge about zinc 1.37 0.64 0.37 5.06 1.37 0.61 0.41 4.62 1.39 0.57 0.44 4.41 
Below poverty line card 0.50 0.12 0.21 1.21 0.56 0.19 0.24 1.34 0.57 0.19 0.25 1.31 
Very poor 1.21 0.81 0.25 5.80 1.34 0.70 0.30 5.91 1.41 0.64 0.33 5.97 
Poor 0.53 0.37 0.13 2.14 0.52 0.34 0.13 2.01 0.57 0.40 0.16 2.10 
Less poor 0.77 0.76 0.14 4.07 0.63 0.57 0.13 3.05 0.76 0.71 0.18 3.28 
Least poor 0.73 0.70 0.15 3.62 0.89 0.88 0.22 3.69 0.94 0.93 0.23 3.79 
Duration of diarrhea <6 days 1.65 0.01** 1.14 2.39 1.73 0.00** 1.22 2.45 1.62 0.01** 1.15 2.28 
Duration of diarrhea ≥6 days 1.00 0.00** 0.00 0.00 1.00 0.00** 0.00 0.00 1.00 0.00** 0.00 0.00 
Blood in stool 0.72 0.72 0.12 4.30 0.68 0.66 0.12 3.88 0.75 0.76 0.12 4.81 
Public facility provider 0.46 0.15 0.16 1.33 0.34 0.06* 0.11 1.02 0.40 0.08* 0.14 1.13 
Public community based provider 0.09 0.00** 0.03 0.24 0.08 0.00** 0.03 0.24 0.08 0.00** 0.03 0.24 
Private provider 37.31 0.00** 13.12 106.10 27.60 0.00** 10.07 75.63 28.29 0.00** 10.62 75.34 
Given ORS 0.91 0.87 0.32 2.57 0.81 0.65 0.33 1.99 0.83 0.68 0.33 2.05 
Given zinc 0.35 0.04** 0.13 0.93 0.60 0.26 0.25 1.44 0.48 0.10 0.19 1.17 
Constant 34.92 0.00** 4.14 294.14 21.50 0.00** 2.94 157.08 14.75 0.01** 2.18 99.84 
*Marginally significant at p<0.10, **Significant at p<0.05 







framework    
Categorical maternal education, 
collapsed caste 















  Study phase 0.79 0.60 0.32 1.94 0.79 0.60 0.32 1.94 
Demographic 
characteristics 
Household size 0.91 0.18 0.80 1.04 0.91 0.18 0.80 1.04 
Child sex 1.27 0.58 0.55 2.97 1.27 0.58 0.55 2.97 
Characteristics 
of the social 
structure 
Maternal education categorical 0.75 0.27 0.45 1.25 
    Paternal education categorical 
    
0.75 0.27 0.45 1.25 
Any vulnerable caste 0.42 0.28 0.09 2.03 0.42 0.28 0.09 2.03 
Caregiver 
knowledge 
Knowledge about ORS 0.65 0.35 0.26 1.60 0.65 0.35 0.26 1.60 
Knowledge about zinc 1.59 0.48 0.45 5.65 1.59 0.48 0.45 5.65 
Enabling factors 
Below poverty line card 0.55 0.17 0.23 1.29 0.55 0.17 0.23 1.29 
Very poor 1.50 0.59 0.35 6.40 1.50 0.59 0.35 6.40 
Poor 0.60 0.44 0.16 2.18 0.60 0.44 0.16 2.18 
Less poor 0.89 0.89 0.19 4.24 0.89 0.89 0.19 4.24 
Least poor 1.03 0.96 0.26 4.16 1.03 0.96 0.26 4.16 
Need factors 
Duration of diarrhea <6 days 1.62 0.01** 1.15 2.28 1.62 0.01** 1.15 2.28 
Duration of diarrhea ≥6 days 1.00 0.00** 0.00 0.00 1.00 0.00** 0.00 0.00 
Blood in stool 0.71 0.71 0.12 4.18 0.71 0.71 0.12 4.18 
Source of care 
Public facility provider 0.41 0.10 0.14 1.20 0.41 0.10 0.14 1.20 
Public community based provider 0.08 0.00** 0.03 0.23 0.08 0.00** 0.03 0.23 
Private provider 29.13 0.00** 10.74 79.04 29.13 0.00** 10.74 79.04 
Treatment given 
Given ORS 0.83 0.69 0.33 2.08 0.83 0.69 0.33 2.08 
Given zinc 0.41 0.07* 0.16 1.07 0.41 0.07* 0.16 1.07 
  Constant 22.10 0.00** 2.82 173.52 22.10 0.00** 2.82 173.52 
*Marginally significant at p<0.10, **Significant at p<0.05 





Table 10. Sensitivity analysis according to variables tested in Rheingans et al (2012) (95) 
 





conf interval Coeff p-value 
95% 
conf interval 
Study phase 0.73 0.13 0.48 1.10 -$1.36 0.01** -$2.32 -$0.39 
Very poor 1.80 0.06* 0.97 3.36 $0.15 0.79 -$0.91 $1.20 
Poor 1.31 0.36 0.73 2.37 $1.46 0.07* -$0.13 $3.05 
Less poor 0.96 0.91 0.52 1.79 $0.05 0.95 -$1.47 $1.57 
Least poor 1.57 0.18 0.81 3.03 $1.06 0.08* -$0.14 $2.25 
Female child 1.00 0.99 0.69 1.44 -$0.20 0.68 -$1.15 $0.75 
Paternal primary education 1.10 0.73 0.64 1.90 $0.48 0.68 -$1.84 $2.81 
Paternal secondary education 1.02 0.95 0.65 1.59 $0.19 0.68 -$0.73 $1.12 
Mother primary education 1.08 0.72 0.71 1.63 -$1.37 0.05* -$2.73 $0.00 
Mother secondary education 0.86 0.59 0.49 1.49 $0.58 0.24 -$0.39 $1.54 
Age of child 1.08 0.01** 1.02 1.15 $0.02 0.74 -$0.11 $0.15 
Blood in stool 1.94 0.12 0.84 4.50 $1.03 0.27 -$0.80 $2.86 
Duration of diarrhea <6 days 1.51 0.00** 1.31 1.73 $0.56 0.02** $0.08 $1.04 
Duration of diarrhea ≥6 days 0.49 0.00** 0.33 0.71 $8.20 0.12 -$2.10 $18.49 
Constant 1.35 0.37 0.71 2.57 $4.81 0.00** $2.76 $6.86 





Table 11. Factors associated with the amount of economic cost to caregivers for diarrhea treatment 
Conceptual framework  GLM Gamma Bivariable Multivariable 
category   Coef p-value 95% conf interval Coef p-value 95% conf interval 
  Study phase -$1.88 0.00** -$2.89 -$0.88 -$1.49 0.03** -$2.80 -$0.17 
Demographic 
characteristics 
Household size -$0.11 0.27 -$0.32 $0.09 -$0.02 0.91 -$0.43 $0.38 
Child sex -$0.55 0.31 -$1.60 $0.50 $0.13 0.77 -$0.73 $0.99 
Characteristics of the 
social structure 
Paternal primary education $0.47 0.46 -$0.76 $1.70 $0.17 0.76 -$0.96 $1.30 
Paternal secondary education -$0.20 0.70 -$1.25 $0.84 $0.41 0.37 -$0.49 $1.30 
Mother primary education -$1.15 0.04** -$2.25 -$0.05 -$0.77 0.19 -$1.91 $0.38 
Mother secondary education $0.03 0.96 -$1.00 $1.05 $0.89 0.18 -$0.42 $2.20 
Scheduled caste -$0.27 0.64 -$1.39 $0.86 -$1.17 0.19 -$2.94 $0.59 
Scheduled tribe -$0.08 0.88 -$1.09 $0.94 -$0.89 0.36 -$2.77 $1.00 
Other backwards caste $0.04 0.94 -$1.14 $1.22 -$1.44 0.08* -$3.05 $0.17 
Caregiver knowledge 
Knowledge about ORS -$1.14 0.08* -$2.39 $0.12 -$1.06 0.04** -$2.06 -$0.05 
Knowledge about zinc $0.66 0.26 -$0.47 $1.79 $1.28 0.10 -$0.25 $2.82 
Enabling factors 
Below poverty line card $0.30 0.61 -$0.85 $1.44 -$0.34 0.42 -$1.18 $0.49 
Very poor -$0.65 0.15 -$1.53 $0.23 $0.20 0.79 -$1.29 $1.70 
Poor $1.33 0.22 -$0.81 $3.47 $0.33 0.83 -$2.64 $3.29 
Less poor -$0.40 0.50 -$1.55 $0.75 -$0.32 0.72 -$2.06 $1.42 
Least poor $0.39 0.51 -$0.76 $1.54 -$0.40 0.67 -$2.23 $1.44 
Need factors 
Duration of diarrhea <6 days $0.75 0.00** $0.28 $1.23 $0.54 0.00** $0.23 $0.85 
Duration of diarrhea ≥6 days $8.96 0.04** $0.29 $17.63 $9.24 0.07* -$0.77 $19.24 
Blood in stool $0.92 0.23 -$0.56 $2.39 $0.87 0.46 -$1.43 $3.17 
Source of care 
Public facility provider -$0.67 0.31 -$1.94 $0.61 $1.69 0.02** $0.25 $3.13 
Public community based provider -$0.81 0.28 -$2.28 $0.67 $0.13 0.90 -$1.85 $2.12 
Private provider $2.60 0.00** $1.36 $3.85 $3.16 0.00** $2.13 $4.20 
Treatment given 
Given ORS $0.90 0.19 -$0.44 $2.24 $0.94 0.08* -$0.10 $1.99 
Given zinc $0.20 0.70 -$0.79 $1.18 $0.74 0.43 -$1.09 $2.56 
 Constant         $3.52 0.00** $1.61 $5.43 
*Marginally significant at p<0.10, **Significant at p<0.05 




Table 12. Sensitivity analysis: Factors associated with the amount of economic cost to caregivers for diarrhea treatment  
Conceptual framework    
Categorical maternal education, collapsed 
caste 
Categorical paternal education, 
collapsed caste 
Category Parameter Coef 
p-





  Study phase -$1.60 0.00** -$2.47 -$0.73 -$1.60 0.00** -$2.47 -$0.73 
Demographic characteristics 
Household size -$0.09 0.53 -$0.36 $0.19 -$0.09 0.53 -$0.36 $0.19 
Child sex $0.33 0.43 -$0.48 $1.14 $0.33 0.43 -$0.48 $1.14 
Characteristics of the social 
structure 
Maternal education categorical $0.25 0.15 -$0.09 $0.59 
    Paternal education categorical 
    
$0.25 0.15 -$0.09 $0.59 
Any vulnerable caste -$1.10 0.16 -$2.62 $0.42 -$1.10 0.16 -$2.62 $0.42 
Caregiver knowledge 
Knowledge about ORS -$1.04 0.02** -$1.90 -$0.17 -$1.04 0.02** -$1.90 -$0.17 
Knowledge about zinc $1.06 0.17 -$0.46 $2.59 $1.06 0.17 -$0.46 $2.59 
Enabling factors 
Below poverty line card -$0.46 0.18 -$1.13 $0.21 -$0.46 0.18 -$1.13 $0.21 
Very poor $0.03 0.96 -$0.99 $1.05 $0.03 0.96 -$0.99 $1.05 
Poor $0.44 0.46 -$0.72 $1.60 $0.44 0.46 -$0.72 $1.60 
Less poor -$0.09 0.85 -$0.97 $0.80 -$0.09 0.85 -$0.97 $0.80 
Least poor -$0.52 0.30 -$1.51 $0.46 -$0.52 0.30 -$1.51 $0.46 
Need factors 
Duration of diarrhea <6 days $0.52 0.03** $0.04 $1.00 $0.52 0.03** $0.04 $1.00 
Duration of diarrhea ≥6 days $9.34 0.06* -$0.53 $19.20 $9.34 0.06* -$0.53 $19.20 
Blood in stool $0.67 0.44 -$1.04 $2.39 $0.67 0.44 -$1.04 $2.39 
Source of care 
Public facility provider $1.53 0.03** $0.15 $2.91 $1.53 0.03** $0.15 $2.91 
Public community based provider $0.24 0.80 -$1.58 $2.06 $0.24 0.80 -$1.58 $2.06 
Private provider $3.17 0.00** $2.13 $4.21 $3.17 0.00** $2.13 $4.21 
Treatment given 
Given ORS $0.84 0.12 -$0.22 $1.89 $0.84 0.12 -$0.22 $1.89 
Given zinc $0.60 0.36 -$0.67 $1.86 $0.60 0.36 -$0.67 $1.86 
  Constant $3.26 0.00** $1.25 $5.28 $3.26 0.00** $1.25 $5.28 
*Marginally significant at p<0.10, **Significant at p<0.05 



















Study phase -$1.25 0.01** -$2.11 -$0.38 -$1.53 0.00** -$2.41 -$0.65 -$1.38 0.00** -$2.31 -$0.46 
Household size -$0.04 0.74 -$0.30 $0.21 -$0.05 0.43 -$0.18 $0.08 $0.03 0.43 -$0.05 $0.11 
Female child $0.22 0.56 -$0.50 $0.94 $0.24 0.58 -$0.61 $1.10 $0.60 0.23 -$0.38 $1.57 
Paternal primary education $0.24 0.59 -$0.64 $1.13 
        Paternal secondary education $0.43 0.22 -$0.26 $1.12 
        Mother primary education -$0.85 0.06* -$1.72 $0.02 
        Mother secondary education $0.94 0.11 -$0.21 $2.09 
        Any vulnerable caste -$1.24 0.12 -$2.79 $0.31 
    
-$1.34 0.11 -$2.98 $0.29 
Scheduled caste 
    
-$1.24 0.16 -$2.97 $0.49 
    Scheduled tribe 
    
-$0.88 0.32 -$2.60 $0.84 
    Other backwards caste 
    
-$1.60 0.05* -$3.23 $0.02 
    Knowledge about ORS -$1.08 0.03** -$2.07 -$0.09 -$0.87 0.10 -$1.92 $0.18 -$0.87 0.13 -$1.99 $0.26 
Knowledge about zinc $1.27 0.08* -$0.17 $2.70 $1.25 0.07* -$0.12 $2.63 $1.32 0.06* -$0.06 $2.69 
Below poverty line card -$0.43 0.16 -$1.03 $0.17 -$0.31 0.35 -$0.97 $0.34 -$0.28 0.48 -$1.06 $0.50 
Very poor $0.41 0.48 -$0.71 $1.52 -$0.11 0.87 -$1.39 $1.17 $0.16 0.78 -$0.96 $1.28 
Poor $0.67 0.42 -$0.95 $2.29 $0.00 1.00 -$1.20 $1.20 $0.10 0.89 -$1.33 $1.53 
Less poor -$0.22 0.72 -$1.41 $0.97 -$0.22 0.73 -$1.46 $1.03 -$0.05 0.93 -$1.10 $1.01 
Least poor -$0.34 0.64 -$1.80 $1.11 -$0.56 0.49 -$2.14 $1.01 -$0.44 0.40 -$1.46 $0.58 
Duration of diarrhea <6 days $0.52 0.00** $0.26 $0.79 $0.52 0.03** $0.06 $0.98 $0.34 0.18 -$0.15 $0.83 
Duration of diarrhea ≥6 days $9.24 0.07* -$0.61 $19.09 $9.57 0.07* -$0.74 $19.89 $10.16 0.05* $0.05 $20.27 
Blood in stool $0.77 0.47 -$1.33 $2.86 $0.69 0.47 -$1.18 $2.56 $0.48 0.59 -$1.24 $2.20 
Public facility provider $1.57 0.00** $0.56 $2.58 $1.89 0.00** $0.78 $3.00 $2.13 0.00** $1.12 $3.13 
Public community based provider $0.03 0.97 -$1.55 $1.61 $0.27 0.79 -$1.66 $2.19 $0.14 0.88 -$1.57 $1.85 
Private provider $3.12 0.00** $2.40 $3.85 $3.40 0.00** $2.66 $4.14 $3.69 0.00** $2.96 $4.43 
Given ORS $0.83 0.04** $0.03 $1.63 $0.81 0.11 -$0.19 $1.81 $0.64 0.16 -$0.25 $1.54 
Given zinc $0.57 0.40 -$0.76 $1.91 $0.63 0.26 -$0.47 $1.73 $0.67 0.26 -$0.50 $1.84 
Constant $3.41 0.00** $1.60 $5.21 $3.45 0.00** $1.23 $5.66 $2.90 0.00** $1.32 $4.48 
*Marginally significant at p<0.10, **Significant at p<0.05 









22 March - 21 May 2011 
Midpoint survey 
14 Sep - 8 Oct 2012 
Endpoint survey 
29 Sep - 18 Nov 2012 
  n % 
 
n %   n %   
Total sample of children 2-59 months 4200 1072 5080 
Children with diarrhea in preceding 2 
weeks 594 
14% 165 15% 553 11% 
Cases of diarrhea in one year 15,444     4,290     14,378     
Caregivers who sought advice or 
treatment outside home   
399 67.2% 126 76.4% 412 74.5% 
Caregivers who sought care outside the 
home~ Outpatient 
393 66.2% 122 73.9% 409 74.0% 
Caregivers who sought care outside the 
home~ Hospitalizations 
6 1.0% 4 2.4% 3 0.5% 
Caregivers who provided home based 
care 
195 32.8% 39 23.6% 141 25.5% 
Out of pocket expenditures for 
diarrhea treatment per caregiver 
N=594 
 
  N=165 
 
  N=553 
 
  
n median mean n median mean n median mean 
Outpatient treatment costs per patient 
(mean, median) 393 
$3.14  $5.11  
122 
$1.60  $3.56  
409 
$1.83  $2.98  
Hospitalization cost per patient (mean, 
median) 
6 $22.33  $33.09  4 $70.12  $85.55  3 $6.90  $8.32  
Home based treatment cost per patient 
(mean, median) 195 $0.00  $0.04  39 $0.00  $0.25  141 $0.00  $0.04  
Total costs per 1 million population n median mean n median mean n median mean 
Total number of children < 5 per 1 




    
 
  
Total number of cases of diarrhea per 
million population in one year       342,579  
 
      372,832  
 
      263,685  
 
  
Total cost   $789,987  $1,275,883  
 
$1,075,263  $1,777,522    $366,704  $595,898  
Outpatient treatment seeking  226,656  $712,729  $1,157,140  275,670  $441,525  $982,535  195,022  $356,832  $581,196  
Hospitalizations 3,460  $77,258  $114,504  9,038  $633,738  $773,273  1,430  $9,872  $11,901  




Figure 4. Quantile-Quantile plot of studentized residuals from linear regression on costs showing 
non-normality in the outcome 
a) No transformation 
 
 
b) Log costs 
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c) Reciprocal cost 
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Figure 6. Locally weighted scatterplot smoothing (LOWESS) curve testing linearity of the 
regression line against continuous variables 
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Figure 8. Component economic costs related to diarrhea treatment services to treat child diarrhea per 1 million population. The dark grey 
component represents direct non-medical costs, light grey component represents indirect costs, and black components represent direct medical 
costs. n represents the number of children that can be expected to have diarrhea among a population of 1 million for each study phase 
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11.3 Paper 2 
Box 1. Formula for power calculation 
Formulas to calculate power with different sample sizes and different standard deviations for 
costs and effects in each phase (adapted from Glick et al (2011) (135) supplementary material)   
Formula 1 
NMB = Q * W – C 
 
Formula 2 





































C Expected point estimate in the difference in mean cost 
Q Expected point estimate in the difference in mean effect 
 Correlation in the difference in cost and effect 
sd c1 expected standard deviation in the cost in intervention group 
sd c0 expected standard deviation in the cost in control group 
sd q1 expected standard deviation for the effect in intervention group 
sd q0 expected standard deviation for the effect in control group 
W maximum valuation of treatment for an episode of diarrhea  
z alpha z statistic for the type 1 error 
z beta z statistic for the type 2 error 
n1 Sample size in the starting point survey  





Table 14. Sample size available 
 
Survey Number of participants Dates 
Initial survey 4,200 Mar 22-May 21, 2011 
Monsoon season 
 
June through beginning of September* 
Midpoint survey 1,072 Sep 14-Oct 8, 2012 
Endpoint survey 5,080 Sep 29 -Nov 18, 2013 






















C $6.03 $6.03 $6.03 $6.03 $12.06 $3.02 $0.00 
Q 0.79 1.58 0.39 0 0.79 0.79 0.79 
W $14.80 $14.80 $14.80 $14.80 $14.80 $14.80 $14.80 
NMB $5.64 $17.32 -$0.19 -$6.03 -$0.39 $8.66 $11.67 
 0.2 0.2 0.2 0.2 0.2 0.2 0.2 
sd c1 $0.85 $0.85 $0.85 $0.85 $0.85 $0.85 $0.85 
sd c0 $4.17 $4.17 $4.17 $4.17 $4.17 $4.17 $4.17 
sd q1 0.03 0.03 0.03 0.03 0.03 0.03 0.03 
sd q0 0.04 0.04 0.04 0.04 0.04 0.04 0.04 
z alpha 1.96 1.96 1.96 1.96 1.96 1.96 1.96 
Starting point to endpoint 
(4200, 5080)  
Z 6.50 24.00 -1.67 7.08 -1.38 11.02 15.54 









Table 16. Power calculation on net benefit: Sensitivity analyses on ceiling ratio, correlation coefficient, and different levels of alpha 
Parameter 
Different ceiling ratios 
Different correlation 
coefficients 
Different levels of alpha 
  $0.50 $3.00 $5.50 $8.00 $10.50 0.00 0.30 0.70 99% 90% 80% 
C $6.03 $6.03 $6.03 $6.03 $6.03 $6.03 $6.03 $6.03 $6.03 $6.03 $6.03 
Q 0.79 0.79 0.79 0.79 0.79 0.79 0.79 0.79 0.79 0.79 0.79 
W $0.50 $3.00 $5.50 $8.00 $10.50 $14.80 $14.80 $14.80 $14.80 $14.80 $14.80 
NMB -$5.64 -$3.66 -$1.69 $0.28 $2.25 $5.64 $5.64 $5.64 $5.64 $5.64 $5.64 
 0.2 0.2 0.2 0.2 0.2 0.0 0.3 0.7 0.2 0.2 0.2 
sd c1 0.85 0.85 0.85 0.85 0.85 $0.85 $0.85 $0.85 $0.85 $0.85 $0.85 
sd c0 4.17 4.17 4.17 4.17 4.17 $4.17 $4.17 $4.17 $4.17 $4.17 $4.17 
sd q1 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 
sd q0 0.04 0.04 0.04 0.04 0.04 0.04 0.04 0.04 0.04 0.04 0.04 
Z 1.96 1.96 1.96 1.96 1.96 1.96 1.96 1.96 2.58 1.64 1.28 
Starting point to endpoint (4200, 5080)  
Z 6.18 3.38 0.53 -1.54 1.40 5.93 6.82 8.37 5.88 6.82 7.18 







Table 17. Program costs for the DAZT program according to public (MI) and private (FHI-360) 
sectors 
  FHI-360 MI 
Annualized Capital Costs 
  Furniture and Equipment $4,724 $5 
Delhi $6,976 $5 
Gujarat $1,236 $0 
Trainings $1,310 $0 
Delhi $0 $0 
Gujarat $1,310 $0 
Launch Expenses $0 $23,556 
Delhi $0 $0 
Gujarat $0 $23,556 
Total Capital Costs $6,034 $23,562 
Recurrent Costs     
Personnel $102 $282,644 
Delhi $203 $44,265 
Gujarat $0 $192,549 
HO $0 $45,830 
Vehicles  $0 $19,636 
Delhi $0 $8,236 
Gujarat $0 $11,400 
Buildings $29,508 $33,021 
Delhi $42,921 $17,381 
Gujarat $8,048 $15,640 
Zn and Supplies $0 $200,393 
Delhi $0 $0 
Gujarat $0 $200,393 
IEC Material $12,295 $0 
Delhi $0 $0 
Gujarat $12,295 $0 
Subcontracts $335,101 $0 
TOTAL RECURRENT COSTS $377,005 $535,694 
TOTAL ANNUALIZED PROGRAM COSTS $383,039 $559,256 
TOTAL ANNUALIZED PROGRAM COSTS PER MILLION 







Table 18.  Descriptive statistics of the sample of children under 5 with and without diarrhea from six 
districts of Gujarat 
a) Continuous variables 
  Baseline Endline Statistical tests 
Variable Mean  95% Confidence Mean  95% Confidence F-test p-value 
Diarrhea in the past 2 
weeks 
14.14% 12.82% 15.45% 10.89% 10.06% 11.71% 17.35 0.000** 
Household size 6.638 6.472 6.804 6.497 6.370 6.624 2.04 0.155 
Duration of diarrhea 0.22 0.19 0.25 0.20 0.18 0.23 1.04 0.310 
**Significant at p<0.05, *Marginally significant at p<0.10 
b) Dichotomous variables 
  Baseline Endline Statistical tests 
Variable Mean  Mean  F-test p-value 
Female child 45.56% 43.72% 2.719 0.101 
Paternal primary education 80.27% 85.97% 13.345 0.000** 
Paternal secondary education 44.43% 49.58% 4.110 0.044* 
Mother primary education 51.44% 59.13% 7.518 0.007** 
Mother secondary education 19.20% 22.91% 3.208 0.075* 
Scheduled caste 12.22% 17.01% 4.525 0.035** 
Scheduled tribe 30.67% 25.39% 1.509 0.221 
Other backwards caste 41.25% 44.43% 0.701 0.404 
Knowledge about ORS 54.66% 65.62% 25.260 0.000** 
Knowledge about zinc 5.02% 14.94% 107.392 0.000** 
Below poverty line card 40.12% 48.05% 10.637 0.001** 
Blood in stool 1.04% 0.68% 3.767 0.054* 
Public facility provider 1.41% 1.53% 0.1721 0.6787 
Public community based provider 0.49% 1.63% 20.607 0.000** 
Private provider 7.60% 6.03% 8.011 0.005** 
Given ORS 2.17% 4.31% 30.485 0.000** 
Given zinc 0.35% 2.45% 46.447 0.000** 
Poorest wealth quintile 28.77% 12.62% 35.097 0.000** 
Very poor wealth quintile 21.43% 18.69% 2.491 0.116 
Poor wealth quintile 18.05% 21.48% 5.047 0.026** 
Less poor wealth quintile 13.39% 25.34% 54.036 0.000** 
Least poor wealth quintile 17.59% 21.83% 2.368 0.125 






Table 19. Sample statistics from deterministic economic evaluation  
Group variable Mean SD SE 
Overall analysis       
Initial survey (N = 4200) 
   Cost $0.55 $3.55 $0.05 
Effect 14.14% 34.85% 0.54% 
Correlation =  0.5477 
  
    Endpoint survey (N = 5080) 
   Cost $0.29 $1.35 $0.02 
Effect 10.89% 31.15% 0.44% 
Correlation =  0.3787 
  
    Incremental differences between phases 
   Cost difference -$0.25 









Table 20. Net benefit of the DAZT program relative to status quo - Simple net-benefit regression 
estimates  
a)  Generalized linear model with a gamma family and log link with Huber White robust 
standard errors and accounting for clustering 
Variable 




NB with  
= $1 
NB with  
= $1.5 
NB with  
= $2 












































    
 
 Deviance 26598 26320 27080 27945 28788 29583 
AIC 844 3625 6034 8161 10067 11793 
BIC 859 3639 6049 8176 10081 11807 
[se] (p-value)             
 
b)  Generalized linear model with a gamma family and an identity link with Huber White 
robust standard errors and accounting for clustering 
Variable 




NB with  
= $1 
NB with  
= $1.5 
NB with  
= $2 












































    
 
 Deviance 26599 26321 27080 27945 28788 29583 
AIC 845 3625 6034 8162 10067 11792 
BIC 859 3639 6049 8176 10081 11807 
[se] (p-value) 







c) Generalized linear model with a gamma family and an identity link with robust standard 
errors 
Variable 




NB with  
= $1 
NB with  
= $1.5 
NB with  
= $2 












































    
 
 Deviance 26599 26321 27080 27945 28788 29583 
AIC 845 3625 6034 8162 10067 11793 
BIC 859 3639 6049 8176 10081 11807 
[se] (p-value)            
 
d) Generalized linear model with a gamma family and an identity link 
Variable 




NB with  
= $1 
NB with  
= $1.5 
NB with  
= $2 












































    
 
 Deviance 26599 26321 27080 27945 28788 28788 
AIC 845 3625 6034 8162 10067 10067 
BIC 859 3639 6049 8176 10081 10081 
[se] (p-value) 







e) Negative binomial model with robust standard errors and accounting for clustering  
Variable 
NB with  
= $0 
NB with = 
$0.5 
NB with  
= $1 
NB with  = 
$1.5 
NB with  
= $2 












































    
 
 Deviance 10962 11255 11949 12706 13469 14220 
AIC 15397 16782 18059 19245 20353 21394 
BIC 15411 16796 18073 19259 20368 21409 
[se] (p-value)            
 
f) Ordinary least squares with robust standard errors and clustering 
Constant term 
NB with  
= $0 
NB with = 
$0.5 
NB with  
= $1 
NB with  = 
$1.5 
NB with  
= $2 












































    
 
 R2 0.0025 0.0026 0.0028 0.0029 0.003 0.0031 
F 14.570 15.93 17.2 18.38 19.45 20.4 
Prob >F 0.000 0.0001 0.000 0.000 0.000 0.000 
AIC 44012 44504 45038 45606 46200 46814 
BIC 44027 44518 45052 45620 46214 46828 
[se] (p-value) 







g) Ordinary least squares with robust standard errors 
Variable 




NB with  
= $1 
NB with  
= $1.5 
NB with  
= $2 












































    
 
 R2 0.0025 0.0026 0.0028 0.0029 0.003 0.0031 
F 19.800 21.3 22.67 23.89 24.97 25.9 
Prob >F 0.000 0.0001 0.000 0.000 0.000 0.000 
AIC 44012 44504 45038 45606 46200 46813 
BIC 44027 44518 45052 45620 46214 46828 
[se] (p-value)            
 
h) Net benefit of the DAZT program relative to status quo - Ordinary least squares 
Variable 




NB with  
= $1 
NB with  
= $1.5 
NB with  
= $2 












































    
 
 R2 0.0025 0.0026 0.0028 0.0029 0.003 0.003 
F 22.820 24.46 25.91 27.18 28.27 28.27 
Prob >F 0.000 0.0001 0.000 0.000 0.000 0.000 
AIC 44012 44504 45038 45606 46200 46200 
BIC 44027 44518 45052 45620 46214 46214 
[se] (p-value) 
    
 




Table 21. Net benefit of the DAZT program relative to status quo - Multivariable regression GLM 








 = $1 
NB with 
 = $1.5 
NB with 





































































































































































































































































































































































































Deviance 15845 15995 16988 18023 18995 19892 
AIC -18951 -15240 -12198 -9610 -7353 -5349 
BIC -18808 -15097 -12056 -9467 -7210 -5206 
y-hat-squared 0.000 0.000 0.005 0.071 0.382 0.989 
[se] (p-value) 





Table 22. Net benefit of the DAZT program relative to status quo - Multivariable regression GLM 








 = $1 
NB with 
 = $1.5 
NB with 






































































































































































































































































































































































































































































































































































































































































































































































AIC -20245 -16066 -12850 -10169 -7856 -5815 
BIC -19973 -15795 -12579 -9898 -7584 -5544 
Y hat squared 0.000 0.000 0.000 0.000 0.001 0.016 
[se] (p-value) 





Table 23. Net benefit of the DAZT program relative to status quo according to covariates used in 
Rheingans et al (2012) (95) - Multivariable regression GLM Gamma link log specification with 








 = $1 
NB with 
 = $1.5 
NB with 






















              
Treatment-covariate 
interactions 


































































































































































































Covariates             











































































































































































Deviance 19,614 19,758 20,713 21,716 22,663 23,538 
AIC -12,349 -8,984 -6,170 -3,745 -1,611 296 
BIC -12,207 -8,841 -6,027 -3,602 -1,468 439 
y-hat-squared 0.000 0.000 0.000 0.000 0.001 0.015 
[se] (p-value) 





Table 24. GLM Gamma link log specification comparing full dataset to a specification omitting the 
top ten most influential observations. Note that models contained all independent covariates, but only 
the treatment variable is presented in this table for brevity. 




NB with  
= $1 
NB with  
= $2 
NB with  
= $0 
NB with  
= $1 









































Deviance 15922 16919 18861 15918 16915 18856 
AIC -20245 -12850 -7856 -20228 -12838 -7846 
BIC -19973 -12579 -7584 -19957 -12567 -7575 
Y hat squared 0.000 0.000 0.001 0.000 0.000 0.001 
[se] (p-value) 










Figure 11. Z score and power for type 2 error for the starting point to endpoint comparison according to different values for willingness to pay for 











































































































































































Figure 12. Cost effectiveness plane showing regions of adequate power according to incremental costs and effects (illustration from another 
model since stochastic results do not exist yet for the current model). Blue dots represent cost-effectiveness outputs, and black lines represent 






























Incremental diarrhea episodes averted 






Figure 13. Cost-effectiveness acceptability curve showing the same concept as the cost-effectiveness plane in Figure 11, but emphasizing the 
probability that the intervention is cost-effective on the y-axis. Levels of  that correspond with power thresholds in figures 10 & 11 are indicated 






































Figure 14. Quantile-Quantile plot of studentized residuals from linear regression on net 









15195 62207154673505014913 75 81610102 732 4411 936
38 4404261 9535645 0727834 255036238411 33 2895 42 877180 05 77994175423365 61
62 9932 11 8645 013 43 132775695240141 935624058836772439030 762 95 1083 01 242 589131956251754334857
2 43 8296 55196730 022 134458823819495 07117360 03423 2312955146352074 610 787 351424 8556 09616245 0371984 332 1218 26 840 450793 3242 19607137 4263 760960839 19371460859837544 9152 182275064135227 784603195849765 39842507639240271633 5982147631955 21084679
513200 846571302986548 17023859410762385940716325498073261954087236195408172369540812379658012346978012354976028153704698213570986241357904286135704289653147028935614729081536427890536142790853641729803564127983650412978365014792385601972483560192743586019274580613924758601932475806193247586091372458609134725860193247856031742985603142798650137295468013792645083179264580312794658031792654803179264580137295468013729564801372956480173925648017326594801732659480137269548017236594801732698450713269485071329654807132698450713269804751326980573124698753012946753081296475038219647053218946302158749630827154932617508943780152496380214569738165942073856410792385674901238928 757 00 63542356 5129402
41 73861 8637 491025 793 684249 05 23276 87351608 36491 411852 90 754 292363745 581 003676728 341 49120 85263 243381 946
716035 752479105 487 98620 153 23244 91356356172876470598029822443 31711 5946531985667 307597220 44023
63 58243 945 18611 1895579260 02 374328 24 073 458 883 11 66911 552 745 36 2034 7204395 40731 191 168
948672 56035 452045 3228 097417313 1682608652 44471523709205 95 43 13 8362475189325307648509217104653278651980745 323 5390817 64421 53904137802 514 7913203 81 542 95 68 12 48 37610336 04 8
2 54 61 9455 13 034 74051 22 248205995179468 112 23 35 7662347816233 552 400510 874 41195 62 623 92082
46 35 953 42 110764 82 45 289331 547015 70562288 83270413 901 6923144543 871 95160
2081 64453794081 230955201169

































-4 -2 0 2 4
Inverse Normal




Figure 15. Residual plots for net-benefit regressions on negative cost (equivalent to net 
benefit when  = 0) and effect (equivalent to net benefit when  →∞) for each of the 
three models 
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Value of averting a diarrhea episode 









11.4 Paper 3 
Table 25. Attributes of each health provider considered in cost-effectiveness analysis of bundled diarrhea and pneumonia interventions 
a) Community health worker 
 
Population ratio 














   
Children 6-
59 months Vitamin A 50% Vitamin A capsules 6 13% 
ASHA 1/1068 2 
Children 0-
59 months ORS 50% ORS sachets 10 22% 
AWW 1/1000 2 
Children 0-
59 months 
Zinc treatment of 
uncomplicated 
diarrhea 70% Zinc tablets 10 22% 
   
Children 1-
59 months 
Oral antibiotics for 
case management of 
pneumonia in 



























































Nurses 17/10000 (2011) 4     
    
 
1/1264 2 Births 
Breastfeeding 
promotion 50% None 70 30% 
 
1.73 / 10,000 (qualified 
practitioners), 4.9 / 
10,000 census 1 
Children 0-
59 months ORS 50% ORS sachets 10 4% 
   
Children 0-
59 months 
Zinc treatment of 
uncomplicated 
diarrhea 30% Zinc tablets 10 4% 
   
Births Rotavirus vaccine 100% Rotavirus vaccines 6 3% 
   
Births HiB vaccine 100% HiB vaccines 6 3% 
   
Births 
Pneumococcal 
conjugate 100% Pneumococcal vaccines 6 3% 




dysentery 100% Antibiotic capsules 4 2% 
   
Children 0-
59 months 
Oral antibiotics for 
case management of 
pneumonia in 
children 50% Antibiotic capsules 15 6% 
   
Children 0-
59 months 
Treatment of severe 
diarrhea 100% 
IV kit, electrolyte solution, 
syringe, needle, cotton, take 
home materials with advice on 
preventing diarrhea at home 20 8% 
   
Children 0-
59 months 
Treatment of severe 
pneumonia 100% 
Ampicillin, gentamycin, 
oxygen, pediatric nasogastric 
























   





2.6 / 10,000 1 
Children 0-
59 months 
Treatment of severe 
diarrhea 100% 
IV kit, electrolyte solution, 
syringe, needle, cotton, take 
home materials with advice on 
preventing diarrhea at home 30 38% 
 
6 / 10,000 2 
Children 0-
59 months 
Treatment of severe 
pneumonia 100% 
Ampicillin, gentamycin, 
oxygen, pediatric nasogastric 
tubes, salbutamol, steroids 50 63% 
 
3.8 / 10,000 (qualified 
practitioners), 6.07 / 
10,000 census 1 
        5.1 / 10,000 1     
 






Table 26. Input parameters and distributions for cost-effectiveness analysis of bundled diarrhea and pneumonia interventions 
  Triangular distribution Gamma   
  
Best 
estimate Low High   Source 
Gamma distributions 
      Antibiotics 
      Ciprofloxacin (250mg tablet) $0.03 $0.01 $0.06 15.16 0.00 MSH 
Amoxicillin $0.02 $0.01 $0.03 59.54 0.00 MSH 
Ampicillin $0.15 $0.09 $0.38 11.41 0.02 MSH 
Gentamycin $0.06 $0.04 $0.15 12.99 0.01 MSH 
Dicloxicillin $0.04 $0.03 $0.07 28.40 0.00 MSH 
Other drugs 
      Vitamin A 100,000 dose $0.03 $0.02 $0.03 277.17 0.00 MSH 
Vitamin A 200,000 dose $0.03 $0.03 $0.04 347.99 0.00 MSH 
ORS sachets $0.10 $0.09 $0.13 154.38 0.00 MSH 
20 mg zinc tablet $0.03 $0.02 $0.06 31.05 0.00 MSH 
Salbutamol - tablets $0.00 $0.00 $0.01 14.96 0.00 MSH 
Salbutamol - liquid $0.24 $0.08 $0.35 15.23 0.01 MSH 
Oral prednisone $0.01 $0.01 $0.01 14.96 0.00 MSH 
Paracetamol $0.002 $0.001 $0.003 25.41 0.00 MSH 
Oxygen $3.70 $0.99 $6.41 11.19 0.33 Madsen et al (2009) (418) 
X-ray $6.13 $4.64 $7.61 101.96 0.06 Madsen et al (2009) (418) 
Inpatient stay $11.78 $11.01 $12.55 1410.10 0.01 Patel et al (2013) (85) 
Vaccines             
Rotavirus $2.50 $1.66 $5.00 18.53 0.16 UNICEF, Verguet et al (2013) (167) 
Hib $2.23 $1.82 $3.90 34.61 0.08 UNICEF 





 Triangular distribution Gamma  
  
Best 
estimate Low High   Source 
Materials             
IV kits $2.21 $2.07 $2.90 174.08 0.01 Amazon, Boundtree 
Pediatric nasogastric tubes $3.00 $1.53 $3.21 47.66 0.05 Vitality medical, Boundtree 
electrolyte solution $0.33 $0.01 $2.17 3.09 0.27 Patel et al (2013) (85) 
syringe $0.03 $0.01 $0.05 13.50 0.00 Alibaba 
needle $0.01 $0.00 $0.02 7.60 0.00 Alibaba 
cotton $0.01 $0.00 $0.02 7.60 0.00 Assumption 
Safety box $21.97 $14.96 $28.98 7.60 0.00 UNICEF 
Salaries             
Auxiliary nurse midwife $3,975 $3,701 $4,248 1264.12 3.14 Provider assessment survey 
Medical officer $8,452 $7,003 $9,902 203.95 41.44 Provider assessment survey 
ASHA $240 $228 $251 2518.59 0.10 Provider assessment survey 
AWW $240 $228 $251 2518.59 0.10 Provider assessment survey 
  Triangular distribution Beta   
Beta distributions 
Best 
estimate Low High     
Diarrhea episodes per year 2.9 2.3 3.4 162.55 0.02 Fischer Walker et al (2012) (8) 
Pneumonia Incidence 0.28 0.21 0.78 8.42 144.59 Rudan et al (2004) (420) 
Wastage rates, pneumococcal vaccine, 
single dose 5.5% 1.0% 10.0% 5.84 35.90 Parmar et al (2010) (421) 
Wastage rates, pneumococcal vaccine, two 
dose 14.0% 1.0% 27.0% 6.33 20.03 Parmar et al (2010) (421) 
Wastage rates, pneumococcal vaccine, ten 
dose 24.0% 4.0% 44.0% 14.82 30.09 Parmar et al (2010) (421) 
Wastage rate, HiB vaccine 33.0% 
16.0
% 50.0% 13.07 422.44 Noaves et al (2011) (422) 









components Dose Wastage Human resources Assumptions Source 
Vitamin A 
supplementation 
Vitamin A capsules 6-11 months: 
100,000 IU  
12-59 months: 
200,000 IU 
5% 3 visits * 2 minutes 
CHW time 
3 visits * 2 minutes 
nurse time 
1) Often delivered through 
national campaigns 
(previously stand alone, but 
increasingly child health day) 
2) The intervention is 
delivered while the child is 
seeing the health provider for 










3 sachets (One 
Health) (DAZT 
used two sachets) 
0% 1 visit * 10 minutes 
CHW time 
1 visit * 10 minutes 
nurse time 
Based on WHO CHCET 
model 
80% mild diarrhea 





























70 minutes CHW 
time 
70 minutes nurse 
time 
1) Two antenatal sessions, 
one immediately after birth, 
one first week after birth, one 
at six weeks, one between 5-
6 months of life 
2) No additional training was 
assumed as breastfeeding 
counselling is already part of 
ASHA responsibilities 
3) 1-5% of breastfeeding 




Two new oral 
rotavirus vaccines 
(Rotarix, Rotateq) 
2 doses 5% 3 visits * 2 minutes 
nurse time 
1) 5% wastage based on 
national wastage rates for 
most countries (425) 
2) Cold chain costed 
separately 
3) No sharps management 






2 tablets per day, 3 
days 
0% 2 visits * 2 minutes 
nurse time 
1) 1.7-2.78 episodes per year 







tablets (20mg for 
children 6-59 
months, 10mg for 
children 0-6 
months) 
14 days  0% 2 visits * 5 minutes 
CHW time 
2 visits * 5 minutes 
nurse time 
1) 1.7-2.78 episodes per year 




ORS, IV kit, 
Electrolyte 
solution, syringe, 
needle, cotton, take 
home materials 
with advice on 
5 days ORS 0% 10 minute diagnosis  
3 inpatient days in a 
general ward (doctor 
3 days x 10 minutes, 
nurse 3 days x 20 
minutes) 
1) 1% of diarrhea cases will 
require treatment for severe 
diarrhea (DAZT data are 
consistent with 1%, no 

















syringe (0.5 ml) 
with needle and 
safety box for used 
syringes 
2 primary doses 





3 visits * 2 minutes 
of doctor or nurse's 
time 
 (429), (424) 




with needle, safety 
box used for 
syringes 
3 doses 16%-50% 3 visits * 2 minutes 
of doctor or nurse's 
time 










3 days amoxicillin * 
twice daily  
6 doses (average) 
4 days salbutamol 
(one 2mg tablet for 
infants 2-11 
months, one 2mg 
tablet 3 times per 
day for children 1-5 
years) 
0% CHW - 3 visits  (10 
minute initial visit 
and 5 minutes for 
each follow up) 
Clinic nurse - 2 
visits  (10 minute 
initial visit and 5 
minutes for follow 
up) 
50% of children are brought 
to facilities for care 
Salbutamol for wheezing for 

















salbutamol (50% of 
wheezing children) 




steroids for 4 days 
Chest x-ray 
5 days outpatient 
care 
 -Ampicillin 
(50mg/kg IM every 
6 hours for 5 days) 
-Gentamycin 
(7.5mg/kg IM once 




nasal prongs for 
about 3 days) 
-Pediatric 
nasogastric tubes 
for children who 
cannot drink (20% 
of very severe cases 
for 3 days) 
-Salbutamol 
(2.5mg/4 times per 
day/5 days) 
-Prednisolone 




times/day for 5 
days) 
-Hospital days: 5 
days inpatient, 5 
days outpatient 
0% Hospital:  
Nurse (1x10 minute, 
6x5 minute per day) 
Medical doctor 10 
minutes / day 
Outpatient follow 
up: 
Nurse 10 minutes 
per day 
1) Standard management of 
very severe acute respiratory 
infections at the referral level 
2) 2-3% of pneumonia cases 






Table 28. Excluded studies from league table analysis of the cost-effectiveness of diarrhea and pneumonia interventions 
Intervention Reason for exclusion from league table 
Breastfeeding promotion – effect on pneumonia One study was available, although did not present 
costs disaggregated from the ICER. Lack of detail 
about implementation context (431) 
Daily, weekly, and intermittent preventive zinc 
supplementation 
These scenarios were presented by Brown et al 
(2013) (125); however, it was assumed that zinc 
supplementation is not feasible given difficulties 
India is having in scaling up zinc. 
Zinc supplementation (preventive) Did not present costs disaggregated from the ICER. 
Lack of detail about implementation context  (431) 
Rotavirus vaccination Disaggregated costs not presented. Lack of detail 
about implementation context (432). 
Measles vaccine One study evaluating measles vaccine in India 
(324) was not included as deaths averted by the 
measles vaccine are attributed to measles and not 
diarrhea (90). 
HiB vaccine A study from Haryana State was found (329), but 
excluded due to more direct evidence from Gujarat 
(166) 
Oral rehydration salts  Studies evaluate zinc treatment and ORS jointly 
(70) 
Complementary feeding education No economic evaluation exists 
Complementary feeding education and supplements No economic evaluation exists 
Antibiotics for dysentery No economic evaluation exists 
Vitamin A supplementation No economic evaluation exists 









Table 29. League table evaluation of the cost-effectiveness of interventions to address diarrhea and pneumonia 
Intervention   Setting 
Cost/DALY 
averted Budget Source 
Zinc supplementation 
(treatment) 
India $46 $2,968,203 Lefevre et al (forthcoming) (70) 




for GAVI - India 
is listed 
$215 $1,995,958 Sinha et al (2007) (168) 
HiB vaccine - 
Government + household 
costs - India, Gujarat 
India, Gujarat $612 $30,350,386 Clark et al (2013) (166) 
Breastfeeding - Effect on 
diarrhea 
South Asia (World 
Bank regions) 






Table 30. Coverage values for diarrhea and pneumonia interventions considered in bundled cost-effectiveness analysis 
  Conservative scale up Universal coverage 
  2011 2012 2013 2014 2015 2011 2012 2013 2014 2015 
Vitamin A supplementation 15.6% 29.7% 43.8% 57.9% 72.0% 15.6% 34.2% 52.8% 71.4% 90.0% 
Oral rehydration solution 15.3% 27.5% 39.6% 51.8% 63.9% 15.3% 34.0% 52.7% 71.3% 90.0% 
Exclusive breastfeeding   
   
    
   
  
0-1 mo 69.0% 69.3% 69.5% 69.8% 70.0% 69.0% 74.3% 79.5% 84.8% 90.0% 
1-5 mo 27.6% 38.2% 48.8% 59.4% 70.0% 27.6% 43.2% 58.8% 74.4% 90.0% 
Predominant breastfeeding   
   
    
   
  
0-1 mo 18.8% 16.6% 14.4% 12.2% 10.0% 18.8% 15.4% 11.9% 8.5% 5.0% 
1-5 mo 32.0% 26.5% 21.0% 15.5% 10.0% 32.0% 25.3% 18.5% 11.8% 5.0% 
Partial breastfeeding   
   
    
   
  
0-5 mo 9.5% 9.6% 9.8% 9.9% 10.0% 9.5% 7.1% 4.8% 2.4% 0.0% 
12-23 mo 38.8% 31.6% 24.4% 17.2% 10.0% 38.8% 29.1% 19.4% 9.7% 0.0% 
Any breastmilk   
   
    
   
  
6-11 mo 93.7% 93.7% 93.7% 93.7% 93.7% 93.7% 94.0% 94.4% 94.7% 95.0% 
6-23 mo 82.3% 82.3% 82.3% 82.3% 82.3% 82.3% 83.0% 83.7% 84.3% 85.0% 
Rotavirus vaccine 0.0% 18.0% 36.0% 54.0% 72.0% 0.0% 22.5% 45.0% 67.5% 90.0% 
Antibiotics for dysentery 13.0% 23.0% 32.9% 42.9% 62.8% 13.0% 32.3% 51.5% 70.8% 90.0% 
Zinc supplementation (treatment) 2.5% 7.5% 12.5% 17.4% 22.4% 2.5% 24.4% 46.3% 68.1% 90.0% 
Treatment of severe diarrhea 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 
Antibiotics for treatment and management of 
pneumonia 11.7% 16.7% 21.7% 26.6% 31.6% 11.7% 31.3% 50.9% 70.4% 90.0% 
Treatment of severe pneumonia 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 
Pneumococcal vaccine 0.0% 18.0% 36.0% 54.0% 72.0% 0.0% 24.0% 48.0% 72.0% 96.0% 






Table 31. Additional cost per capita to achieve targeted coverage rates for conservative and universal scale up scenarios by 2015 
a) Conservative coverage 
Intervention 
2011 2012 2013 2014 2015 Cost/year Total 5-year % allocation 
Breastfeeding promotion $1,022,725 $996,535 $971,002 $946,112 $921,847 $971,644 $4,858,221 10.05% 
Antibiotics for treatment and    
    management of pneumonia $31,288 $43,293 $79,653 $113,858 $146,003 $82,819 $414,094 0.86% 
Antibiotics for dysentery $4,393 $7,530 $10,481 $13,253 $18,857 $10,903 $54,514 0.11% 
Pneumococcal vaccine $0 $370,991 $720,371 $1,049,083 $1,358,037 $699,696 $3,498,482 7.24% 
Vitamin A supplementation $151,641 $254,340 $350,927 $441,673 $526,834 $345,083 $1,725,415 3.57% 
Oral rehydration solution $3,140,658 $3,995,141 $4,797,184 $5,549,116 $6,253,177 $4,747,055 $23,735,277 49.11% 
HiB vaccine $0 $778,850 $1,512,330 $2,202,423 $2,851,033 $1,468,927 $7,344,636 15.20% 
Rotavirus vaccine $0 $259,901 $504,663 $734,946 $951,386 $490,179 $2,450,896 5.07% 
Zinc supplementation  
  (treatment) $237,976 $690,824 $2,009,865 $3,251,483 $4,419,068 $2,121,843 $10,609,216 21.95% 
Treatment of severe diarrhea $18,178 $17,649 $17,135 $16,636 $16,151 $17,150 $85,748 0.18% 
Treatment of severe  pneumonia $504,160 $489,476 $475,219 $461,378 $447,940 $475,635 $2,378,173 4.92% 






b) Universal coverage 
Intervention 2011 2012 2013 2014 2015 Cost/year Total 5-year % allocation 
Breastfeeding promotion $1,022,725 $1,068,487 $1,110,715 $1,149,577 $1,107,347 $1,107,347 $5,536,736 8.80% 
Antibiotics for treatment and  
    management of pneumonia $247,847 $643,218 $1,015,347 $1,365,253 $993,116 $993,116 $4,965,578 7.89% 
Antibiotics for dysentery $4,393 $10,582 $16,406 $21,881 $16,057 $16,057 $80,286 0.13% 
Pneumococcal vaccine $0 $583,854 $1,133,698 $1,651,017 $1,101,161 $1,101,161 $5,505,807 8.75% 
Vitamin A supplementation $151,641 $336,918 $511,273 $675,185 $500,827 $500,827 $2,504,133 3.98% 
Oral rehydration solution $1,519,741 $3,276,427 $4,929,492 $6,483,482 $4,830,382 $4,830,382 $24,151,910 38.37% 
HiB vaccine $0 $1,225,731 $2,380,061 $3,466,108 $2,311,754 $2,311,754 $11,558,771 18.36% 
Rotavirus vaccine $0 $409,025 $794,223 $1,156,636 $771,429 $771,429 $3,857,147 6.13% 
Zinc supplementation    
    (treatment) $217,038 $2,054,481 $3,784,705 $5,412,397 $3,682,136 $3,682,136 $18,410,681 29.25% 
Treatment of severe diarrhea $18,178 $17,649 $17,135 $16,636 $17,150 $17,150 $85,748 0.14% 
Treatment of severe      
         pneumonia $504,160 $489,476 $475,219 $461,378 $475,635 $475,635 $2,378,173 3.78% 








Start up $60,011 
Facility $48,206 
Vehicles $36,220 
In service training $3,340 
Information, education, and communication campaign $16,251 







Table 33. Incremental cost-effectiveness of individual diarrhea and pneumonia interventions 
 
  
Incremental cost Deaths averted DALYs averted 
Individual Cost per 
death averted 
Individual Cost 
per DALY averted 
Intervention Cons* Univ* Cons Univ Cons Univ Cons Univ Cons Univ 
Breastfeeding promotion -$42,614 $220,771 67 578 1,892 16,319 -$636 $382 -$23 $14 
Antibiotics for treatment and management of 
pneumonia $172,979 $1,504,331 1,007 1,512 28,432 42,690 $172 $995 $6 $35 
Antibiotics for dysentery $72,727 $80,894 174 201 4,913 5,675 $418 $402 $15 $14 
Vitamin A supplementation $433,456 $735,738 228 307 6,437 8,668 $1,901 $2,397 $67 $85 
Pneumococcal vaccine $1,416,300 $2,195,502 695 1,022 19,623 28,855 $2,038 $2,148 $72 $76 
Oral rehydration solution $3,170,782 $6,481,290 1,000 1,471 28,234 41,533 $3,171 $4,406 $112 $156 
Rotavirus vaccine (Rotarix, Rotateq) $1,009,650 $1,555,527 243 310 6,861 8,753 $4,155 $5,018 $147 $178 
HiB vaccine $2,909,296 $4,545,135 496 709 14,004 20,018 $5,866 $6,411 $208 $227 
Zinc supplementation (treatment) $4,239,356 $6,783,286 329 484 9,289 13,665 $12,886 $14,015 $456 $496 
Treatment of severe diarrhea $56,236 $56,236 0 0 0 0 N/A N/A N/A N/A 
Treatment of severe pneumonia $2,043 $2,043 0 0 0 0 N/A N/A N/A N/A 








Table 34. Incremental cost-effectiveness of the overall package of diarrhea and pneumonia interventions 
Cost effectiveness outputs Conservative 95% confidence interval Universal 95% confidence interval 
Incremental costs 3% discount $12,053,874 $9,997,968 $14,255,424 $20,392,309 $16,941,682 $24,161,841 
Incremental costs 0% discount $15,688,116 $13,161,090 $18,413,050 $27,575,293 $23,165,933 $32,591,908 
Incremental costs 6% discount $11,497,091 $9,599,016 $13,525,660 $21,209,176 $17,834,292 $25,075,790 
Deaths averted 2,754 
  
4,004 
  Cost/death averted $4,376.86 $3,630.34 $5,176.26 $5,092.98 $4,231.19 $6,034.43 
Cost/DALY (3,0) averted $155.02 $128.58 $183.33 $180.38 $149.86 $213.73 
Cost/DALY (3,1) averted $138.59 $114.96 $163.91 $161.27 $133.98 $191.08 
Cost/DALY (0,0) averted $91.02 $76.36 $106.83 $110.04 $92.45 $130.06 





Table 35. Costs of packages of diarrhea and pneumonia interventions bundled according to service delivery channel 
  Community Outreach 
Intervention Incremental  Cost / year Total 5 year Incremental  Cost / year Total 5 year 
Ambitious coverage 
      Breastfeeding promotion -$40,351 $388,658 $1,943,289 -$40,351 $38,866 $194,329 
Antibiotics for treatment and management of  
   pneumonia $57,358 $41,409 $207,047 
   Antibiotics for dysentery $7,232 $5,451 $27,257 
   Pneumococcal vaccine 
      Vitamin A supplementation $187,596 $172,542 $862,708 $187,596 $172,542 $862,708 
Oral rehydration solution $1,556,259 $2,373,528 $11,867,639 
   HiB vaccine 
      Rotavirus vaccine 
      Zinc supplementation (treatment) $2,926,765 $1,485,290 $7,426,451 
   Treatment of severe diarrhea 
      Treatment of severe pneumonia 
      Totals $4,694,859 $744,480 $22,334,390 $147,245 $105,704 $1,057,037 
Universal coverage 
      Vitamin A supplementation $174,593 $553,674 $2,768,368 $174,593 $553,674 $2,768,368 
Oral rehydration solution $1,655,320 $496,558 $2,482,789 
   Breastfeeding promotion $33,849 $442,939 $2,214,694 $8,462 $1,606 $8,029 
Rotavirus vaccine 
      Antibiotics for dysentery $11,664 $250,413 $1,252,067 
   Zinc supplementation (treatment) $3,465,099 $3,381,267 $16,906,337 
   Treatment of severe diarrhea 
      Pneumococcal vaccine 
      HiB vaccine 
      Antibiotics for treatment and management of pneumonia $745,269 $8,575 $42,874 
   Treatment of severe pneumonia 







  Clinic Hospital 
Intervention Incremental  Cost / year Total 5 year Incremental  Cost / year Total 5 year 






      Antibiotics for treatment and management of pneumonia -$50,439 $485,822 $2,429,111 
   Antibiotics for dysentery $57,358 $41,409 $207,047 
   Pneumococcal vaccine $7,232 $5,451 $27,257 
   Vitamin A supplementation $1,358,037 $699,696 $3,498,482 
   Oral rehydration solution 
      HiB vaccine $1,556,259 $2,373,528 $11,867,639 
   Rotavirus vaccine $2,851,033 $1,468,927 $7,344,636 
   Zinc supplementation (treatment) $951,386 $490,179 $2,450,896 
   Treatment of severe diarrhea $1,254,328 $636,553 $3,182,765 
   Treatment of severe pneumonia 
   
-$1,873 $17,150 $85,748 
Totals 
   
-$68,361 $475,635 $2,378,173 
Universal coverage $7,985,193 $775,196 $31,007,831 -$70,235 $246,392 $2,463,921 
Vitamin A supplementation 
      Oral rehydration solution 
      Breastfeeding promotion $1,655,320 $496,558 $2,482,789 
   Rotavirus vaccine $42,311 $8,029 $40,143 
   Antibiotics for dysentery $771,429 $1,101,161 $5,505,807 
   Zinc supplementation (treatment) $5,832 $250,413 $1,252,067 
   Treatment of severe diarrhea $1,039,530 $1,449,115 $7,245,573 
   Pneumococcal vaccine 
   
-$1,873 $2,311,754 $11,558,771 
HiB vaccine $1,101,161 $771,429 $3,857,147 
   Antibiotics for treatment and management of pneumonia $2,311,754 $3,682,136 $18,410,681 
   Treatment of severe pneumonia $372,634 $8,575 $42,874 
   Totals 
   






Table 36. Cost-effectiveness of different packages of diarrhea and pneumonia interventions bundled according to service delivery channel  
Community Conservative 95% confidence interval Universal 95% confidence interval 
Costs $5,335,758 $4,246,165 $6,577,653 $9,729,797 $7,817,684 $11,969,200 
Deaths averted 1,979 
  
3,117 
  Cost/death averted $2,696 $2,146 $3,324 $3,122 $2,508 $3,840 
Cost/DALY averted $95.49 $75.99 $117.72 $110.56 $88.83 $136.00 
Outreach 
      Costs $818,408 $772,617 $877,103 $1,006,480 $923,125 $1,113,916 
Deaths averted 139 
  
757 
  Cost/death averted $5,888 $5,558 $6,310 $1,330 $1,219 $1,471 
Cost/DALY averted $208.53 $196.87 $223.49 $47.09 $43.19 $52.12 
Clinic 
      Costs $8,626,092 $7,450,238 $9,963,515 $14,849,268 $12,810,437 $17,084,648 
Deaths averted 2,726 
  
3,970 
  Cost/death averted $3,164 $2,733 $3,655 $3,740 $3,227 $4,303 
Cost/DALY averted $112.08 $96.80 $129.45 $132.48 $114.29 $152.42 
Hospital 
      Costs $582,652 $544,903 $612,360 $625,025 $587,276 $612,360 
Deaths averted 0 
     Cost/death averted undefined undefined undefined undefined undefined undefined 

















Study districts         
Banas Kantha 0 1 1 77 16 422 
Dohad 0 1 1 63 11 332 
Panch Mahals 0 1 2 65 12 400 
Patan 1 1 0 32 11 210 
Sabar Kantha 0 1 1 63 20 413 
Surendranagar 1 1 1 35 11 200 
Total 2 6 6 335 81 1977 
Average 0.3 1.0 1.0 55.8 13.5 329.5 
Other districts         
Ahmedabad 2 1 0 42 10 236 
Amreli 0 1 2 38 9 247 
Anand 1 1 0 46 10 274 
Bharuch 0 1 0 38 7 200 
Bhavnagar 1 1 1 46 4 360 
Dangs 0 1 0 9 1 47 
Ghandinagar 0 1 1 24 7 171 
Jamnagar 1 1 1 37 11 265 
Junagadh 0 1 1 57 20 390 
Kheda 0 1 1 50 12 332 
Kutch 1 1 0 39 13 279 
Mehsana 0 1 1 50 13 288 
Narmada 0 1 0 22 4 134 
Navsari 0 1 1 37 10 281 
Porbandar 0 1 0 10 3 84 
Rajkot 1 1 1 44 18 330 
Surat 2 0 0 47 13 345 
Tapi NA 1 NA 30 5 228 
Vadodara 2 1 0 79 16 465 
Valsad 0 1 1 40 9 330 
Grand total 13 25 17 1120 276 7263 
Average 0.5 1.0 0.7 43.1 10.6 279.3 






Figure 20. Overview of the Indian health care sector (434) 
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11.5 Policy chapter 






Caregiver economic cost 
The DAZT program was associated with 
•Reduced cost to caregivers 
•Increased knowledge of ORS  and zinc 
•Increased treatment seeking 
•Increased use of ORS and zinc 
•Reduced cost of antibiotics and 
antidiarrheals 
•Increased use of community based 
services 
•Reduced travel costs and wages lost 
•Costs are particularly high for episodes 
of long duration and caregivers that 
sought care from private providers 
Cost-effectiveness 
•The DAZT program may be an 
attractive investment for the health 
system 
•Adjusting for covariates does not 
affect recommendations to advocate 
the program 
•Results could be used to inform 
hypotheses about cost-effectiveness 
according to subgroups, although 
universal coverage is recommended 
Bundled cost-effectivenss 
analysis 
•Zinc and ORS are cost-effective in a 
broader consideration of 
interventions 
•Consdieration of other investment 
criteria favors implementation 
•Funding is currently inadequate in 





12.1 Initial survey 
BASELINE CROSS SECTIONAL SURVEY 
Standard Codes (1= Yes; 2=No, 8= Does Not Know, 9=Not Applicable) DATE_FILL 
Interviewer code   INT_CODE                 Date of form filling 
PART A: ALL HOUSEHOLDS WITH AT LEAST 1 CHILD UNDER 5 YEARS OF AGE 
01.  Site code (3 = UP, 4 = Gujarat) SITE_CODE  
02.  Village name VILL_NAME __________________________ 
03.  Village Code VILL_CODE  
04.  Name of head of the household NAME_HEAD __________________________ 
05.  Phone number PHONE  
06.  Household ID HH_ID    
07.  Type of family (3 =Nuclear, 4=Joint) TYPE_FAM 
 
08.  How many people are living in this house?  NO_MEMB_M 
NO_MEMB_F 
NO_MEMB_MCH 
             Male (≥5 years) 
             Female (≥5 years) 
             Male child (< 5 years) 




NO_MEMB _FCH              Female child (< 5 years) 
 Details of youngest child in the age category 2 to 59 months  
09.  Name of the child    CH_NAME ________________________ 
10.  Age of the child (in completed years and months) AGE_YR  
AGE_MO 
            Years                Months 
11.  Sex (3=Male, 4=Female)  SEX               
12.  Was the child breast-fed in the previous 24 hrs CH_BF  
13.  Name of the mother  MOTHER_NAM ________________________ 
14.  Name of the father  FATHER_NAM ________________________ 
CAREGIVER’S KNOWLEDGE ABOUT DIARRHEA MANAGEMENT 
15.  What types of symptoms associated with diarrhea would cause you to 
take the child to a doctor or health facility immediately (Mark 1 for YES 
for those mentioned by the caregiver spontaneously and 2 for NO if 
not mentioned) 
 
15.1.  Child has diarrhea for too many days DIAR_DAY  
15.2.  Child passes too many stools  NO_STOOL  
15.3.  Child has watery stools    WAT_STOOL  




15.5.  Child is lethargic  LETHARGIC   
15.6.  Child not able to drink or breastfeed   NOT_DRINK  
15.7.  Child becomes sicker    SICKER   
15.8.  Child develops fever FEVER  
15.9.  Child has fast breathing    FAST_BREATH  
15.10.  Child has difficulty breathing (Mushkil/pareshani  DIFF_BREATH  
15.11.  Child passes blood in the stool   BLD_STL  
15.12.  Child is drinking poorly or not as often  DRINK_POOR  
15.13.  Child has sunken eyes   SUNK_EYE  
15.14.  Child is irritable   IRRETABLE  
15.15.  Child is weak    WEAK  
15.16.  Child is vomiting VOMITING  
15.17.  Others, specify   OTH15_1, OTH15_SP1  
15.18.  OTH15_2 , OTH15_SP2  









16.  What are the appropriate sources of care in your village or outside your 
village where a child with diarrhea can be taken for treatment (Mark1 




16.1.  Primary health centre / Govt hospital / Govt dispensary CARE_PHC  
16.2.  Auxiliary nurse midwife (ANM)/sub centre   CARE_ANM  
16.3.  Private doctor    CARE_PP  
16.4.  Nursing home/Private hospitals   CARE_NUR  
16.5.  Mobile clinic    CARE_MOBCLIN  
16.6.  Anganwadi worker (AWW)/Aganwadi centre (AWC) CARE_AWW  
16.7.  Accredited social health activist (ASHA) CARE_ASHA  
16.8.  Chemist………… CARE_CHEM  
16.9.  Traditional healer………… CARE_THEAL  




16.11.  Others, specify _ CARE_OTH16_1 , CARE_OTH16_SP1  
16.12.  ______ CARE_OTH16_2 , CARE_OTH16_SP2  
16.13.  _______ CARE_OTH16_3 , CARE_OTH16_3  
17.  Have you heard of a product called Jeevan Raksha Ghol/ORS?   
Have you seen this product (show packets available commercially or 
through government channels) HEARD_ORS 
 
18.  If Q17 is NO, has not heard or seen THEN fill questions 18.1 to 18.8 
with 9 
If Q17 is YES, then ask: What is the packet used for?  (Mark YES if 
mentioned by the caregiver spontaneously and NO if not mentioned)  
 
18.1.  Diarrhea……………ORS_DIAR  
18.2.  Dehydration…………ORS_DEHY  
18.3.  Summer……………ORS_SUMM  
18.4.  Vomiting……………ORS_VOMIT  
18.5.  Malnutrition…………ORS_MALN  
18.6.  Others, specify _ORS_OTH18_1 , ORS_OTH18_SP1  
18.7.  ORS_OTH18_2 ,  ORS_OTH18_SP2  




19.  Have you heard of Zinc?  HEARD_ZINC 
Show the zinc tablet/syrup available commercially or through 
government channels and ask have you ever seen a tablet or syrup like 
these?  
 
20.  If Q19 is NO, has not heard or seen THEN fill questions 20.1 to 20.18 
with 9 
If Q19 is YES, then ask: From where did you hear about this product? 
(Mark YES if mentioned by the caregiver spontaneously and NO if not 
mentioned)  
 
20.1.  Primary health centre/Govt hospital / Govt dispensary ZINC_PHC   
20.2.  Auxiliary nurse midwife (ANM)/sub centre…ZINC_ANM  
20.3.  Private doctor………ZINC_PP  
20.4.  Nursing home/Private hospital…ZINC_NUR  
20.5.  Mobile clinic……ZINC_MOBCLIN  
20.6.  Anganwadi worker (AWW)/Aganwadi centre (AWC) ZINC_AWW  
20.7.  Accredited social health activist (ASHA) ZINC_ASHA  
20.8.  Chemist………ZINC_CHEM  
20.9.  Traditional healer………ZINC_THEAL  




20.11.  Radio………ZINC_RADIO  
20.12.  Poster / Wall paintings……ZINC_POSTER  
20.13.  Pamphlets………ZINC_PAMPH  
20.14.  Television………ZINC_TEL  
20.15.  Neighbour / family member……ZINC_NEIGH  
20.16.  Others, specify  ZINC_OTH20_1 ,  ZINC_OTH20_SP1  
20.17.  ZINC_OTH20_2  , ZINC_OTH20_SP2  
20.18.  ZINC_OTH20_3 ,  ZINC_OTH20_SP3  
21.  If Q19 is NO, has not heard or seen THEN fill questions 21.1 to 21.7 
with 9   
If Q19 is YES, then ask: What is zinc used for (Mark YES if mentioned 
by the caregiver spontaneously and NO if not mentioned)  
 
21.1.  Diarrhea ………ZINC_DIAR  
21.2.  Pneumonia ………ZINC_PNEU  
21.3.  Tonic…………ZINC_TONIC  
21.4.  Fertilizer ………ZINC_FERT  




21.6.  ZINC_OTH21_2 ,  ZINC_OTH21_SP2  
21.7.  ZINC_OTH21_3 ,  ZINC_OTH21_SP3  
22.  Was the child admitted to the hospital in the last 3 mo? CH_HOSP 
If NO, fill 22.1, 22.2, 23 and 24 with 9’s for each box 
 
22.1.  If yes, then date of admission.  If more than once, then most recent 
hospitalization…DT_ADM 
 
  DD         MM           YY 
22.2.  Duration of stay………DUR_DAY ,  DUR_HRS               Days                hours      
23.  What was the reason for admission?    
23.1.  Pneumonia…………ADM_PNEU  
23.2.  Diarrhea / dehydration……ADM_DIAR   
23.3.  Fever…………ADM_FEV  
23.4.  Others, specify ADM_OTH23_1 ,  ADM_OTH23_SP1             
23.5.  ADM_OTH23_2 ,  ADM_OTH23_SP2  
23.6.  ADM_OTH23_3 ,  ADM_OTH23_SP3  
24.  What was the cost of the hospitalization? COST_HOSP  
25.  Has your child had any of the following in the past two weeks?  [Prompt 
for each option] 





25.1.  Cough……………COUGH_2WK ,  COUGH_2WK_D  
25.2.  Difficulty in breathing………DBR_2WK ,  DBR_2WK_D  
25.3.  Fast breathing……FBR_2WK ,   FBR_2WK_D  
25.4.  Fever………FEV_2WK ,   FEV_2WK_D  
25.5.  Chest indrawing………CHEST_2WK ,  CHEST_2WK_D  
25.6.  Wheezing………WHEZ_2WK ,  WHEZ_2WK_D  
26.  Did your child have diarrhea (> 3 loose/watery stools in 24 hours)   
26.1.  In the previous 24 hours……DIAR_P24H  
26.2.  In the previous 2 weeks……DIAR_P2WK  
27.  If the child had diarrhea in the last 2 weeks, record for the most recent 
episode (including the ongoing one), record  
 
 Date of onset (could be earlier than the last 14 days) DT_ONSET  
 DD           MM        YY 
27.1.  Did the child recover (The child does not have loose or watery stools 
for at least 72 hours)… CH_RECOVER 
 
27.2.  If yes, date of recovery……DT_RECOVER  




PART B:  RECENT DIARRHEAL EPISODE MORBIDITY AND CARE SEEKING 
TO BE FILLED OUT IF THE CAREGIVER ANSWERED YES TO QUESTION 26 
If Q 26 = NO, then skip PART B and go to PART C 
28.  If the child had diarrhea in the last 14 days, ask the mother about 
each of the following and enter appropriate answer [Prompt for each 
option]   
 
28.1.  Did your child pass blood in the stool during this illness 
BLD_ST_14D 
 
28.2.  Did your child have fever with this diarrheal illness FEV_14D  
28.3.  Did your child have vomiting with this diarrheal illness 
VOM_14D 
 
28.4.  Was the child very thirsty during this illness THIRST_14D  
28.5.  Was the child lethargic or irritable  IRRI_14D  
28.6.  Did your child have sunken eyes  SUNK_14D  
28.7.  Did your child have dehydration (pani ki kami) DEHY_14D  
29.  What were the maximum number of loose or watery stools passed 
on any day during the illness  NO_LW_STL 
 
30.  How much did the child drink during this illness?   
 11= None; 12 = Less than normal; 13=Same as normal;   14 





31.  Did you offer the child food and did the child eat during this illness?  
FOOD_EAT 
 
 11 = Didn’t offer and didn’t eat; 12 = Ate less than normal; 13 
=Ate the same as normal; 14=Ate more than normal 
 
32.  Did you seek advice or treatment outside home?  SEEK_ADV  
33.  (If No to Q32, then fill questions 33.1 to 33.13 with 9) 
If yes for Q32, then ask:  From whom did you seek advice / 
treatment?  
 
33.1.  Primary health centre/Govt hospital/Govt dispensary ADV_PHC  
33.2.  Auxiliary nurse midwife ANM)/sub centre…ADV_ANM  
33.3.  Private doctor……ADV_PP  
33.4.  Nursing home/Private hospital….ADV_NURH  
33.5.  Mobile clinic……ADV_MOBCLIN  
33.6.  Anganwadi worker (AWW)/Aganwadi centre (AWC)ADV_AWW  
33.7.  Accredited social health activist (ASHA) ADV_ASHA  
33.8.  Chemist……ADV_CHEM  




33.10.  Charitable hospital/NGO/Trust…ADV_NGO  
33.11.  Others, specify ADV_OTH33_1 ,  ADV_OTH33_SP1  
33.12.  ADV_OTH33_2 ,  ADV_OTH33_SP2  
33.13.      ADV_OTH33_3  , , ADV_OTH33_SP3  
34.  (If No to Q32, then fill in 999) WAIT_CARE 
If yes for Q32, then ask: How many hours after the start of diarrhea 
did you wait before seeking care?   
 
 
35.  (If YES to Q32, then fill in 9) 
If No for Q32, then ask: Why did you not seek care?  (Yes if 
caregiver mentions the reason listed, No for all NOT mentioned)  
 
35.1.   Child recovered………RECOVER_35  
35.2.  Illness not severe………NSEV_35  
35.3.  Home treatment adequate……HTREAT_35  
35.4.  Already had medicines in the home…MED_HOME35  
35.5.  Source not available………SOUR_NAV  
35.6.  Source too far from home…SOUR_FAR  




35.8.  Nobody to accompany…NO_ACCOMP  
35.9.  Good source not available at that time  NO_WOODSOUR  
35.10.  Money not available at that time…NO_MONEY  
35.11.  No time to take the child to the source…NO_TIME  
35.12.  Medicines given by available source are ineffective MED_INEFF  
35.13.  Family did not support seeking care…FAM_NSUPP  
35.14.  Others, specify OTH35_1 ,  OTH35_SP1  
35.15.  OTH35_2  ,  OTH35_SP2  
35.16.  OTH35_3 ,   OTH35_SP3  
36.  Was the child administered any syrup, tablet, injection or IV fluids 
to treat this episode of diarrhea? ANY_SYP 
 
37.  If Q36 is NO, fill questions 37.1 to 37.12 with 9 
If Q36 is YES, then ask:  What did you give?  (Yes to all 
mentioned / No if not mentioned)  Do not prompt for each 
 
37.1.  Syrup, unknown……SYP_UNK  
37.2.  Tablet, unknown……TAB_UNK  




37.4.  Injection known………INJ_KNOW  
37.5.  Injection unknown………INJ_UNK  
37.6.  Antibiotics, specify ……ANTIBIO ,  ANTIBIO_SP  
37.7.  Antidiarrheal, specify …… ANTIDIA ,  ANTIDIA_SP  
37.8.  Zinc………… ZINC  
37.9.  IV Fluids……… IV_FLUID  
37.10.  Others, specify OTH37_1 ,  OTH37_SP1  
37.11.  OTH37_2  ,  OTH37_SP2  
37.12.  OTH37_3 ,  OTH37_SP3 OTH37  
38.  Was the child administered ORS during this diarrheal episode? 
SHOW PACKETS   ORS_38 
 
39.  If Q38 is NO, fill questions 39.1 to 39.13 with 9 
If Q38 is YES, then ask: Where did you get these packets from? 
(Yes for all mentioned / No if not mentioned)  
 
39.1.  Primary health centre / Govt hospital / Govt dispensary PHC_39  
39.2.  Auxiliary nurse midwife (ANM/subcentred) ANM_39  




39.4.  Accredited social health activist (ASHA) ASHA_39  
39.5.  Chemist…… CHEM_39  
39.6.  Nursing Home/Private hospital… NURSE_39  
39.7.  Kept at home……… HOME_39  
39.8.  From neighbor/relative…… NEIGH_39  
39.9.  Charitable Hospital/NGO/Trust…… NGO_39  
39.10.  Private doctor…… PP_39  
39.11.  Others, specify OTH39_1 , OTH39_SP1  
39.12.  OTH39_2 ,   OTH39_SP2  
39.13.  OTH39_3 ,  OTH39_SP3  
40.  If Q38 is NO, fill box with 9    INST_ORS 
If Q38 is YES, then ask:  Did the provider instruct you how to 
prepare ORS? 
 
41.  If Q38 is NO, fill boxes with 99 
How was the ORS prepared? ORS_41 
11 = 1 liter sachet prepared entirely in 1 liter of water; 12 = 200 ml 






42.  If Q38 is NO, fill box with 9     ORS_FREE 
If Q38 is YES, then ask:  Were the packets given for free or did 
you buy? (3 = free; 4 = bought; 5= some free/some bought) 
 
43.  If Q38 is NO, fill boxes with 99   ORS_DAYUSE 
If Q38 is YES, then ask: How many days did you use it for?  
 
44.  If Q38 is NO, fill boxes with 99    ORS_NOUSE 
If Q38 is YES, then ask:  How many packets did you use during the 
episode? 
 
45.  Did you give any home available fluids HOME_FLUID  
46.  Did you administer zinc tablet/syrup to your child during this 
episode? (SHOW THE ZINC PRODUCTS) ZINC_TAB 
 
47.  If Q46 is NO, fill questions 47.1 to 47.13 with 9 
If Q46 is YES, then ask: Where did you get zinc from (YES if 
mentioned, NO if not mentioned)  
 
47.1.  Primary health centre / Govt Hospital / Govt dispensary PHC_47  
47.2.  Auxiliary nurse midwife (ANM)/sub centre…ANM_47  
47.3.  Anganwadi worker (AWW)/Aganwadi centre (AWC) AWW_47  
47.4.  Accredited social health activist (ASHA)… ASHA_47  




47.6.  Nursing Home/Private hospital…NURH_47  
47.7.  From Neighbour/relative…NEIGH_47  
47.8.  Kept at home……HOME_47  
47.9.  Charitable hospital,/NGO/Trust …NGO_47  
47.10.  Private doctor………PP_47  
47.11.  Others, specify OTH47_1 ,  OTH47_SP1  
47.12.  OTH47_2 ,  OTH47_SP2  
47.13.  OTH47_3 ,   OTH47_SP3  
48.  If Q46 is NO, fill box with 9   
If Q46 is YES, then ask: Did you receive instruction as to how to 





49.  If Q46 is NO, fill box with 9 
If Q46 is YES, then ask: Did you get zinc for free or buy?(3=free; 
4=bought; 5=some free/some bought) ZINC_FREE 
 
50.  If Q46 is NO, fill questions 50.1 to 50.2 with 99 
If Q46 is YES, then ask: How many zinc did you receive / buy?         





50.1.         Bottles ………NO_BOTT               bottles  
50.2.         Tablets………NO_TAB               tablets 
51.  If Q46 is NO, leave line blank 
If Q46 is YES, then ask: Do you have the product (s)?  If so, can I 
see it?   
If not, can you identify the product(s) you used on the chart?  




52.  If Q46 is NO, fill 99 
If Q46 is YES, then ask: How many days did you use it for?  (fill 
number of days till today. Fill 99 if not used)  DAY_USE 
 
53.  If Q46 is NO, fill box with 9  STIL_ZINC 
If Q46 is YES, then ask:  Are you still giving the zinc 
 
54.  How much did you spend in the treatment of this episode (in Rs). 
Fill only those boxes that are applicable with amount spent. Fill 
0000 in others. [Prompt for each] 
 
54.1.  Consultation (the fees paid to the source of care) CONS_54  
54.2.  Dispensing (include costs of medicines dispensed by the 
source)…… DISP_54 
 
54.3.  Purchase of drugs (cost incurred to purchase drugs from the 
chemist or other source)…… DRUG_54 
 




54.5.  Purchase of zinc (Cost paid for zinc tablets/syrup) ZINC_54  
54.6.  Special food purchased (fruits, juice etc.) FOOD_54  
54.7.  Transportation (round trip cost paid for taking to the source of 
care)……… TRAN_54 
 
54.8.  Admission/hospitalization cost…HOSP_54  
54.9.  Did you (or spouse) take time off from work due to this illness 
………OFF_54 
 
54.10.  If yes, how much wages did you lose because of this absence 
from work……WAGE_54 
 
54.11.  Other costs, specify…OTH54 ,  OTH54_SP  
PART C: SES/HOUSEHOLD DATA (FOR ALL HOUSEHOLDS WITH CHILD UNDER 5.  CAN BE 
ANSWERED BY CAREGIVER OR OTHER ADULT LIVING IN HOUSEHOLD IF NECESSARY) 
55.  What are the years of schooling of this child’s father? 
(Fill 00 if father has never been to school or completed less than 
1 year of schooling)  FATH_SCH 
 
56.  What is the occupation of father or male caregiver?  
11=government service, 12=private service, 13=daily wage earner, 
14=self employed, 15=farming, 16=does not work, 17=other, 
specify, 99=not applicable),  FATH_OCC , FATH_OCC_SP 
 




58.  What is the age (in years) of mother (or primary care giver if mother 
has died)? AGE_MOTH 
 
59.  What are the years of schooling of this child’s mother (or primary 
caregiver if mother has died)?  MOTH_SCH 
(Fill 00 if mother has never been to school or completed less than 
1 year of schooling) 
 
60.  What is the occupation of mother/female caregiver?  
(11=government service, 12=private service, 13=daily wage earner, 
14=self employed, 15=farming, 16=does not work, 17=other, 







61.  What are the sources of drinking water used by your family?    
Prompt for each option. 
 
61.1.  Piped water into dwelling/yard/plot…PIPED  
61.2.  Public tap/standpipe…..…PUB_TAB  




61.4.  Hand pump…….HAND_PUMP  
61.5.  Dug well (covered/open)…… DUGWEL  
61.6.  Tanker truck………TANKER   
61.7.  ATM water machine……ATM_WAT  
61.8.  Surface water (River/Dam/Lake/Ponds/Stream/Canal/ Irrigation 
channel/shallow well)…… SUR_WAT 
 
61.9.  Others, specify OTH61_1 ,  OTH61_SP1  
61.10.  OTH61_2 ,  OTH61_SP2  
61.11.  OTH61_3 ,  OTH61_SP3  
62.  Do you purify drinking water PURIFY_WAT  
63.  How much time does it take to obtain drinking water (round trip)?   
TIME_OBTWAT 
3 = Water on premises; 4= Less than 30 minutes; 5=More than 30 
minutes; 8= Don’t know 
 
64.  Is electricity available in your house  ELECT_AV  
65.  If the house has electricity, for an average of how many hours per 
day does it work? (99 if NO to question 64)  ELECT_HRS 










66.  What are the common places of defecation of the household 
members? Prompt for each option. 
 
66.1.  Flush/pour flush to piped sewer system, or septic tank SEWER  
66.2.  Pit latrine with slab……PIT_SLAB  
66.3.   Pit latrine without slab/open pit…PIT_WSLAB  
66.4.  No facility/open space/field…OPEN_SPACE  
66.5.  Others, specify OTH66_1 ,  OTH66_SP1  
66.6.  OTH66_2 ,   OTH66_SP2  
66.7.  OTH66_3 ,  OTH66_SP3  
67.  If answer to Q66 if no facility/open space/field, fill 9 in options of 
Q67    
Is the toilet facility for this household only or shared?  
 
67.1.  This household only……ONLY_HOUSE  




68.  Do you possess a BPL card?   BPLCARD  
69.  Do you possess an Antodaya /Annapurna card? ANM_CARD  
70.  What is the religion of father or head of the household?    
 11=Hindu; 12=Muslim; 13=Sikh; 14=Christian, 15=Others, 
specify________......RELIGION ,   RELIGION_SP 
 
71.  What is the ethnic group (caste/tribe) of father or head of household 
(3=Scheduled Caste, 4= Scheduled Tribe, 5=Other backward castes, 








72.  Does the house have (YES/NO) (observe where possible)  
72.1.  Radio or transistor……RADIO  
72.2.  Mattress…………MATTRESS     
72.3.  Pressure cooker……COOKER  




72.5.  Cot or bed…………COT  
72.6.  Television (TV), black and white……TV_BW  
72.7.  Television (TV), color……TV_COL  
72.8.  Refrigerator (FRIDGE)……… FRIDGE  
72.9.  Mobile Phone (Cell)…… MOBILE  
72.10.  Any other type of telephone……LANDLINE  
72.11.  Computer………COMPUTER  
72.12.  Electric fan……FAN  
72.13.  Sewing machine……SEW_MACH  
72.14.  Watch / clock…………WATCH  
72.15.  Table……………TABLE_72  
72.16.  Tractor………TRACTOR  
72.17.  Thresher……THRESHER  
72.18.  Water pump……………WPUMP  
72.19.  Motorcycle or scooter………SCOOTER  




72.21.  Animal drawn cart………ANI_CART  
72.22.  Car…………CAR  
72.23.  Farm animals of any kind……F_ANIMAL              
73.  Does the family own the house or any other house? [1=Yes (own), 
2=No (rented)]   OWN_HOUS 
 
74.  Does this household own any agricultural land? AGRI_LAND                             
75.  How much agricultural land does the household own? Fill 9999 if 
Q74 is NO    LAND_AREA 
                        Bigha 
76.  Out of the land, how much is irrigated Fill 9999 if Q74 is NO  
LAND_IRRI 
                        Bigha 
77.  Does the household have a bank account?   BANK_ACT  
78.  Is the child covered by a health insurance scheme? INSERT LOCAL 
NAME FOR THIS.  HAVE CAREGIVER SHOW CARD 
HEALTH_SCHEME 
 
79.  How many rooms TOTAL does this household have?  ROOMS  
80.  How many rooms for SLEEPING does this household have?  
ROOM_SLEEP 
 
81.  Record observations for ROOF MATERIAL  




Sod/mud and grass mixture, 15= Plastic/polythene sheeting, 16= 
Rustic mat, 17= Palm/bamboo, 18= Raw wood planks/timber, 
19= Unburnt brick, 20= Loosely packed stone, 21= Metal, 22= 
Wood, 23= Calamine/ cement/concrete, 24= Asbestos sheets, 
25=Reinforced cement concrete (RCC) / cement/concrete, 26= 
Roofing shingles, 27= Tiles, 28=Slate, 
29=others…TYPE_ROOF , ROOF_SP 
82.  Record observations for EXTERIOR WALLS   
 11= No walls, 12= Cane/palm/trunks/ bamboo, 13= Mud, 
14=Grass/reeds/ thatch, 15= Bamboo with mud, 16= Stone with 
mud, 17=    Plywood, 18= Cardboard, 19= Unburnt brick, 20= 
Raw wood/reused wood, 21= Cement/concrete, 22= Stone with 
lime/cement, 23= Burnt bricks, 24= Cement blocks, 25= Wood 
planks/ shingles, 26= Metal/ asbestos sheets, 
27=Other…TYPE_WALL , WALL_SP              
 
 
              
 
83.  Record observations for MAIN FLOOR MATERIAL  
 11=   Mud/clay/earth, 12= Sand, 13= Dung, 14= Raw wood 
planks, 15= Palm/bamboo, 16= Brick, 17= Stone, 18=  Paraquet 
or polished wood, 19= Vinyl or asphalt, 20= Ceramic tiles, 
21=Cement, 22=Carpet, 23=Polished stone/marble/granite, 
24=other) (observe whenever possible……TYPE_FLOOR ,  
FLOOR_SP 
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